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Humans have engineered organisms for thousands of years. The domestication of 
plants and animals are early examples of how humans have changed genotypes of 
organisms for prized traits that persist today. The genotype to phenotype linkage is often 
the result of the expression or performance of proteins found within an organism. The 
modern era of biological engineering has seen the emergence of two fundamentally 
distinct philosophies on how best to alter the genetic code of an organism or sequence of 
a particular protein for desired phenotypic outcomes. Rational design and directed 
evolution are often seen as two competing methodologies working towards the same 
goal—the engineering of proteins and ultimately organisms. Here, I attempt to bridge the 
gap between the two engineering strategies and argue that a combination is needed in 
many cases. Starting with the rationalization of directed evolution experiments using 
software tools, we begin to understand the predictive power and limitations of rational 
computational approaches. We then explore the computational resurfacing of an enzyme 
and discover an unpredicted thermoswitchable phenotype. Next, we rationally design a 
number of fusion proteins, which allow us to create novel point-of-care diagnostics. We 
then turn our attention to the directed evolution of a number of DNA polymerases with 
novel functions. The amalgamation of rational design and directed evolution are then 
 v 
extended to a eukaryotic organism, which enables us to engineer more complex proteins 
and gives us the ability to create novel drug screening and discovery platforms. 
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Chapter 1: Current methods in protein engineering 
 
   “Slow though the process of selection may be, if feeble man can do much by his powers 
of artificial selection, I can see no limit to the amount of change, to the beauty and infinite 
complexity of the co-adaptations between all organic beings, one with another and with their 
physical conditions of life, which may be effected in the long course of time by nature's power of 
selection.” 
    — Charles Darwin, On the Origin of Species 
 
INTRODUCTION 
Natural selection is perhaps the most creative force known to humankind. For over a billion 
years, natural selection has acted on replication systems and organisms to give rise to the enormous 
diversity of life observed in extant and extinct organisms.  Life on Earth is teeming, with organisms 
found in the most extreme environments—from thermal vents to glacial ice. The plasticity of life is 
profound when one considers the range of ecological niche spaces inhabited by Earth’s creatures 
between these extremes. Regulatory and metabolic processes have been fine-tuned for these 
varying environments by genetic mutations that are passed from generation to generation. 
Adaptation to new environments often requires rare genetic mutations that allow variants of 
organisms to thrive in new and dynamic environments.  
Similarly, humans have crafted variations of organisms on much faster timescales than 
natural selection by selectively breeding plants and animals. For example, the domestication of the 
dog is estimated to have happened over 10,000 years ago. The rich diversity seen in Cannus 
familiaris is largely attributed to the phenotypic selection by humans (Vilà et al., 1997, 1999), 
historically referred to as ‘artificial selection’. Plants and other animals have been domesticated for 
a variety of reasons. The breeding of organisms for human consumption (crops and livestock) is 
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thought to have given rise to what we now consider modern civilization. The plants and animals 
consumed by humans today share little resemblance to their wild counterparts (Diamond, 2002).  
Whether ‘natural’ or ‘artificial’, selection occurs at the level of the genes found within 
organisms (Dawkins, 2006). From a reductionist perspective, genotypes lead to phenotypes. This is 
a basic tenet of biology. The flow of information is largely unidirectional; DNA, the storage 
molecule, is transcribed to RNA, which is then translated into proteins (Mahmoudian, 2010). In 
short, genes encode the directions to make proteins. With minor exceptions, proteins then give rise 
to the phenotypes we observe. Taken together these facts suggest that selection often acts on the 
production or function of proteins. 
Proteins make up a diverse set of macromolecules. By combining individual amino acids, 
the ribosome creates polypeptides which then fold and assemble into mature proteins. Proteins then 
carry out much of life’s work, from catalysis to structural integrity to regulation (Eisenberg et al., 
2000). Signaling is often the work of receptors and transcription factors, which bind to both extra- 
and intracellular molecules. Antibodies bind foreign objects and protect a host organism from 
disease or invasion. Enzymes are the chemists, carrying out the reactions needed to sustain life and 
keep an organism from reaching equilibrium (or death). The structure of cells and the movement of 
cargo between compartments is the work of a vast array of different proteins. The examples listed 
above are but a small fraction of the many functions proteins possess. 
In the modern era, biological engineers attempt to modify or design proteins for a variety of 
applications. Today engineered proteins are used in: (1) agriculture and the food industry, (2) 
detergents, (3) diagnostic and pharmaceutical industries, (4) biopolymer production and 
nanotechnology, (5) environmental monitoring and bioremediation, (6) chemical syntheses of 
complex molecules, and (7) biofuel production—to name but a few (Turanli-Yildiz et al., 2012).  
The goal of modern protein engineering is to improve or impart function on existing or 
novel protein scaffolds (Brannigan and Wilkinson, 2002). Protein engineering is a relatively young 
field in that its arrival was contingent upon the advent of recombinant DNA technologies and 
molecular cloning, collectively referred to as the Molecular Biology Revolution of the early 1980s. 
Historically, two distinct, but not mutually exclusive, strategies have been employed to engineer 
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proteins: (1) rational design and (2) directed evolution. Rational design of a protein requires that 
something is known of the structure, function, and mechanism of the target protein. Mutations to 
enhance or change the activity of the protein are made from prior structural and activity 
measurements (Cedrone et al., 2000). On the other hand, directed evolution does not require 
mechanistic knowledge of the protein to be engineered. Rather, it is limited by the throughput of 
screening or selection of new variants (Tobin et al., 2000). Below, we discuss the advances in each 
field and highlight their uses in modern interdisciplinary approaches.  
 
RATIONAL DESIGN 
Structure, function, and intuition 
 It has long been recognized that the function of a protein is predicated upon its properly 
folded 3-dimensional structure. This so-called ‘structure-function relationship’ is at the heart of 
modern molecular biology and biochemistry. How exactly structure informs function from the 
primary sequence of a protein can be probed exhaustively through the use modern computational 
and classical biochemical methods. With structural data from X-ray crystallography or NMR 
spectra, hypotheses about mechanism can be probed in exquisite detail.  
The first two enzymatic activities examined in this fashion were a tyrosine aminoacyl-tRNA 
synthetase (TyrRS) and a β-lactamase in 1982 (Brannigan and Wilkinson, 2002). While these early 
experiments did not produce a gain of function, they were used to probe mechanistic questions that 
could not otherwise be answered by enzymologists at the time and laid the foundation for what 
would later evolve into the field of rational protein design. When combined with prediction, the 
construction of modified proteins based on their structures and biochemical characterization form 
the basis of rational design (Leatherbarrow et al., 1985). In a somewhat prophetic call to arms in as 
early as 1983, Ulmer perfectly anticipated what would become rational design and predicted the 
interplay with directed evolution techniques to form the field of modern protein engineering 
(Ulmer, 1983). 
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At the time, very little structural data were available for diverse protein families. The first 
membrane protein structure wasn’t reported until 1985, and only 186 unique protein structures were 
reported (Berman et al., 2000). As late as 1991, only 648 structures were publicly available. 
Despite a significant lack of structural data from which to make predictions, rational protein design 
saw some early success. For example, from structural data and alanine scanning, human growth 
hormone variants were rationally designed to increase binding preference to either the growth 
hormone or prolactin receptors by factors of 34,000 and 150, respectively (Cunningham and Wells, 
1991).  
A number of examples of utilizing rational design to increase the thermostability of proteins 
have been reported. For example, the thermostability of α-amylase was increased with the 
replacement of asparagine sidechains by one group (Declerck et al., 2000). Another group 
introduced prolines to stabilize structural elements of the protein (Igarashi et al., 1999). Proline 
substitution was also successful in stabilizing d-xylose isomerase by introducing the amino acid 
into the turn of a random coil (Zhu et al., 1999). The engineering of two disulfide bonds in hen 
lysozyme greatly improved its thermotolerance (Ueda et al., 2000). Rational design of increased 
hydrophobic contacts stabilized 3-isopropylmalate dehydrogenase (Akanuma et al., 1999) and 
formate dehydrogenase (Rojkova et al., 1999). Still others have used sequence and structural 
information from thermophilic proteins to rationally design their mesophilic counterparts for 
increased stability (Kumar et al., 2000). 
Beyond thermostability, other properties of proteins have been rationally designed. 
Oxidation-resistant proteins have been engineered through the removal of targeted sulfur 
containing sidechains—methionine and cysteine (Chelius et al., 2000; Ju et al., 2000; Slusarczyk et 
al., 2000). Using structural comparisons of two FAD-dependent oxidoreductases, van Berkel was 
able to switch the entantioselectivity of an (R)-specific vanillyl-alcohol oxidase to (S)-specific 
hydroxylation  of 4-ethylphenol (Heuvel et al., 2000). Other examples of altering stereoselectivity 
through rational design involve the engineering of lipases (Scheib et al., 1998, 1999).  
Often, enzymes require multiple steps along the reaction coordinate and produce any 
number of intermediates or additional side products that do not result in final product formation. In 
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order to increase the carboligase side product of pyruvate decarboxylase, a tryptophan residue in 
the substrate channel was mutated to either methionine or isoleucine, which increased the 
production of the carboligase reaction by nearly 5-fold (Pohl, 2000). PepC, an aminopeptidase, was 
transformed into an oligopeptidase by removing four carboxy-terminus amino acids, which were 
previously shown to interact with the active site (Mata et al., 1999). P450 enzymes are generally 
promiscuous (Guo et al., 2016) in nature. Efforts to extend their substrate range have proven 
successful using rational design. Variants of Cyp101 from Pseudomonas putida were engineered to 
contain two mutations at positions F87 and Y96 in a substrate-binding channel that conferred 
activity to polycyclic aromatic hydrocarbons (Harford-Cross et al., 2000). β-lactamases have also 
been extensively engineered to alter their substrate specificities. PER-1 was rationally designed to 
improve its activity with a number of cephalosporins (Bouthors et al., 1999).  
New enzymatic activities have also been engineered. A tyrosine phenol-lyase was 
transformed into a dicarboxylic amino acid β-lyase, of which no known form exists in nature 
(Mouratou et al., 1999). In a landmark study two decades ago, Shokat and colleagues (Kenski et al., 
2005) used the structural information of a protein kinase to create an orthogonal kinase and 
substrate to aid in identifying phosphorylated target proteins. 
This list of rational design achievements described above is by no means comprehensive. 
Rational design of antibody fusions and CDR grafting are examples that deserve consideration 
(Jones et al., 1986; Liu et al., 2016; Sharma and Bagshawe, 2017). Changes in mechanism, 
substrate promiscuity, cofactor dependence, stability, and enantioselectivity have all been reported 
for a number of proteins using rational site-directed mutagenesis. See the references listed here for 
a full review (Cedrone et al., 2000; Harris and Craik, 1998; Jones and DeSantis, 1999). 
 
Computational protein design 
A subgenre in rational design is pure computational design of proteins for enhanced or 
novel function. Rather than give an exhaustive list of software packages that are used in the design 
process, this section will focus on the core components needed, the general framework used to 
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computationally design proteins, and examples of their usage. Computational protein design is born 
from the idea that we can understand and engineer structures for desired functions from first 
principles or approximations (Pantazes et al., 2011). Natural proteins are strings of amino acids, 
which tuned by evolutionary forces, fold into functional molecular entities. These proteins can 
range in size from tens to thousands of amino acid residues, each with varying degrees of freedom. 
The number of conformations a single sequence can adopt is enormous. The energy landscape a 
protein must traverse in order to achieve its mature folded state is complex. However, the native 
state must be sufficiently low in energy to thwart falling into local misfolded minima (Lippow and 
Tidor, 2007).  
Due to the exponential increase of conformational and sequence space with each additional 
amino acid in a protein sequence (20N), computational protein design is necessarily built on a 
number of assumptions and in many cases semi-empirical design rules or empirical data sets. A 
typical computer protein design protocol can be broken down into the following: (1) target 
objectives, (2) parametrization and component consideration, (3) the energy function, (4) search 
and sampling methods, and finally (5) the output of sequence(s) and 3-dimensional structure(s) 
(Samish et al., 2011). 
From the outset, one must define what the program is targeting. This can range from a 
portion of a protein to the complete de novo design of a novel protein. In any case, any one or a 
combination of structure, function, or biophysical properties define the target objectives. For 
example, semi-artificial enzymes were previously designed to carry out the Kemp elimination 
reaction. To do so, quantum mechanical calculations of the ideal transition state were performed 
and amino acids were computationally inserted templated protein scaffolds to structurally stabilize 
the idealized state. While the rate enhancement without further engineering was a modest 
improvement over the uncatalyzed reaction, the artificial enzyme was functional and capable of 
performing multiple turnovers (Röthlisberger et al., 2008). 
The degrees of freedom the backbone and sidechains are given is of particular importance 
when designing protein design protocols. While fixed backbone design strategies largely mitigate 
large conformational sequence space, they do not allow for main chain adjustments that may be 
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optimal for a targeted objective. Often proteins require some level of flexibility in backbone 
conformations for stability, activity, and solubility (Samish et al., 2011). For sidechain 
conformations, rotamer libraries are often employed, which dramatically reduce search space. 
Historically, these libraries were built from idealized bond lengths and dihedral angles derived from 
X-ray crystal structures. Two commonly used libraries reduce the degrees of freedom to 350 or 
less, dramatically decreasing the computational load when searching conformational space 
(Dunbrack, 2002; Dunbrack and Karplus, 1993; Lovell et al., 2000). However, more than 10% of 
residues in high-resolution structures are unable to be matched using these commonly used rotamer 
libraries. More recently, rotamer libraries and conformer libraries (bond lengths) have been 
constructed that more closely match empirical data from empircal structures. With the advent of 
cheap processing power, the need for smaller libraries has waned (Lassila et al., 2006; Porebski et 
al., 2016; Subramaniam and Senes, 2012).  
Models are judged on scores derived from energy functions. While these can vary, the core 
energy function attempts to quantify energetic contributions from: Van der Waals interactions, 
electrostatics, solvation, hydrogen bonding, conformational strain, and a number of additional 
terms depending on the application. The potentials are generally parameterized in a way that 
naturally occurring protein structures represent local energy minima. Forcefields account for the 
parameter sets used in the potential energy calculations of atoms within the system. AMBER, 
CHARMM, and GROMOS are the most commonly used all-atom forcefields (Jo et al., 2017; Smith 
et al., 2015; Wang et al., 2017). Next, using negative design rules and folding criteria, sequences 
and structures are searched using a range of parameters. Sequence searches are initiated with either 
stochastic or deterministic approaches. For stochastic search methods, Monte Carlo methods 
employing a Boltzmann distribution are commonly used. Once the search criteria have been met, a 
number of output sequences and models are produced (Pantazes et al., 2011). These designs are 
then tested empirically using standard biochemical techniques. 
Despite the enormous challenge, computational protein design has garnered success over 
the last 30+ years. An early win for the field included the computational design of the tightest-
binding peptide (17 amino acid) inhibitor of calmodulin (DeGrado et al., 1985). In 1991, active 
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sites of predefined geometry could be designed using Hellinga’s DEZYMER software package. A 
copper-binding site was successfully introduced into thioredoxin with the substitution of four 
amino acids predicted by the software (Hellinga et al., 1991). In 2003, the Baker lab designed the 
first α/β protein called Top7. This was the first novel fold of a protein designed and shown to 
possess angstrom-level accuracy (1.2 Å RMSD) (Kuhlman et al., 2003). More recently, a 
conglomerate of laboratories used computational protein design to engineer pseudo-viral epitopes 
for vaccine development. The designed epitopes were able to induce neutralizing antibody 
production, and one of the designs was bound by an existing antibody (Correia et al., 2014). The 
ability to engineer novel proteins or enhance existing proteins through computational design is 
gaining traction and will only improve with better tools and more computational power. 
 
DIRECTED EVOLUTION 
Introduction 
Directed evolution of proteins attempts to mimic natural selection on much shorter 
timescales and has given rise to a number of therapeutically and industrially significant proteins. In 
contrast to rational design, detailed structure-function relationships are not needed in advance to 
screening or selection (Tobin et al., 2000). Through simulated Darwinian evolution, antibodies, 
enzymes, receptors, transcription factors, and components of biosynthetic pathways have all been 
crafted in the laboratory in practical time frames. In addition to functional or host optimization, 
entirely new properties and chemistries have been imparted on a number of proteins (Packer and 
Liu, 2015). The two main pillars of directed evolution are the generation of diversity and methods 
to select or screen variants for improved or novel function. Below we describe the current 
techniques in library design and selection. 
 
Creating library diversity 
There are many ways to generate genetic diversity. However, each of the techniques falls 
into one of three main categories: (1) random mutagenesis, (2) focused mutagenesis, and (3) 
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recombination or sexual reproduction. Random mutagenesis can be achieved in a number of ways. 
First, chemical agents that promote random mutations during replication can be added supplied to 
an organism. The use of this technique in living organisms has declined in recent years because of 
the generation of off-target mutagenesis in the host or plasmid. Typically, random mutagenesis is 
achieved with ‘mutagenic’ or ‘error-prone’ polymerase chain reaction (PCR) amplification of the 
targeted gene (Cadwell and Joyce, 1994). DNA polymerases can be easily tuned to predefined 
error-rates with the addition of metals and base analogs to the PCR reaction (Wong et al., 2004). 
Other methods involving mutator strains exist, but they suffer from the same off-target effects 
mentioned above. Focused or targeted libraries are constructed through the use of degenerate 
codons during traditional oligonucleotide synthesis or more defined through the use of chip-based 
DNA synthesis (Tang et al., 2014). Here multiple positions can be mutated in a site-specific 
manner. This technique is particularly useful if some structure-function relationships are known. 
Finally, random recombination of related genes can be used in ‘sexual’ selection of protein 
variants. The most common variation of recombinatorial generation of library diversity is ‘DNA 
Shuffling’ (Stemmer, 1994). Through the use of DNAse- or sonication-fragmentation of DNA 
sequences, combinations of related genes can be randomly put together in novel ways. This 
technique resembles crossing over of chromosomes in sexually reproducing organisms. Variations 
on this theme exist. See RACHITT (Coco et al., 2001), NExT (Müller et al., 2005), StEP (Zhao et 
al., 1998), assembly PCR (Stemmer et al., 1995), ITCHY (Ness et al., 2002), and NRR (Zha et al., 
2003). Over the course of a directed evolution experiment, it is common to use a combination of 
any the library generation methods mentioned. 
 
Screening and selecting mutant libraries 
Traditional techniques 
After the library has been constructed, it must then be screened or selected in order to 
amplify variants of improved or novel function. Careful considerations must be made when 
designing screening or selections methods. Screens are typically performed by spatially separating 
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variants. By spatially separating individual members of the library, the coveted genotype to 
phenotype linkage is preserved. Often, protein variants are expressed recombinantly in model 
organisms and isolated on either solid media or individual culture wells (Forsburg, 2001). For 
bacterial screens, Escherichia coli is commonly used. Saccharoymyces cerevisiae is the preferred 
eukaryotic screening organism, although other yeasts, mammalian, and insect cells have been used 
(Singh et al., 2016). Screening is compatible with a several assay platforms where ~103-104 
mutants can be measured in parallel or temporally close together. Commonly, genetic reporters that 
result in fluorescence (GFP), colorimetry (β-gal), or luminescence (luciferase) are used to screen 
functional variants. However, medium to highthroughput screens are compatible with NMR, 
HPLC, GC-MS, and LC-MS (Packer and Liu, 2015).  
The most common and accessible screening platform is fluorescence-activated cell sorting 
(FACS). Fluorescence of individual cells is monitored, and those cells exhibiting fluorescence 
above an arbitrarily selected value or sorted and allowed to grow. Typically, enrichment factors of 
10-200 are reported—more commonly near 20-fold enrichment (Aharoni et al., 2005). Yeast-
display is another FACS-based technique that can be used to engineer protein-protein interactions 
as wells as tune enzymatic activities. Recently, yeast-display has been used extensively in the 
selection of antibodies (Wang et al., 2016a). By attaching a fluorophore to a target antigen, cells 
that display antibodies specific to a particular antigen are enriched. 
The drawbacks to screening methods listed above are time and throughput. In traditional 
selections, libraries of over 108 can be selected from at once. During selection, larger sequence 
space is sampled, and there is no requirement for spatially or temporally separating library 
members because selections are performed in bulk. The genotype to phenotype linkage can be 
preserved in many ways. Historically, the most common selection strategies rely on binding affinity 
or host survival. Affinity-based selections rely on a target protein to be displayed on surfaces of 
cells, phage (McCafferty et al., 1990), mRNA (Wilson et al., 2001), or ribosomes (Amstutz et al., 
2002). Phage display is perhaps the most common and has been used to select for a number of 
protein and small-molecule binding proteins, most notably antibodies. In this regime, survivors are 
selected by passing library members over immobilized target reagents. Those library members that 
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do not bind are washed away. Binders are collected and propagated to the next round of 
mutagenesis and selection. Still other selections are coupled to survival of the host organism. A 
protein variant that confers a growth advantage or survival of its host under strong selective 
pressure (auxotrophic or antibiotic) is selected for and propagated. The linkage of genotype to 
phenotype is maintained in the context of the host cell expressing the variant that led to an increase 
in fitness. While a number of life/death selections have been successful, this selection strategy is 
limited. Often, cheaters arise in populations of these selections because there is a strong selective 
pressure for the organism to mutate something outside of the selection circuit in order to survive to 
the next round. This selection strategy can not be used for the evolution of toxic proteins or protein 
function under harmful conditions to host fitness (Packer and Liu, 2015; Tobin et al., 2000). 
 
In vitro compartmentalization 
Genotype to phenotype linkage can be maintained through the use of in vitro 
compartmentalization (IVC). Using this strategy, selection is performed within water-in-oil 
emulsions that are physically separated from one another. After assaying variants, the emulsions 
are broken, and DNA corresponding to survivors or superior performers is amplified for the next 
round of selection. In many cases, IVC removes the need to express protein variants in the context 
of cells, negating toxicity issues noted above. Another key feature is that substrates can be 
compartmentalized that would otherwise be inaccessible to living cells. This method was pioneered 
by Tawkfik in the engineering of a methyltransferase (Tawfik and Griffiths, 1998). Other enzymes 
have been engineered using IVC. For example, β-galactosidase activity has been imparted on a 
protein with unknown function.  
In another instantiation of IVC, Holliger designed selections for the engineering of 
thermostable DNA polymerases, termed Compartmentalized Self-Replication (Ghadessy et al., 
2001a). In CSR, DNA polymerase variants are expressed within bacterial cells and isolated within 
water-in-oil emulsions in PCR buffer with primers specific for the polymerase. Successful 
amplification of the target polymerase is only achieved by the function of a variant polymerase. In 
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a typical water-in-oil emulsion, up to 1010 compartments are formed. Thus, a library of 108 can be 
readily selected from using a standard thermalcycler. CSR has been used to engineer novel 
properties of DNA polymerases (Ghadessy and Holliger, 2007) and is the basis for Chapter 5 of 
this dissertation. 
Compartmentalized Partnered Replication, a directed evolution strategy developed in our 
laboratory, is the natural progression from CSR. Instead of selecting for polymerase variants in the 
emulsion PCR, CPR selects for biomolecules that lead to the production of the thermostable DNA 
polymerase (Ellefson et al., 2014). Selection circuits are generated such that the function of one 
biomolecule is tied to the production of the replicative DNA polymerase to be used in the emulsion 
PCR. The production of the ‘partnered’ gene and subsequent in vivo stage is short-lived in CPR. 
After induction of the partnered gene, its function is directly tied to the production of the 
thermostable DNA polymerase. That is, the more active a particular variant is, the more represented 
it will become after the emulsion PCR because more polymerase production leads to more 
amplification. In contrast to FACS-based screens, CPR enjoys enrichment factors in the 103 to 104 
range due to the exponential amplification inherent to PCR (Maranhao and Ellington, 2017). 
Additionally, genetic circuits that lead to fluorescent proteins in traditional screens are easily 
converted to CPR circuits by replacing the fluorescent protein with a thermostable DNA 
polymerase, such as Taq or KOD. To date, CPR has been used to evolve: a panel of orthogonal T7 
RNA polymerases (Meyer et al., 2014a), aminoacyl tRNA synthetase:tRNA pairs for unnatural 
amino acid incorportation (Ellefson et al., 2014; Maranhao and Ellington, 2017), repressors, and 
transcription factors. CPR forms the basis of Chapters 6 and 7 where we introduce CPR circuits 
into eukaryotic organisms for the first time. 
 
Continuous evolution 
Continuous evolution strategies attempt to break the laborious cycle of discrete library 
diversification and selection or screening. Many of these strategies rely on the fitness of an 
organism under continual dilution conditions. This technique has been successful in the creation of 
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improved antibiotic resistance markers and the evolution of chorismate mutase. Care must be taken 
that only the target gene is mutated, which is difficult to maintain in bacterial or yeast cells. 
Recently, a continuous evolution scheme has been adapted to phage. Phage-assisted continuous 
evolution (PACE) has been used to change the promoter preference of the T7 RNA polymerase. 
Other examples have used PACE to evolve proteases and DNA binding proteins (Packer and Liu, 
2015). While limited success has been reported for continuous evolution, the adoption of these 
techniques has been slow due to the problematic nature of such selections—cheaters and 
contamination. 
 
Conclusions 
Up to this point, we have treated rational design and directed evolution as separate entities. 
In reality, it is now rare for successful protein engineers to employ only one of these strategies. 
Protein engineering is no longer binary in nature and is best thought to operate along a continuum 
of these complementary fields. While many labs possess more expertise in either of the two 
methodologies, optimal answers are seldom (if ever) found by utilizing one approach over the 
other. Recent years have seen the explosion of crystal structures, which now number in the tens of 
thousands. These structural data combined with bioinformatics inform both directed evolution and 
rational design. The advent of increased processing power, improved forcefields, and machine 
learning algorithms have increased the bandwidth that protein engineers can operate within. The 
next 35 years of protein engineering will see an unprecedented level of success in answering the 
challenges of modern society. The words of Ulmer and Darwin will echo along this path. 
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Chapter 2: Molecular Modeling of Laboratory Evolution Experiments and 
Protein:Small Molecule Interactions 
ABSTRACT 
This chapter is the culmination of several successful collaborations during my tenure as a 
graduate student. The main theme presented in this chapter is molecular modeling and how 
computational tools can be applied to the post facto rationalization of laboratory evolution 
experiments (Sections 1-3). Examples of the predictive power of modern computational approaches 
are also discussed. In section one, we find that mutations observed in Citrate Synthase (CS) during 
the Lenski long-term evolution experiment (LTEE) occurred both before and after Escherichia coli 
evolved to utilize citrate aerobically as a carbon source. Detailed kinetic, molecular modeling, and 
metabolic flux analyses provide support of a model of evolution where mutations in CS were 
needed to first potentiate and then later refine central metabolic regulatory networks for the use of 
the newly available nutrient. In section two, we addict a diverse set of bacteria to noncanonical 
amino acids through engineering TEM-1 β-lactamase. The creation of rotamer libraries and 
simulations provide mechanistic clues to the addiction of the enzyme to two tyrosine analogs and 
may provide a framework for future engineering efforts of other enzymes. Extending upon our 
noncanonical amino acid work, section three rationalizes rifampicin resistance in Escherichia coli 
in the context of standard and extended genetic codes. Finally, section four uses homology 
modeling, molecular dynamics simulations, and docking studies in an attempt to explain 
differences in thiabendazole (TBZ) resistance in human and fungal β-tubulins. While covering 
seemingly disparate topics, the training in the use of various software packages provided me with a 
diverse toolkit that would aid in my development as a scientist and taught me to appreciate 
structure-function relationships at a much deeper level. Lessons learned in these four sections 
would help shape projects described hereafter.  
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2.1 FINE-TUNING CITRATE SYNTHASE FLUX POTENTIATES AND REFINES METABOLIC INNOVATION 
IN THE LENSKI EVOLUTION EXPERIMENT 
Introduction 
 Natural selection has provided the world with a vast array of diverse life forms, each with 
complex regulatory mechanisms and metabolic processes. Metabolism, life’s chief use of 
chemistry, has been brilliantly crafted by evolution to enable organisms the ability to occupy niches 
over a staggering range of environments. The ability to adapt to a changing world, encoded by rare 
genetic mutations, gives rise to varying levels of fitness, which then in turn, leads to expansion of 
inherited traits and observable phenotypes (Ryall et al., 2012). In nature, this process rarely 
happens on observable timescales (Barrick and Lenski, 2013). However, the Lenski long-term 
evolution experiment (LTEE) has provided key insights into how metabolic and regulatory 
networks have evolved in Escherichia coli under laboratory conditions and gives clues as to how 
evolution works in nature. The LTEE has been an ongoing endeavor for more than 25 years and 
continues to enrich our understanding of evolutionary forces and provides us with a dataset from 
which to design and test new hypotheses (Lenski and Travisano, 1994; Lenski et al., 1991). 
 The ability of a single population to aerobically utilize citrate as a carbon source is perhaps 
the most widely regarded result of the LTEE to date. After roughly 31,500 generations (~15 years), 
only one of the original twelve populations evolved the ability to colonize this ecological niche, 
giving access to an abundant nutrient not previously accessible (Blount et al., 2008). After more 
than a decade since the observation of this phenotype, none of the other populations have gained 
this metabolic trait. Due to the rarity of this innovation, it is clear that a multi-step mutational 
pathway was necessary to occupy this new niche. 
 Three stages of evolution were required in the LTEE for robust citrate utilization: 
potentiation, actualization, and refinement. The first appearance of Cit+ cells is referred to as the 
actualization step and was caused by a promoter duplication event that allowed the citrate:succinate 
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antiporter (citT) to be expressed under aerobic conditions (Blount et al., 2012). This so called 
‘promoter capture’ event is insufficient to explain the strong citrate utilization phenotype (Cit++) 
however. Additional refinement mutations are necessary to confer Cit++ cells, which can grow to 
density in a single 24 hour growth cycle (Blount et al., 2008). One pathway involves yet another 
promoter mutation that activates the C4-dicarboxylate:H+ symporter (dctA). Together these 
mutations confer strong growth on citrate in reconstructed strains, but this two-step pathway was 
apparently inaccessible at the time this trait evolved in the LTEE, giving rise to the notion that 
other ‘potentiating’ mutations were needed (Blount et al., 2008). 
 A phylogenetic study of the LTEE pointed to likely key potentiating and refinement 
mutations on the pathway to Cit++  (Blount et al., 2012). In the current work, we characterize 
Citrate Synthase (CS), encoded by the gltA gene, which was mutated both before and after the 
evolution of citrate utilization. CS catalyzes the aldol condensation of oxaloacetate (OAA) and 
acetyl-CoA to create citrate and is the first irreversible step in the Krebs cycle. Due to the enzyme’s 
importance in central metabolism and appearance of multiple mutations in isolates of Cit++ strains, 
it has been postulated that CS mutations were largely refinement mutations in Cit+ strains (Blount 
et al., 2012).  
 Here we show that mutations in CS were important for potentiating the evolution of the 
Cit+ phenotype, and additional mutations in the enzyme were later needed to refine the Cit++ 
phenotype. Whole-genome sequencing of isolated clones from the Ara-3 LTEE population revealed 
a number of mutations to CS (Blount et al., 2012). In every Cit+ strain identified, CS A258T was 
present (Quandt et al., 2015). A258T was also present in Cit- backgrounds at this point. Thus, we 
interpret this to mean that this mutation was present before the weak citrate utilization phenotype. 
In addition to A258T, protein coding secondary CS mutations (A124T, V152A, or A162V) were 
found independently in isolated Cit++ strains.  
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Metagenomics analysis was performed by Erik Quandt and has been discussed at length 
(Quandt et al., 2015). Briefly, A258T was first detected at 25,000 generations but had dropped 
significantly by 30,000 generations. By 33,500 generations, A258T was found at nearly 100% 
frequency in the population. Coincident with the expansion of Cit++ subpopulations, secondary 
mutations arose in A258T, citT duplication, and dctA mutational backgrounds.  
Biochemical characterization alongside computational modeling and metabolic flux analysis 
provide a clear picture of how these mutations affected cellular regulatory networks. Early 
mutations in CS increased activity of the enzyme by losing allosteric regulation of NADH. Later, 
refining mutations led to a decrease in enzyme activity and partial restoration of allosteric control. 
Differences in enzyme activities due to these mutations are in good agreement with flux modeling 
predictions, which are not shown here for brevity. Here, we zoom in to CS and discuss the kinetics 
and modeling of the various mutations observed in the LTEE. 
Results & Discussion 
Most Secondary Citrate Synthase Mutations Reduce Enzyme Activity 
 We characterized the enyzmatic activity of A258T alone and with the other secondary 
mutations found in CS and compared kinetic parameters against the wildtype enzyme. We found 
that the A258T mutation did not significantly change the kinetic parameters of the enzyme (Table 
2-1). However, addition of either A162V or A124T was found to reduce activity. The A162V 
substitution increased the Km values for both substrates of the reaction, oxaloacetate (OAA) (143.4 
± 11.1 μM vs. 84.2 ± 10.4 μM) and acetyl-CoA (AcCoA) (374.1 ± 41.2 μM vs. 138.6 ± 17.6 μM). 
The A124T mutation resulted a doubling of the  Km for acetyl-CoA (295.1 ± 52.6 μM vs. 138.6 ± 
17.6 μM) and reduced catalytic efficiency (kcat  = 33.9 ± 2.7 s-1 vs. 51.1 ± 2.5 s-1). We interpret these 
results in a framework where secondary mutations in CS likely impact flux through cellular 
metabolism in a similar manner (Quandt et al., 2015).  
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The Initial A258T Mutation Loses Allosteric Inhibition by NADH   
 CS is allosterically inhibited by the primary product of the Krebs cycle, NADH (Weitzman, 
1966a, 1966b; Weitzman and Jones, 1968). Since we were unable to see differences in kinetic 
parameters between A258T and the wildtype enzyme, we hypothesized that A258T would affect 
regulation by NADH. To test this hypothesis, NADH binding to purified enzyme variants was 
measured by monitoring changes in NADH fluorescence that occur upon binding to the protein 
(Duckworth and Tong, 1976), and allosteric inhibition was measured by measuring kinetic 
parameters in the presence of varying concentrations of NADH.  
 In complete agreement with previous studies, the wildtype enzyme exhibited a Kd and a Ki 
for NADH of  nearly 1 μM each (Table 2-1 and Figure 2-1) (Anderson and Duckworth, 1988; 
Pereira et al., 1994; Stokell et al., 2003). In contrast, A258T was largely incapable of binding 
NADH at concentrations within the range of our the binding assay, which extends up to ~10 μM 
NADH (Dickinson, 1970). A258T also showed an enormous increase in Ki for NADH, >30-fold 
relative to the wildtype enzyme. Each of the secondary mutations restored both NADH binding and 
allosteric inhibition to varying degrees. In fact, A162Vdisplayed near wild-type Kd and Ki values 
for NADH (Table 2-1).  
 To gain further insight into how these mutations affected allosteric inhibition by NADH, we 
performed 3D modeling and molecular dynamics (MD) simulations using the Molecular Operating 
Environment and NAMD, respectively. Mutations were first introduced into a computationally 
corrected structure of E. coli citrate synthase (Maurus et al., 2003). After energy minimization and 
ns-timescale MD in a 6 Å water sphere, we observed subtle differences in the predicted 
conformation of each enzyme variant, most notably around the NADH binding site. The most 
pronounced changes were in the orientation of H110 (Figure 2-1), even though this amino acid is 
distant from the A258T mutation. In the wild-type CS structure, H110 adopts an upward 
conformation that allows for accommodation of NADH in the binding pocket. The A258T mutation 
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is predicted to reorient the H110 side chain toward the binding pocket, presumably creating an 
unfavorable steric barrier to NADH binding. Addition of the secondary mutations (A162V or 
A124T) resulted in simulated structures with H110 oriented between these two extremes, 
potentially explaining the varying levels of binding and inhibition described above. We next used 
template-based docking of NADH to these mutant CS structures to determine relative binding 
energies. We found that these binding energies were correlated with the experimentally determined 
NADH binding affinities (Tables 2-1and 2-2).   
Conclusions 
 Together our results suggest that metabolism and regulation are tuned specifically to an 
ecological niche. However, as shown here, they can be refit to a new niche with the addition of 
only a few mutations to important enzymes and regulatory proteins. What we observed here may 
indeed be broadly used by evolution. Complex regulatory networks and epistatic relationships must 
be fine-tuned within the genetic and mutational landscape they find themselves if the organism 
carrying them is to survive and flourish in a dynamic environment. 
Methods & Materials 
Enzyme Activity Measurements 
 Citrate synthase activity of purified His6-tagged GltA variants was measured using a 5′,5′-
dithiobis-(2-nitrobenzoate) (DTNB) colorimetric assay (Srere, 1969). Readings at 412 nm were 
taken in 96-well plates at 25°C using a Synergy HT plate reader (BioTek). Standard CS assay 
buffer consists of 20 mM Tris•Cl (pH 7.8), 100 mM KCl, and 1 mM EDTA (Duckworth and Tong, 
1976). Enzyme was present at a concentration at least 100-fold lower than both substrates in all 
assays. Under these conditions, E.coli CS has been shown to conform to the ordered bisubstrate 
mechanism (Anderson and Duckworth, 1988). Kinetic data was fit to the Ordered Bi Bi equation 
using SigmaPlot 10 (Systat Software, San Jose, CA). 
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NADH Binding and Inhibition Measurements 
 NADH equilibrium binding assays were performed as previously described in CS buffer 
lacking KCl (Duckworth and Tong, 1976). Briefly, enzymes were equilibrated with varying 
concentrations of NADH (0–6.4 µM) for 1 h at 25°C. Fluorescent measurements were made with 
excitation at 340 nm and emission reading at 425 nm in a Tecan M200 plate reader. The observed 
changes in fluorescence versus NADH concentration were fit to a hyperbolic ligand-binding curve 
using SigmaPlot 10. 
 Inhibition assays were performed essentially as described elsewhere (Stokell et al., 2003). 
Varying concentrations of NADH were equilibrated with enzyme in CS buffer lacking KCl at 25°C 
for 1 h. Substrates OAA and AcCoA were both added at 100 μM and initial reaction rates were 
measured using the DTNB assay described above. Enzyme activities were normalized to the 
activity of wild-type GltA in the absence of NADH. Percent inhibition was plotted versus NADH 
concentration and fit to a hyperbolic model in SigmaPlot 10. 
Molecular Modeling 
 Wild-type and mutant citrate synthase structures were analyzed using the Molecular 
Operating Environment (MOE2013.08). Dimeric models of ligand-free and NADH-bound E. coli 
citrate synthase (PDB: 1NXE and 1NXG) (Maurus et al., 2003) were prepared for analysis by 
reverting alanine-383 to phenylalanine and processing with the Structure Preparation application 
within MOE. Each model was then protonated (37°C, pH 7.4, 0.1 salt) using Protonate3D. As 
further preparation for QM/MM analyses, non-bridging solvent molecules were removed, a 6 Å 
solvent sphere was added, and charges were neutralized by the addition of KCl. Lastly, amino acid 
substitutions in a given CS variant were added sequentially with energy minimization to an RMS 
gradient of 10-3 kcal/mol/Å2 using the Amber12 force field with Extended Hückel Theory and R-
field solvation electrostatics after each mutation. NADH binding energies for the resulting models 
were calculated using the Ligand Interactions subroutine. 
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Table 2-1. Kinetic and regulatory properties of citrate synthase variants 
Variant kcat (s-1) 
Km OAA 
(μM) 
Km 
AcCoA 
(μM) 
Kd 
NADH 
(μM) 
Ki 
NADH 
(μM) 
Maximum 
% 
inhibition 
Docking 
energy 
(kcal/mol) 
Wildtype 51.1 ± 2.5 
84.2 ± 
10.4 
138.6 ± 
17.6 
1.2 ± 0.1 1.7 ± 0.1 80.5 ± 1.0 –80.3 
A258T 49.1  ± 5.3 
90.3 ± 
22.5 
148.0 ± 
41.1 
N.D. 
30.2 ± 
4.6* 
83.2 ± 3.1 –28.8 
A258T, 
A162V 
55.0 ± 3.0 
143.4 ± 
11.1* 
374.1 ± 
41.2* 
1.5 ± 0.4 1.9 ± 0.1 68.7 ± 0.7* –63.8 
A258T, 
A124T 
33.9 ± 2.7* 
88.1 ± 
12.8 
295.1 ± 
52.6* 
9.5 ± 
1.7* 
17.1 ± 
6.2* 
64.6 ± 5.1* –47.8 
Data are represented as fit mean ± S.E. Significant differences from the wild-type enzyme are 
marked with an asterisk (two-tailed t-test, p-value < 0.05). N.D. indicates no detectable binding. 
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Table 2-2. Representative Binding Energy Evaluation of NADH and wildtype citrate synthase 
Interaction Type Distance E (kcal/mol) 
1 H-donor 2.94 -0.1 
2 H-donor 2.63 -3.8 
3 H-donor 2.85 -2.6 
4 H-acceptor 2.69 -2.6 
5 H-acceptor 2.62 -4.2 
6 H-acceptor 2.74 -15.1 
7 H-acceptor 2.76 -1.6 
8 H-acceptor 2.84 -1.3 
9 H-acceptor 2.74 -1.2 
10 H-acceptor 2.97 -7.4 
11 H-acceptor 2.69 -3.2 
12 H-acceptor 2.72 -8.6 
13 H-acceptor 2.64 -2.9 
14 H-acceptor 2.66 -0.7 
15 ionic 2.74 -6.4 
16 ionic 2.97 -4.7 
17 ionic 3.73 -1.1 
18 ionic 3.18 -3.4 
19 ionic 3.64 -1.4 
20 ionic 2.72 -6.7 
21 pi-H 3.59 -0.7 
22 pi-H 4.03 -0.6 
23 pi-pi 3.9 0 
  
Total -80.3 
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Figure 2-1. CS mutations alter allosteric regulation by NADH 
 
CS mutations alter allosteric regulation by NADH (Top) NADH-mediated inhibition citrate synthase activity for the wild-type 
enzyme and evolved variants with combinations of gltA mutations (Bottom) Molecular modeling predicts that the observed changes 
in allosteric regulation in evolved CS sequences are primarily caused by how mutations affect the orientation of H110 in the NADH 
binding pocket. The A258T mutation is predicted to redirect this side chain into the binding pocket creating a steric clash with 
NADH (red surface). The two characterized variants of citrate synthase with an additional mutation are predicted to reorient H110 
back toward the wild-type conformation. The degree of this predicted structural change correlates with the relative levels of NADH 
inhibition experimentally measured for these CS variants (Table 2-1).  
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2.2 ADDICTION OF DIVERSE BACTERIA BY AN ENGINEERED NONCANONICAL AMINO ACID BETA-
LACTAMASE (ENABL) 
Introduction 
The seemingly static genetic code has shaped life on Earth as we know it. The proteomes of 
all known organisms rely on the same 20 canonical amino acids. Naturally occurring expansion of 
the code has given rise to the use of additional rare amino acids, selenocysteine and pyrrolysine. 
Recent advances in engineering orthogonal translation systems (OTSs) comprised of tRNA and 
aminoacyl-tRNA synthetase (aaRS) pairs have enabled expansion of the genetic code using 
nonstandard amino acids (NSAAs), typically using Amber (UAG codon) suppression (Liu and 
Schultz). The biological and biochemical impact of NSAAs across the proteome are poorly 
understood because it has proven difficult to maintain new genetic codes in organisms. Often the 
OTS is completely lost or kept but inactivated, even when Amber suppression is required (Wang et 
al).   
In an effort to overcome loss or inactivation, we reengineered the protein core of TEM-1 
beta-lactamase to generate an antibiotic resistance marker that is dependent upon the incorporation 
of    3-nitro-  and    3-iodo-tyrosine. TEM-1 β-lactamase confers resistance to β-lactam antibiotics 
across a wide range of Gram-negative bacteria. High-resolution crystal structures are also available, 
making it an ideal candidate for engineering NSAA-dependence across multiple species. In order to 
addict the protein to an unnatural amino acid, we sought core amino acids that would disrupt 
activity when replaced with 3-nitro-tyrosine (3nY) or 3-iodo-tyrosine (3iY). Using the Engineered 
Noncanonical Amino acid Beta-Lactamase (ENABL) variant, we could maintain a functional OTS 
and NSAA dependence in E. coli cells for more than 250 generations without detectable escape. In 
addition, ENABL allowed the retention of an OTS across a range of different bacterial species 
without modification of the host genomes (Shigella flexneri, Salmonella enterica, Yersinia ruckeri, 
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and Acinetobacter baylyi). Here, we describe the selection and modeling of ENABL and outline a 
methodology to addict diverse organisms to NSAAs. 
Results & Discussion 
Design of Library Positions 
Visual inspection of the structure (PDB: 1XPB) revealed potential sites, which were then 
scored on solvent accessibility or orientation to the inner core of the enzyme. Naturally, we omitted 
sidechains directly involved or immediately adjacent to catalytic or substrate binding residues. 
Using these guideposts, we identified 3 possible sidechains: F66, L162, and T189 (Figure 2-2). 
Mutant enzymes with Amber codons at these positions were then tested using the standard 
Methanocaldococcus jannaschii tyrosyl-tRNA synthetase:tRNA (MjYRS/tRNACUA) pairs, which 
incorporate tyrosine, 3nY, and 3iY. L162X and T189X both abolished activity in the presence of Y, 
3nY, and 3iY (Tack et al., 2016). 
Selection of Addicted TEM-1 Variants 
Having confirmed loss of activity with tyrosine, 3nY, and 3iY, we next designed libraries 
based off of positions L162 and T189. The 6 closest residues to each suppressed position were 
saturated (Figure 2-3) and selected on solid media supplemented with carbenicillin and either 3nY 
or 3iY. The L162 library was shown to be the most robust, having more than 95% of isolated 
clones still requiring the unnatural amino acid with the orthogonal translation machinery still intact. 
To mitigate reversion, 23 clones from this population were tested with leucine and tyrosine 
replacing the Amber codon. Only two of the clones were shown to have reduced resistance with the 
canonical solutions (MIC <1000 µg/mL carbenicillin; Fig. 1a, TEM-1.B9 and TEM-1.F2). We next 
determined if any other canonical solutions might exist at this position and found that TEM-1.B9 
activity could only be rescued by phenylalanine. It was subsequently shown that the OTS 
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machinery could be maintained for over 250 generations in E. coli and successfully inserted into a 
set of diverse bacterial species (Tack et al., 2016).  
Molecular Modeling of ENABL 
 To gain insight into how 3nY and 3iY were incorporated into ENABL, we turned to 
molecular modeling and simulation. Using the Molecular Operating Environment (MOE) software 
package, we prepared the published, 1.9 Å structure for simulation by protonating and energy 
minimizing the structure. Our corrected structure was inspected for anomalies and aligned against 
the reference structure (0.433 RMSD), giving us confidence that we had not significantly altered 
the empirically derived coordinates.  
 Due to the fact that 3nY and 3iY are noncanonical amino acids and are not currently found 
in state-of-the-art modeling programs, it was necessary to build rotamer libraries de novo. To do so, 
we employed short ~1 pS timescale molecular dynamics simulations on individual noncanonical 
amino acids at constant temperature (LowModeMD). Capped and free termini were used in 
generating conformational searches.  The AMBER:EHT forcefield was used with tethering to 
refine and score individual confirmations. Partial charges were scored using AM1-BCC. A total of 
10,000 iterations were used in creating the initial conformational library. Duplicates were scored by 
alignment to a common backbone (<0.3 Å) and removed. At this stage, having the rotamer library 
in hand allowed us to mutate residues in silica in a physics-based manner and rationalize key 
positions within the protein that shaped the enzyme’s addiction for the noncanonical amino acid. 
 We mutated F66, L162, and T189 in the context of the native residues to determine if any 
energy barriers might have been present in our initial experiments that would explain inactivity at 
those positions. This was also an interesting test case in that if modeling could predict the known 
site, then the methodology developed here might be more widely adopted for future addiction 
experiments. Consistent with our in vivo results, F66X was able to comfortably incorporate tyrosine 
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with a decrease (-15.2 kcal/mol) in potential energy of the system.  Meanwhile, severe steric 
clashes were observed with 3nY and 3iY along with large increases in potential energy (+40 
kcal/mol) of the system (Table 2-3). Additionally, the noncanonical amino acid substitutions 
resulted in the loss of a salt bridge among R43, E64, and the backbone carbonyl of R65   (Figure 2-
4), likely destabilizing the protein. Potential Energy differences alone do not explain T189X/Y 
inactivity. Rather, it appears as though a key hydrogen bonding network among D157, T160, and 
T189 is disrupted (Figure 2-5). Finally, in complete agreement with our in vivo screening, L162X 
resulted in large perturbations in potential energy of the system upon incorporation of Y, 3nY, or 
3iY (+35, +48, and +91 kcal/mol, respectively; Table 2-4) and were the least favorable 
substitutions in the context of native residues. 
 Given that our modeling at this stage was largely consistent with our experimental 
observations, we next sought to model ENABL in its final form. Using our corrected structure as a 
template, we made the following mutations to the enzyme: M68F, F72G, L139T, L152M, and 
L162X. Sidechains were repacked to allow for a robust conformational search of rotamers within 
the local environment and minimized in a 6 Å water sphere. In our final model of ENABL, which 
only deviated from our corrected structure by 0.627 Å RMSD (Figure 2-6), M68F is oriented 
above the noncanonical amino acid and appears to make a Π-stacking interaction with the aromatic 
ring of the noncanonical amino acid, perhaps stabilizing the structure of the enzyme. F72G makes 
room for the hydroxyl of the tyrosine analog, which hydrogen bonds to the backbone carbonyl of 
F72G. L152M is a conservative mutation that likely shapes the core to allow for the bulkier 
noncanonical amino acids. Interestingly, L139T is predicted to participate in a newly formed 
hydrogen bonding network with a water molecule and the orth- substituent in 3nY. Together, the 
hydrogen bonding observed due to these changes contributes -5.4 kcal/mol (Figure 2-7; Table 2-
5). A similar halogen bonding interaction may also be present in the 3iY variant. 
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 To determine if potential energy predictions could account for activity of canonical 
solutions at position 162, we mutated X162 with each amino acid in the context of the surrounding 
ENABL mutations (Table 2-6). The 3iY substitution was shown to decrease the potential energy of 
the system more than 3nY (-15 kcal/mol), despite 3nY conferring a higher MIC in our experiments. 
The only canonical solution to rescue NSAA dependence, phenylalanine,  slightly increased the 
potential energy by +1.5 kcal/mol. Tryptophan and tyrosine were unable to rescue dependence in 
our in vivo assays but were shown to possess some activity. Our simulations predicted that these 
two canonical solutions would lower the potential energy in the context of ENABL. X162R/Q/N/L 
were all shown to have lower predicted potential energies than 3nY. Given that some of these 
mutations were empirically shown not to confer resistance, we conclude that potential energy alone 
is not sufficient in predicting activity.  
However, the change in stability (ΔGs) of each mutation in the context of surrounding 
residues, which is calculated as a change in Gibbs free energy after mutating the protein 
(ΔGs=α[ΔEvdWf+0.5(ΔEcoulf+ΔEsolf)]+βESS+γΔΔGsolu+ϵΔδgly+ζΔδHis), more accurately predicted activity. Using 
ΔGs as a metric, we observed small differences between 3nY and 3iY at position 162 (0.77 
kcal/mol). W, F, and Y are each within 2 kcal/mol of 3nY. All other amino acid substitutions, 
empirically shown to be nonfunctional solutions, were found to be far less stable (+3.4 to +8.9 
kcal/mol) in the context of ENABL mutations. While the rank order did not perfectly match the 
empirical data, the values were clearly divided into functional and non-functional groups (Figure 
2-8). Below a change of +2 kcal/mol of PE, variants are functional. 
This was a somewhat surprising result in that molecular simulation was adequate in 
identifying functional solutions without empirical input. First, potential energy perturbations could 
predict candidate sites for selection. In the case of ENABL, both NSAAs were the most 
energetically unfavorable substitutions at position 162. Next, key contacts were identified in the 
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mutant enzyme that rationalized addiction at the molecular level. Finally, changes in stability of the 
enzyme upon mutation crudely predicted activity of enzymes without training data. Future in silica 
selections of neighboring residues adjacent to the NSAA may be useful in narrowing the number of 
potential enzyme variants to test or simplifying library design for traditional in vivo selections.  
Conclusions 
Our ENABL selection allowed us to maintain OTSs over a diverse set of bacterial species 
using expanded genetic codes. We were unable to detect escape after hundreds of generations of 
evolution. In addition, modeling proved useful in rationalizing our ‘blind’ engineering efforts. 
Taken together, our results provide a framework that could be extended to other enzymes. Having 
trained our modeling regiment on empirical data, it should now prove possible to develop other 
resistance markers, perhaps even addicting industrially relevant bacterial strains or eukaryotic 
organisms to NSAAs. For example, KanMX is a commonly used marker that confers resistance to 
various aminoglycosides, kanamycin in bacteria and geneticin (G418) in eukaryotes. 
Saccharomyces cerevisiae is a model eukaryotic organism and can be engineered to suppress 
Amber codons using heterologous OTSs. By performing in silica scanning mutagenesis at residues 
distant from the catalytic or substrate binding residues in KanMX, candidate sites for selection 
should be identifiable by perturbations in potential energy of the system. A similar selection 
mechanism outlined here could then be applied allowing for the generation of the first ‘addicted’ 
eukaryotic organism to an expanded genetic code. 
Materials and Methods 
Residue Selection and Library Design 
TEM-1 β-lactamase libraries were designed by manual inspection of the TEM-1 structure 
(PDB: 1XPB) using the molecular visualization program pymol (v1.3). For the L162 library, the six 
residues with side chains in closest proximity to the leucine side chain were selected for site-
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saturation (NNS) mutagenesis. These corresponded to residues M68, F72, L139, L148, L152, and 
L169. 
Molecular Modeling of TEM-1 Library Variants 
The wild-type structure of TEM-1 (PDB: 1XPB) was prepared for mutational analyses 
using the Molecular Operating Environment (MOE.09.2014) software package from Chemical 
Computing Group. The structure was inspected for anomalies and protonated/charged with the 
Protonate3D subroutine (310K, pH 7.4, 0.1 M salt). The protonated structure was then lightly 
tethered to reduce significant deviation from the empirically determined coordinates and minimized 
using the Amber10:EHT forcefield with R-field treatment of electrostatics to an RMS gradient of 
0.1 kcal mol-1 Å-1. Next, we created rotamer libraries for each non-canonical amino acid using a 
low-mode molecular dynamics (LowModeMD) methodology. Library positions of representative 
variants from the selection were mutated and repacked within the local environment. 
Conformational analysis of the loop was evaluated with LowModeMD. Mutated structures were 
then solvated with water and counterions in a 6 Å sphere and minimized to an RMS gradient of 
0.001 kcal mol-1 Å-1. 2-D contact maps of the non-canonical solutions were inspected with Ligand 
Interactions after arbitrarily setting the non-canonical amino acid to the ligand position. 
Measurements of stability and potential energy were scored within MOE. 
 
 
 
 
 
 
 53 
 
 
Figure 2-2: Potential sites for NSAA dependence 
 
Potential sites for NSAA dependence. Positions F66, L162, and T189 are highlighted. Each of these 
positions are solvent shielded and oriented away from catalytic and substrate binding residues. 
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Figure 2-3: Library positions for NSAA dependence 
  
 
Library positions for NSAA. Amber codons were inserted individually into positions 66, 162, and 
189 (green residues). The surrounding resiudes, highlighted in blue, were randomized using NNS 
codons. 
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Table 2-3: In silica analysis of position 66 
Mutation Stability dStability E dE 
1:F66R -9.49 4.19 -7276.66 -67.74 
1:F66N -9.20 4.48 -7245.39 -36.47 
1:F66W -12.78 0.90 -7230.97 -22.05 
1:F66T -9.79 3.89 -7227.16 -18.24 
1:F66Y -12.24 1.45 -7224.11 -15.19 
1:F66Q -9.75 3.93 -7214.48 -5.56 
1:F66V -10.74 2.94 -7210.51 -1.59 
1:F66F -13.68 0.00 -7208.92 0.00 
1:F66I -10.51 3.17 -7186.70 22.22 
1:F66E -8.78 4.90 -7183.55 25.37 
1:F66M -10.84 2.84 -7181.04 27.88 
1:F66K -8.41 5.27 -7180.66 28.26 
1:F66L -11.03 2.65 -7178.15 30.77 
1:F66H -5.91 7.77 -7173.41 35.51 
1:F66[(Niy)] -13.43 0.25 -7169.72 39.20 
1:F66[(Ioy)] -13.38 0.30 -7168.05 40.87 
1:F66S -8.63 5.05 -7167.85 41.07 
1:F66C -8.87 4.82 -7164.51 44.41 
1:F66D -7.90 5.78 -7153.32 55.60 
1:F66G -5.87 7.81 -7151.37 57.55 
1:F66A -8.87 4.81 -7149.83 59.09 
1:F66P -7.35 6.33 -7118.13 90.79 
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Figure 2-4: F66X breaks a salt bridge 
 
F66X breaks a salt bridge. Upon mutation, the increased size of the NSAAs cause a salt bridge to 
break between E64 and R43, depicted in blue. This potentially destabilizes the enzyme, causing it 
to become inactive. 
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Figure 2-5: T189X disrupts a hydrogen-bonding network 
 
T189X disrupts a hydrogen-bonding network. The NSAA at position 189 disrupts bonding with an 
aspartic acid at the end of neighboring helix. This library was the most unstable in our experiments, 
highlighting the importance of this interaction. 
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Table 2-4: L162X destabilizes TEM-1 
Mutation Stability dStability E dE 
1:L162R -11.31 2.01 -7386.37 -104.31 
1:L162N -10.35 2.97 -7322.01 -39.95 
1:L162Q -11.86 1.46 -7312.36 -30.30 
1:L162V -12.40 0.92 -7290.84 -8.78 
1:L162K -10.59 2.72 -7289.09 -7.03 
1:L162M -12.55 0.76 -7286.09 -4.03 
1:L162T -11.35 1.97 -7285.62 -3.56 
1:L162L -13.32 0.00 -7282.06 0.00 
1:L162G -7.79 5.52 -7277.13 4.93 
1:L162I -13.15 0.17 -7276.27 5.79 
1:L162E -10.58 2.73 -7276.18 5.88 
1:L162S -10.51 2.81 -7268.30 13.76 
1:L162C -10.91 2.41 -7262.32 19.74 
1:L162F -12.76 0.55 -7257.22 24.84 
1:L162A -10.86 2.46 -7250.96 31.10 
1:L162D -9.25 4.07 -7247.74 34.32 
1:L162Y -11.28 2.03 -7246.58 35.48 
1:L162H -8.51 4.81 -7244.50 37.56 
1:L162P -9.59 3.72 -7239.73 42.33 
1:L162W -13.37 -0.05 -7236.00 46.06 
1:L162[(Niy)] -13.10 0.22 -7233.73 48.33 
1:L162[(Ioy)] -13.21 0.11 -7190.76 91.30 
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Figure 2-6: Final ENABL model 
 
Final ENABL model. Representative structure of ENABL produced by MOE. Library positions are 
shown  in blue. A stabilized hydrogen-bonding network is observed between T139, 3nY162, and a 
water molecule. A total of -5.3 kcal/mol of stabilizing energy is added with this network. We 
hypothesize that a similar stabilizing interaction may be present with 3iY, presumably due to a 
halogen-bonding interaction. 
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Figure 2-7: 2D contact map of ENABL mutations 
 
2D contact map of ENABL. By setting the NSAA to a ligand, we were able to measure interactions 
to the amino acids using the LigandInteractions subroutine. Hydrogen bonding between the 
hydroxyl of the NSAA and G72 is predicted. Further, the nitro substituent makes contact with a 
bridging water, which is stabilized by T139. 
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Table 2-5: ENABL stabilization interactions 
Interaction Type Distance (Å) E (kcal/mol) 
1 H-donor 3.00 -2.1 
2 H-donor 2.87 -1.2 
3 H-acceptor 2.70 -1.0 
4 H-acceptor 3.04 -1.0 
  
Total -5.3 
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Table 2-6: In silica analysis of position 162 in the context of surrounding ENABL mutations 
Mutation Stability dStability E dE 
1:(Niy)162[(Ioy)] -16.90 -0.77 -88679.8 -15.80 
1:(Niy)162[(Niy)] -16.13 0.00 -88664 0.00 
1:(Niy)162W -15.96 0.17 -88667 -3.02 
1:(Niy)162F -14.21 1.91 -88662.5 1.51 
1:(Niy)162Y -14.14 1.99 -88675.9 -11.93 
1:(Niy)162I -12.75 3.38 -88651.1 12.93 
1:(Niy)162L -12.49 3.64 -88664.5 -0.49 
1:(Niy)162V -12.12 4.01 -88644.8 19.22 
1:(Niy)162M -11.88 4.25 -88631.5 32.50 
1:(Niy)162Q -11.58 4.55 -88693.4 -29.43 
1:(Niy)162R -11.38 4.74 -88759.9 -95.95 
1:(Niy)162T -11.23 4.90 -88645.3 18.70 
1:(Niy)162A -10.83 5.30 -88624.8 39.20 
1:(Niy)162C -10.82 5.31 -88628.4 35.61 
1:(Niy)162N -10.65 5.48 -88675.6 -11.59 
1:(Niy)162S -10.48 5.65 -88632.1 31.88 
1:(Niy)162K -10.10 6.03 -88634.8 29.22 
1:(Niy)162E -9.74 6.39 -88609.7 54.34 
1:(Niy)162P -9.41 6.72 -88600.4 63.63 
1:(Niy)162D -9.39 6.74 -88628.7 35.34 
1:(Niy)162G -7.79 8.34 -88626.9 37.13 
1:(Niy)162H -7.19 8.94 -88650.1 13.88 
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Figure 2-8: Change in stability of position 162 in the context of ENABL 
 
Change in stability of position 162 in the context of ENABL mutations. We measured the energy 
differences for each amino acid at position 162 (left). Consistent with our in vivo characterization 
(right), NSAAs dominated stability and activity. The canonical solutions were within 2 kcal/mol of 
ΔStability. Each amino acid above +2 kcal/mol was shown to be nonfunctional. 
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2.3 MOLECULAR MODELING OF RIFAMPICIN RESISTANCE IN ESCHERICHIA COLI USING 
EXPANDED GENETIC CODES 
Introduction 
In the previous section, we engineered a resistance marker to be dependent upon NSAA 
incorporation. Here, we investigate how genetic code expansion in E. coli influences evolution in 
the context of antibiotic resistance. Expansion of the genetic code with NSAAs changes not only 
the protein-coding potential of an organism but also the network topology of the code itself 
(Freeland and Hurst, 1998; Knight et al., 2001). For example, by recoding the Amber codon to a 
NSAA, a nonsense mutation is translated into a missense mutation. The connectivity of the code is 
fundamentally changed and in turn gives evolution more protein-coding options from which to 
explore. This property is in addition to the availability of a unique geometry or chemical potential 
of a particular NSAA. Taken together, it could be argued that NSAA expansion of the genetic code 
should make organisms more evolvable (Hammerling et al., 2014). 
Rifampicin is a polyketide antibiotic, commonly prescribed to treat Mycobacterium 
infections. The broad spectrum antibiotic inhibits the bacterial RNA polymerase, disrupting 
elongation of DNA-dependent RNA synthesis. Resistance is conferred by single mutations along 
the β-subunit of RNAP, which inhibit rifampicin binding by disrupting hydrogen-bonding 
interactions or sterically occluding the antibiotic. Crystal structures of the Thermophillus aquaticus 
RNAP and more recently E. coli RNAP bound to rifampicin have shed light on the mechanism of 
inhibition and modes of resistance at the molecular level (Campbell et al. 2001; Molodtsov et al. 
2013). Resistance has been well-characterized and shown to require a single codon mutation in 
amino acids located in three regions of rpoB, providing an easily tractable system for studying 
impacts of expanded genetic codes.  
In collaboration with Dr. Michael Hammerling, we sought to explain resistance mutations at 
the molecular level in E. coli rpoB in the context of standard and expanded genetic codes (Figure 
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2-9). Several spontaneous mutations at position 513 in ropB were observed and conferred 
resistance in strains lacking native Amber codons, but capable of incorporating NSAAs with 
functional OTSs. Further, using recombineering at Region 1 of rpoB (residues 509-533) 
(Hammerling et al., 2016), we found an additional number of single- and double-Amber mutations 
using a number of NSAAs. The modeling and impacts of these mutations on the rifampicin binding 
pocket are discussed in detail. 
Results & Discussion 
Molecular Modeling of RNAP Mutants 
We initially attempted to model the effects of 3-halo-substituted tyrosines on our 
computationally corrected structure by: (1) mutating Q513 to tyrosine, (2) adding the halogen 
substituent to the ring at the ortho position, and then (3) calculating the lowest conformational 
dihedral angles for optimal geometry of the newly formed noncanonical amino acid. We then 
superimposed rifampicin onto the mutated structure using coordinates from the crystal structure, 
optimized dihedral geometry again (Figure 2-10), and minimized the complex. We measured 
contact energies between rifampicin and the mutated structure and found positive energy values, 
representing unfavorable interactions or clashing between rifampicin and the sidechains. In 
contrast, the wildtype enzyme had -9.8 kcal/mol of contact energy (Tables 2-7). While this 
methodology proved useful in predicting binding or occlusion of the ligand in mutated structures 
(Table 2-8), the rotamer-by-dihedral methodology was slow and laborious; it was also unlikely to 
generate realistic sidechain conformations. Further, it was impossible to compare to native amino 
acids at that position using standard algorithms in a high-throughput manner.   
Instead, using the same methodology discussed in Section 2.2, we added rotamer 
conformations for 3-substitueted halo-tyrosines, 4-azidophenylalanine (AzF) and 5-
hyrdoxytrytophan (5HTP) to our nancanonical amino acid rotamer library. This allowed us to 
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quickly screen conformational space without visually inspecting dihedral angles and manually 
calculating contact or repulsion energies. It also allowed for physics-based solutions to 
conformational searches using validated forcefields alongside Extended Hückel Theory 
calculations. Having the additional rotamers also allowed us to use standard subroutines within 
MOE to make in silica measurements and comparisons across all sequence space. 
With our rotamer library updated to include the additional NSAAs, we investigated all 
possible amino acids, standard and noncanonical, at position 513 in an effort to full characterize all 
evolutionary possibilities at this position. By examining changes in the stability of the antibiotic-
bound complex in comparison to the energy minimized apo-reference structures, we were able to 
accurately predict all known resistance mutations from the literature and those found independently 
in the current study. Changes in the predicted stability of the RNAP-rifampicin complexes spanned 
nine orders of magnitude (Table 2-9; Figure 2-11). The larger values reflect the obviously 
insurmountable steric occlusion of the rifampicin binding pocket imposed by bulkier side chain 
substituents.  
In our simulations, rifampicin-resistant mutations display positive values in ΔΔG of 
complex stability, denoting large energetic barriers to binding. On the other hand, amino acids that 
are known to display susceptible phenotypes result in more favorable negative ΔΔG values for 
complex formation. For 3-iodotyrosine incorporated at position 513, our modeling predicts that the 
iodine atom attached to the aromatic ring of the side chain at the ortho position projects directly 
into the rifampicin binding pocket, completely abolishing binding (Figure 2-12). The other halo- 
and nitro-substitueted NSAAs followed with similar geometries. These results are consistent with 
the growth advantage observed in the presence of rifampicin of all ortho-substituted nsAA 
resistance mutants and tryptophan over tyrosine at this position, and further imply that the rotamers 
 67 
identified in our modeling experiments may be sufficient in explaining how these amino acids lead 
to faster-growing phenotypes (Figure 2-13A). 
We next sought to understand how the NSAA contributed to resistance in our spontaneous 
double-Amber mutants. These mutations were shown to require the OTS and noncanonical amino 
acids in our in vivo assays. Again, we modeled the rifampicin resistant variant and compared the 
stability of the ligand:enzyme complex to reference structures lacking rifampicin. We observed 
strong complex destabilization upon addition of the NSAAs. In each case, both NSAAs were 
predicted to occlude binding to rifampicin (Figure 2-13C, Table 2-10). Template-based docking of 
rifampicin into a library of conformational variants at each of these positions failed to produce 
productive binding complexes, giving way to the notion that there may exist some epistatic 
relationship among the NSAAs in the double-mutants.  
Conclusions 
This section revealed the ability of NSAAs to impart rifampicin resistance on the E. coli 
RNAP. Expanded mutational connectivity, enabled by the expanded genetic code, allowed us to 
observe the potential role of NSAAs and additional canonical amino acids solutions, tyrosine and 
tryptophan in bacterial rifampicin resistance. The canonical solutions were previously unobserved 
due to the distance between the wildtype glutamine (CAG) codon and the tyrosine (TAC/TAT) or 
tryptophan (TGG) codons. In our recombineering experiments, we found a number of double-
Amber mutations that lead to robust rifampicin resistance, which may point to so far unidentified 
epistatic relationships among these and other residues in the local environment. In both cases, our 
modeling accurately predicted known mutations at these positions and rationalized the molecular 
basis for rifampicin resistance in the context of standard and expanded genetic codes by measuring 
not only affinity of the mutated RNAPs but also complex stability. 
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Materials & Methods 
Molecular modeling 
The wild-type structure of E. coli RNA polymerase (PDB: 4KMU chains C and D) 
(Molodtsov et al., 2013) was prepared for mutational analyses using the Molecular Operating 
Environment (MOE.09.2014) software package from Chemical Computing Group. The structure 
was inspected for anomalies and protonated/charged with the Protonate3D subroutine (310K, pH 
7.4, 0.1 M salt) (Labute, 2009). The protonated structure was then lightly tethered to reduce 
significant deviation from the empirically determined coordinates and minimized using the 
Amber10:EHT forcefield with R-field treatment of electrostatics to an RMS gradient of 0.1 kcal 
mol-1 Å-1.  Next, we created rotamer libraries for each non-canonical amino acid using the low-
mode molecular dynamics method (LowModeMD) (Labute, 2010a). Library positions of 
representative variants from the selection were mutated and repacked within the local environment. 
The final model for each variant was further refined by placing the protein within a 6 Å water 
sphere and minimizing the solvent enclosed structure to an RMS gradient of 0.001 kcal mol-1 Å-1.  
Models were evaluated by calculating Phi-Psi angles and superimposed against the reference 
structure to ensure that the native fold was maintained (Clark and Labute, 2007). Measurements of 
stability, potential energy, and contact interactions on a fixed-ligand structure for each variant were 
scored within MOE using an apo structure with each substitution and no Rif present as a reference. 
Conformational variants of Rifampicin were created in 3-D within MOE. A database of 
conformations was then used to dock the small molecule to the models using induced fit and 
template similarity protocols using the empirically derived structure. Placement was scored with 
Triangle Matcher and rescored with London ΔG. Poses were refined with the Amber10:EHT 
forcefield with GVBI/WSA ΔG scoring. Candidate poses were then identified by inspecting polar 
contacts. Geometry optimization was carried out with MOPAC 7.0 using AM1. Conformational 
analysis of the bound structure was evaluated with LowModeMD (Labute, 2010a). RMSD values 
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from the reference structure were calculated. 2-D contact maps of were created with Ligand 
Interactions (Clark and Labute, 2007). 
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Figure 2-9: Expanded genetic codes grant access to more protein coding solutions at Q513 
 
Expanded genetic codes grant access to more protein coding solutions at Q513. (Top) In the 
canonical genetic code, the rifampicin-sensitive wildtype glutamine codon CAG (red) has 7 
possible point-mutational routes to rifampicin resistance, with the CAG→TAG and the 
CAG→CAA mutations being inaccessible due to lethality and rifampicin sensitivity, respectively. 
Of the 7 available mutants, only 4 are reported to confer rifampicin resistance, and only 1 is a 
transition mutation. (Bottom) Incorporating NSAAs at the Amber codon alters the network 
topology surrounding the CAG codon. It provides an additional transition mutation, which confers 
resistance in the cases we studied. In addition, it creates new mutational routes to the codons 
directly adjacent to the TAG codon, several of which have been shown to be resistant in this study. 
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Figure 2-10: 3iY rotamer-by-dihedral example 
 
3iY rotamer-by-dihedral example. We manipulated dihedral angles based on energy values to 
determine bond geometry. The NSAA is shown in blue. After adding the substituent to the 3 
position of tyrosine, we determined the lowest energy conformation of each bond. 
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Table 2-7: 3iY Clashing observed using rotamer-by-dihedral method 
# Chain Atom A Chain Atom B Distance (Å) 
Repulsion 
(kcal/mol) 
1 3:[4KMU.C]TYR 513 (CD1) 7:[4KMU.C]RFP 1401(O9) 2.45 1.59 
2 3:[4KMU.C]TYR 513 (CE1) 7:[4KMU.C]RFP 1401(C1) 2.64 1.38 
3 3:[4KMU.C]TYR 513 (CE1) 7:[4KMU.C]RFP 1401(C9) 2.74 1.38 
4 3:[4KMU.C]TYR 513 (HE1) 7:[4KMU.C]RFP 1401(O1) 2.35 2.90 
5 3:[4KMU.C]TYR 513 (HE1) 7:[4KMU.C]RFP 1401(C1) 1.33 2.52 
6 3:[4KMU.C]TYR 513 (HE1) 7:[4KMU.C]RFP 1401(C2) 1.38 2.52 
7 3:[4KMU.C]TYR 513 (HE1) 7:[4KMU.C]RFP 1401(N1) 2.5 3.55 
8 3:[4KMU.C]TYR 513 (HE1) 7:[4KMU.C]RFP 1401(C3) 2 2.52 
9 3:[4KMU.C]TYR 513 (HE1) 7:[4KMU.C]RFP 1401(C9) 1.91 2.52 
10 3:[4KMU.C]TYR 513 (HE1) 7:[4KMU.C]RFP 1401(C4) 2.42 2.52 
11 3:[4KMU.C]TYR 513 (HE1) 7:[4KMU.C]RFP 1401(C1) 2.38 2.52 
12 3:[4KMU.C]TYR 513 (CZ ) 7:[4KMU.C]RFP 1401(C9) 2.8 1.38 
13 3:[4KMU.C]TYR 513 (CZ ) 7:[4KMU.C]RFP 1401(C8) 2.26 1.38 
14 3:[4KMU.C]TYR 513 (CZ ) 7:[4KMU.C]RFP 1401(O2) 2.04 1.59 
15 3:[4KMU.C]TYR 513 (OH ) 7:[4KMU.C]RFP 1401(C9) 2.15 1.59 
16 3:[4KMU.C]TYR 513 (OH ) 7:[4KMU.C]RFP 1401(C8) 1.09 1.59 
17 3:[4KMU.C]TYR 513 (OH ) 7:[4KMU.C]RFP 1401(O2) 0.87 1.83 
18 3:[4KMU.C]TYR 513 (OH ) 7:[4KMU.C]RFP 1401(C7) 2.1 1.59 
      
Total 36.86 
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Table 2-8: Doubling rates and contact energies from rotamer-by-dihedral method 
 
Doubling Rate Computed Energies (kcal/mol) 
Amino Acid Media Rifampicin Contact PE 
3-I-Y 1.18 0.94 36.9 -74286 
W 1.03 1.03 29.6 -74293 
3-Cl-Y 1.13 0.97 26.6 -74286 
3-Br-Y 1.19 0.99 34.6 -74283 
NitroY 1.14 0.9 43.1 -74282 
Y 0.7 0.61 15.3 -74298 
Q 1.29 n.d. -9.8 -74301 
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Table 2-9: Q513 in silica site saturation measurements 
 
No Ligand Ligand 
Mutation Stability dStability Affinity dAffinity Stability dStability ddStability 
1:Q513Q -5.94 0.00 -11.81 0.00 -6.44 0.00 -0.50 
1:Q513A -5.80 0.13 -11.03 0.79 -6.40 0.03 -0.60 
1:Q513R -6.61 -0.67 -6.85 4.96 31.06 37.50 37.67 
1:Q513N -5.50 0.44 -11.59 0.23 -6.46 -0.02 -0.97 
1:Q513D -4.39 1.54 -11.35 0.46 -4.90 1.54 -0.51 
1:Q513C -5.57 0.37 -11.18 0.63 -6.38 0.06 -0.81 
1:Q513E -4.99 0.95 -11.26 0.55 -5.29 1.14 -0.30 
1:Q513G -3.22 2.71 -10.79 1.02 -3.35 3.09 -0.13 
1:Q513H -2.17 3.77 -11.49 0.33 -4.27 2.17 -2.10 
1:Q513I -7.48 -1.54 28.35 40.17 65.64 72.08 73.12 
1:Q513L -7.30 -1.37 -10.18 1.64 -5.68 0.76 1.63 
1:Q513K -4.77 1.17 -9.63 2.19 0.89 7.32 5.65 
1:Q513M -6.68 -0.74 -11.33 0.48 10.84 17.27 17.52 
1:Q513F -8.24 -2.30 -10.66 1.15 788.47 794.90 796.71 
1:Q513P -4.76 1.18 -11.25 0.56 54.06 60.50 58.82 
1:Q513S -5.36 0.57 -11.15 0.67 -6.09 0.35 -0.73 
1:Q513T -5.96 -0.02 -10.60 1.21 -5.81 0.62 0.15 
1:Q513W -9.62 -3.68 155500.35 155512.16 229975.84 229982.28 229985.46 
1:Q513Y -8.01 -2.07 -10.01 1.80 141.08 147.52 149.09 
1:Q513V -6.79 -0.85 -10.39 1.42 -3.99 2.44 2.80 
1:Q513[(Bry)] -9.21 -3.27 7.47 19.28 146098.07 146104.50 146107.27 
1:Q513[(Cly)] -9.14 -3.20 92.72 104.53 29136345.34 29136351.78 29136354.48 
1:Q513[(Ioy)] -9.49 -3.55 115.20 127.01 31955.80 31962.24 31965.29 
1:Q513[(Niy)] -8.08 -2.14 17.07 28.88 34162.07 34168.51 34170.15 
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Figure 2-11: Predicted changes in complex stability of Q513 site saturation 
 
Predicted changes in complex stability of Q513 site saturation . Bars represent ΔΔG values 
(kcal/mol) of protein stability calculated for the substitution of all 20 canonical amino acids and 4 
nonstandard amio acids substituted at position 513 of rpoB. The wild-type amino acid (Q) is 
indicated in red, along with known resistance-conferring amino acids (cyan) and amino acids of 
unknown phenotype (black). 3-iodotyrosine (IoY), 3-nitrotrosine (NO2Y), 3-bromotyrosine (BrY) 
and 3-chlorotyrosine (ClY) are modeled in addition to canonical amino acids. At the Q513 position, 
no amino acids with a negative ΔΔG as calculated in MOE have been observed to confer rifampicin 
resistance, and are assumed to be rifampicin-sensitive. All resistant mutants have a positive value 
of ΔΔG, with the nonstandard amino acids having the highest calculated values. Values are 
consistent with observed growth rates for tyrosine, tryptophan, and nsAA mutants at this position. 
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Figure 2-12: Q513X occludes rifampicin binding to rpoB 
 
Q513X occludes rifampicin binding to rpoB. Modeling of Q513 3-iodotyrosine mutant (blue) in 
complex with a superimposed rifampicin molecule (gold). Space-filling models of the sidechain 
and rifampicin are depicted. A heavy steric clash is shown between the residue and antibiotic, 
presumably conferring resistance by occluding rifampicin from the complex. 
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Figure 2-13: Double-amber mutants confer robust rifampicin resistance 
 
Double-amber mutants confer robust rifampicin resistance. (Left) Doubling times of RifR rpoB 
mutants incorporating nsAAs in the absence (blue) or presence (red) of Rif. Error bars represent 
95% confidence interval. The presence of Rif in the growth medium does not statistically impact 
the growth rate of any RifR mutants. (Middle) Wild-type rpoB in complex with Rif (gold). Residues 
514 and 526 are highlighted in blue. The orientation of the sidechains allows for a productive 
binding complex and inhibition of the enzyme. (Right) A double-amber mutant MJH227 (F514X, 
H526X) variant is shown with an overlay of Rif (gold) in the binding pocket. The occlusion of Rif 
from binding is achieved by steric occlusion involving the ortho-substituents of the nsAA. Rotamer 
exploration and docking failed to produce conformational variants that would allow for Rif: rpoB 
complex formation. 
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Table 2-10: Representative Double-Amber Mutation Binding Analysis 
Mutation Affinity dAffinity Stability dStability E 
1:F514F -11.4 0.0 -7.6 0.0 -21656.7 
1:F514[(Ioy)] 2.9 14.3 23.9 31.5 -21484.4 
1:H526H -12.1 0.0 1.7 0.0 -21614.8 
1:H526[(Ioy)] 2070.0 2082.1 118553899.4 118553897.6 645556290.0 
1:F514F,1:H526H -11.2 0.0 -5.5 0.0 -21606.9 
1:F514F,1:H526[(Ioy)] 2070.9 2082.1 118553892.1 118553897.6 645556290.0 
1:F514[(Ioy)],1:H526H 3.1 14.3 26.0 31.5 -21433.6 
1:F514[(Ioy)],1:H526[(Ioy)] 2085.2 2096.5 118553923.5 118553929.1 645556420.0 
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2.4 CHARACTERIZATION OF A NOVEL ANGIOGENESIS INHIBITOR AND VASCULAR DISRUPTING 
AGENT 
Introduction 
Evolutionarily conserved genetic traits often manifest in similar, obvious phenotypes. 
However, some phenotypes are nonobvious in distantly related organisms. Recently, the Marcotte 
laboratory developed a method that identifies conserved genetic modules among different species 
and found that lovastatin sensitivity in yeast and the regulation of blood vessel formation in 
vertebrates are controlled by conserved, distantly related genes (McGary et al., 2010). This 
somewhat surprising result gives credence to the notion that genes responsible for the maintenance 
of cell walls in yeast were later reconfigured to regulate vertebrate angiogenesis.  
Angiogenesis refers to the formation of blood vessels and is essential for organismal 
development and tissue repair. Malfunctions in angiogenesis lead to major physiological defects 
(Carmeliet and Jain, 2011; Folkman, 2007). Cancer cells are also nourished by angiogenesis, and 
focused studies on anti-angiogenic therapeutics have rapidly increased in recent years (Carmeliet 
and Jain, 2011; Folkman, 2007; Heath and Bicknell, 2009; Kerbel, 2008). Vascular disrupting 
agents (VDAs) are a new class of anti-vascular drugs that have given promise for fighting 
developed tumors. However, VDAs have not been approved for human therapy, although a small 
number are currently undergoing clinical trials (Hinnen and Eskens, 2007; Tozer et al., 2005). In 
previous work, the Marcotte laboratory identified Thiabendazole (TBZ) as a novel angiogenesis 
inhibitor and vascular disrupting agent. Interestingly, TBZ has been approved by the FDA for 
treating various infections not only affecting humans but many other distantly related organisms. 
Moreover, the Marcotte laboratory demonstrated that TBZ also slows tumor growth and decreases 
intratumoral vessel density in mouse xenograft models (Cha et al., 2012). 
Many VDAs bind endothelial tubulins, depolymerizing the microtubule cytoskeleton, and 
thus causing the vascular structure to collapse (Hinnen and Eskens, 2007; Tozer et al., 2005). TBZ 
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has been shown to work in a similar fashion on fungal infections of plants and animals. In fact, 
TBZ directly interacts with fungal tubulins and disturbs microtubule assembly (Davidse, 1986; 
Davidse and Flach, 1978). Thus, we hypothesized that TBZ might act in a similar or related fashion 
on human endothelial cells. Here we computationally assess TBZ binding to evolutionarily distant 
fungal and human tubulins. We present a model consistent with known resistance mutations in 
yeast and propose a molecular mechanism for anti-angiogenesis in TBZ-treated endothelial cells. 
Results & Discussion 
Sequence Alignment of Human β-tubulins 
TBZ has previously been shown to directly interact with purified tubulins in the nematode 
Ascaridia galli and the fungus Penicillium expansum and perturbs polymerization of these proteins 
(Davidse and Flach, 1978; Dawson et al., 1984). The mitotic inhibition by TBZ observed in the 
worm and fungal studies was not replicated on tubulin assembly from mammalian brains (Dawson 
et al., 1984). Tubulin dynamics and interactions with other accessory proteins have been shown to 
be largely dependent upon its primary sequence (Asakawa et al., 2006; Paluh et al., 2004). For 
example, many TBZ-resistant mutations have been found in fungi and worms. Among those 
mutants, a number of studies have reported that one single amino acid mutation (F200Y) in the -
tubulin is sufficient to confer TBZ resistance in worm and fungus (Jung et al., 1992; Kotze et al., 
2012; Lee et al., 2011; Paluh et al., 2004; Qiu et al., 2011; Schmidt et al., 2006). This conserved 
residue is positioned at the internal interface between two structural tubulin domains and is thus 
involved in inter-domain motion, which can cause conformational changes of tubulins and increase 
microtubule stability (Paluh et al., 2004). Notably, most -tubulins in vertebrates have tyrosine at 
this position whereas some eukaryotes, (e.g. fungi, worm, and Antarctic fish) inherently have 
phenylalanine (Paluh et al., 2004). 
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Vertebrate species have many β-tubulin isoforms, and their usage and expression varies by 
cell and tissue type. In humans Tubb1 is expressed constitutively over a range of cells and tissues; 
however Tubb3 is exclusively found in the brain and neurons (Leandro-García et al., 2010; 
Sirajuddin et al., 2014). Interestingly, the mitotic inhibition by TBZ observed in the worm and 
fungal studies was not replicated on tubulin assembly from mammalian brains (Dawson et al., 
1984). The specific roles of each tubulin isoform are not fully understood, but recent work show 
that sequence diversity seems to modulate binding affinity to tubulin-binding drugs, and shapes 
microtubule dynamics by interacting directly with molecular motors (Kavallaris, 2010; Sirajuddin 
et al., 2014). We hypothesized that some human tubulin isotypes might have the same amino acid 
as fungal tubulins at the position 200, and thus have increased susceptibility to TBZ. A multiple 
sequence alignment of human -tubulin isotypes to wild type and mutant -tubulin sequences of 
fission yeast indeed revealed that two human -tubulin isotypes, TUBB1 and TUBB8, have a 
phenylalanine at this position, while tyrosine is expressed in all other human -tubulins at this 
position (Figure 2-14).  
Molecular Modeling Predictions of TBZ Binding to Fungal and Human β-tubulins 
 Given the strong sequence conservation among β-tubulin isotypes and resistant phenotypes 
observed in some orthologs, we next sought to understand potential TBZ binding to both fission 
yeast and human isotypes at the molecular level. To do so, we employed molecular modeling and 
simulation. It was first necessary to create homology models, as high-resolution crystal structures 
of human and yeast versions of these proteins are not available. We searched the Protein Data Bank 
(PDB) for homologous structures and found 3UT5.B and 3N2G.D, corresponding to sheep brain β-
tubulin, to be suitable reference structures. A total of 625 models were made for each isoform of β-
tubulin and averaged to make each final model. Each model was: (1) encapsulated in a 6 Å 
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hydration sphere, (2) energy minimized using Amber10:EHT, (3) subjected to 2.5 ns NAMD 
molecular dynamics simulations, and (4) inspected for anomalies against the reference structure. 
 Using the Schizosaccharomyces pombe wildtype and the TBZ-restistant F200Y β-tubulin 
homology models, we employed MOE’s Site Finder application to determine potential binding sites 
of TBZ to the energy minimized structures. A total of 20 sites were identified in the wildtype 
structure with the most probable site including F200 ((Table 2-11; Figure 2-15). In contrast, the 
single F200Y mutation, observed to be TBZ-resistant, greatly reduced the size of this potential site 
(Table 2-12; Figure 2-16). Next, we performed an induced fit docking protocol with TBZ at this 
site to see if we could observe differences in the susceptible wildtype protein and the resistant 
F200Y mutant. The induced fit protocol allowed us the most flexibility in sampling conformational 
space in both variants. As expected, TBZ fit comfortably within the proposed binding pocket of the 
wildtype β-tubulin but was incapable of adopting a productive binding conformation in the F200Y 
mutant (Figure 2-17; Table 2-13). Further, we found that the orientation of TBZ bound to the 
wildtype protein perfectly matched computational predictions on parasitic β-tubulins binding 
benzimidazoles (Aguayo-Ortiz et al., 2013a, 2013b) and recent crystal structures of benzimidazole-
derivatives binding to bovine brain β-tubulins (McNamara et al., 2015). Template-based docking 
from the bovine structure yielded almost identical results to our previous induced fit docking 
experiments. In each case, the wildtype protein was shown to have productive binding energies, 
while F200Y was unable adopt a favorable conformation within the cleft and completely distorted 
the conformation of TBZ (Tables 2-14 and 2-15). 
Next, we measured polar contacts and clashing energies of TBZ to both fungal tubulins. We 
found that the wildtype β-tubulin bound to TBZ with -9.9 kcal/mol of favorable contact energy, 
whereas F200Y was shown to contribute +27.6 kcal/mol of repulsion energy (Figure 2-18; Table 
2-16). For the wildtype protein bound to TBZ, polar contacts are predicted to include E198 and 
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Q134. Arene-hydrogen interactions between the ligand and protein included contributions from 
F200, L250, and L253. For the F200Y mutant, repulsion was observed in our fixed ligand 
experiments, caused by TBZ making unfavorable contacts with Y200, F240, L250, and L253. From 
these data, it appears that the F200Y makes a hydrogen bond to E198 in the resistant mutant, thus 
constricting the pocket and occluding binding. 
Confident in our docking results with the fungal tubulin, we next sought to model all human 
β-tubulin isoforms and predict TBZ binding energies (Figure 2-19; Table 2-16). Using a quantum 
mechanically corrected TBZ:wildtype fungal tubulin complex as a template, we docked TBZ into 
the same pocket in each of the human β-tubulins and measured interactions between ligand and 
protein in superimposed structures. In agreement with our primary sequence driven predictions for 
binding at position 200 (phenylalanine for susceptible and tyrosine for resistant), only Tubb1 and 
Tubb8 were shown to allow binding in our docking studies and displayed favorable binding 
energies, -1.8 and -8.3 kcal/mol, respectively. The large difference in contact energy among these 
two isoforms can be explained by differences at position 198. In Tubb1, position 198 is an alanine. 
In contrast, Tubb8 has a glutamate, which is predicted to heavily contribute to the binding energy in 
all of our simulations where F200 and E198 are present. Thus, we believe that TBZ binding is 
stabilized by hydrogen bonding interactions with residues Q134 and E198 in the context of F200, 
which allows TBZ into the binding pocket. Taken together, strong TBZ binding is predicted in 
isforms containing: Q134, E198, and F200. From this model, we conclude that TBZ strongly binds 
Tubb8, may only weakly bind Tubb1, and does not bind the rest of the human β-tubulin isoforms 
(Table 2-16). 
Conclusions 
The conserved residues at positions 134, 198 and 200, which seem to determine 
thiabendazole susceptibility from yeast to humans, have also been shown to be essential for the 
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activity of many benzimidazoles in fungus (Koenraadt, 1992; Yarden and Katan, 1993). Since some 
benzimidazoles are reported to be effective for cancer therapy (Hammond et al., 2001; 
Mukhopadhyay et al., 2002), our modeling suggests that the composition of tubulin isotypes in 
cancer cells may need to be considered before treatment. Microtubule targeting agents have long 
been used as classical cytotoxic cancer drugs, but more recently, a number of studies have reported 
that at low concentrations, many of them also have anti-angiogenic properties (Bocci et al., 2002; 
Pasquier et al., 2005; Pourroy et al., 2006). Although some studies suggest that microtubule 
targeting agents at low concentration might increase microtubule dynamic instability specifically in 
endothelial cells (Pasquier et al., 2005; Pourroy et al., 2006), the cellular and molecular 
mechanism—how these drugs have the selective activity on endothelial cells—is not fully 
understood. Encouragingly, we expect that specific effect of thiabendazole on the cellular 
component in endothelial cells and on different human tubulin isotypes can be employed as a 
model to understand the general mechanism of anti-angiogenic microtubule targeting agents. 
Understanding the detailed mechanism of repurposed drug is important for extending these drugs’ 
therapeutic usage. This research provides a great example of using selective conservation of genes 
and modeling to determine the mode of action of a drug. 
Methods & Materials 
Molecular Modeling of β-Tubulins 
Homology models of human and yeast β-tubulins were constructed using two reference 
structures (PDB: 3UT5.B and 3N2G.D) (Barbier et al., 2010; Ranaivoson et al., 2012). The 
template was prepared using the Molecular Operating Environment (MOE.09.2014) software 
package from Chemical Computing Group. The structure was inspected for anomalies and 
protonated/charged with the Protonate3D subroutine (310K, pH 7.4, 0.1 M salt). The protonated 
structure was then lightly tethered to reduce significant deviation from the empirically determined 
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coordinates and minimized using the Amber10:EHT forcefield with R-field treatment of 
electrostatics to an RMS gradient of 0.1 kcal mol-1 Å-1.  Homology models of the wild-type yeast β-
tubulin were prepared by creating 25 main chain models with 25 sidechain samples at 298K (625 
total) within MOE. Intermediates were refined to an RMS gradient of 1 kcal mol-1 Å-1, scored with 
the GB/VI methodology, minimized again to an RMS gradient of 0.5 kcal mol-1 Å-1, and 
protonated. The final model for each variant was further refined by placing the protein within a 6 Å 
water sphere and minimizing the solvent enclosed structure to an RMS gradient of 0.001 kcal mol-1 
Å-1.  Models were evaluated by calculating Phi-Psi angles and superimposed against the reference 
structure. 
TBZ Docking 
Potential binding sites were evaluated using the Site Finder application and recent 
computational work on benzimidazole binding to parasitic β-tubulins . Conformational variants of 
TBZ were created in 3-D within MOE. A database of conformations was then used to dock TBZ to 
the wild-type homology model using induced fit and template similarity protocols. Placement was 
scored with Triangle Matcher and rescored with London dG. Poses were refined with the 
Amber10:EHT forcefield with GVBI/WSA dG scoring. Candidate poses were then identified by 
inspecting polar contacts. Geometry optimization was carried out with MOPAC 7.0 using AM1. 
Conformational analysis of the bound structure was evaluated with LowModeMD. 2-D contact 
maps of were created with Ligand Interactions. 
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Figure 2-14: Human β-tubulin Alignment 
 
Human β-tubulin alignment. Strong sequence conservation is observed in all human isoforms. Key 
positions for this study are 134, 198, and 200. Two human tubulins, TUBB1 and TUBB8, have 
phenylalanine at position 200 similar to the wild type fungal tubulin, while all other human tubulins 
have tyrosine, which corresponds to the tubulin from TBZ-resistant yeast. TUBB1 also differs from 
fungal and other human tubulins at position 198 (E198A). 
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Table 2-11: Wildtype Yeast Site Finder Statistics 
 
 
 
 88 
 
 
Figure 2-15: Wildtype yeast site finder locations 
 
Wildtype yeast site finder locations. The SiteFinder application within MOE was used to assess 
potential binding sites in the wildtype fungal β-tubulin. Alpha centers, red and white spheres, are 
depicted. Red denote potential hydrophilic atoms, and white denote potential hydrophobic atoms. 
F200, neighboring the largest pocket, is shown in blue for context. This pocket was used in 
subsequent docking studies. Statistics for sites shown here can be found in Table 2-11. 
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Table 2-12: Yeast F200Y Site Finder Statistics 
Site Size PLB Hyd Side
1 42 2.85 17 33 3:(THR23 HIS227 LEU228 SER230 ALA231 PHE270 PRO272 LEU273 ALA274 ALA275 ILE276 SER278 SER279 SER280 PRO358 LYS359 ASP360 LEU361)
2 20 0.72 2 14 3:(ARG156 PRO160 ASP161 ARG162 VAL193 GLU194 ASN195 SER196 ASP197 ARG251 PRO261 ARG262 HIS264)
3 19 0.69 12 21 3:(PRO272 SER280 PHE281 GLN282 ALA283 VAL284 ASP360 LEU361 LYS362 MET363)
4 20 0.57 3 20 3:(GLY10 GLN11 CYS12 ASN99 SER138 GLY141 SER176 ASP177 THR178 GLU181 TYR222)
5 24 0.56 8 21 3:(GLU3 ASN48 PHE51 ASN52 GLU53 ARG62 ALA126 CYS127 ASP128)
6 18 0.45 12 17 3:(SER239 GLU245 LYS252 LEU253 ASN256 MET257 ALA314 LEU316 LEU350 LYS351 ALA352)
7 7 0.29 10 19 3:(TRP101 TYR106 LEU187 HIS190 GLN191 GLU407 GLU410)
8 23 0.25 5 19 3:(GLN15 ALA18 ALA19 SER22 THR23 ASP223 HIS227 SER230 LYS359)
9 10 0.16 5 9 3:(PHE242 PRO243 GLY244 VAL353 CYS354 SER355 VAL356)
10 17 0.14 9 14 3:(LEU215 PRO272 LEU273 ALA274 SER278 SER279 SER280 PHE281 VAL284 ASP360 LEU361)
11 33 0.09 7 24 3:(MET1 ARG2 GLU45 ARG46 ASN48 VAL49 ASN247 SER248 ASP249 LYS252)
12 19 -0.13 12 18 3:(LEU68 TYR92 GLY93 GLN94 SER95 GLU108 GLU111 LEU112 ALA115)
13 15 -0.16 13 26 3:(GLN291 PHE294 ASP295 PRO305 ARG306 TYR310 VAL333 ASN337)
14 15 -0.19 5 6 3:(GLU205 ALA206 ILE210 ALA296 ASN297 VAL301 ALA302 ALA303 ASP304)
15 10 -0.51 4 19 3:(HIS307 GLY308 SER373 GLN375 GLU376 ARG379 GLN423 GLN426)
16 7 -1.15 6 7 3:(PHE389 ARG390 ARG391 LYS392)
17 5 -1.37 5 7 3:(GLN423 GLN424 GLU427 ALA428 ASP431 GLU432)
18 4 -1.57 4 11 3:(GLN291 GLN292 ASP295 ASN297 ASN298)
19 5 -1.69 8 12 3:(ALA271 PRO272 VAL284 GLU288 LEU289 GLN292 ASN298)
Residues
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Figure 2-16: Yeast F200Y Site Finder Locations 
 
Yeast F200Y site finder locations. The SiteFinder application within MOE was used to assess 
potential binding sites in the F200Yfungal β-tubulin. Alpha centers, red and white spheres, are 
depicted. Red denote potential hydrophilic atoms, and white denote potential hydrophobic atoms. 
Y200, the position of TBZ-resistance, is shown for context. In contrast the wildtype, this pocket is 
considerably smaller and does not allow TBZ docking (Table 2-12, Figure 2-18). 
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Figure 2-17: Wildtype yeast (Nda3) 3D Model and 2D Contact Map 
 
 
  
Figure 2-17. Left, wild-type yeast β-tubulin bound to TBZ. Right, 2-D contact map. Polar contacts contribute -9.9 
kcal/mol. 
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Table 2-13: Wildtype yeast induced fit docking of TBZ 
Pose S rmsd rmsd_refine E_conf E_place E_score1 E_refine E_score2 
1 -7.21 0.20 0.78 20.35 -65.04 -9.78 -27.90 -7.21 
2 -7.15 5.53 0.69 19.77 -74.50 -10.09 -25.25 -7.15 
3 -7.11 5.62 1.04 21.83 -65.20 -9.54 -26.64 -7.11 
4 -7.08 5.52 0.87 21.03 -67.68 -9.52 -24.44 -7.08 
5 -6.95 1.58 0.58 22.12 -65.14 -9.56 -25.61 -6.95 
6 -6.87 5.84 0.95 19.70 -57.47 -9.50 -23.99 -6.87 
7 -6.87 1.90 1.28 19.83 -58.92 -9.48 -24.49 -6.87 
8 -6.85 5.74 0.79 21.92 -57.94 -9.48 -22.60 -6.85 
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Table 2-14: Wildtype yeast template-based docking of TBZ 
Pose S rmsd rmsd_refine E_conf E_place E_score1 E_refine E_score2 
1 -1.07 7.45 1.60 49.16 -11.70 -7.32 32.45 -1.07 
2 -1.00 5.22 1.84 44.04 -11.44 -7.44 27.97 -1.00 
3 -0.90 7.24 1.29 51.13 -8.21 -8.12 34.40 -0.90 
4 -0.69 4.24 1.45 49.57 -9.33 -7.21 26.34 -0.69 
5 0.16 5.19 1.07 46.44 -14.27 -7.54 40.00 0.16 
6 0.60 5.18 3.12 53.73 -11.56 -7.48 42.84 0.60 
7 0.76 10.79 1.05 61.73 -8.30 -8.07 65.27 0.76 
8 1.67 10.69 0.81 70.74 -9.42 -8.41 76.12 1.67 
9 1.70 8.48 1.25 64.83 -9.86 -7.68 68.17 1.70 
10 1.81 9.06 0.57 62.10 -8.71 -9.91 70.72 1.81 
11 1.84 4.32 1.10 47.94 -12.64 -7.14 47.87 1.84 
12 2.30 8.29 1.05 80.35 -8.43 -7.95 74.57 2.30 
13 3.18 8.12 0.78 62.00 -8.38 -7.34 78.27 3.18 
14 3.89 7.89 1.07 59.92 -8.49 -8.69 84.22 3.89 
15 4.06 8.00 1.41 70.22 -8.86 -9.63 88.26 4.06 
16 4.37 10.54 0.67 58.71 -10.22 -7.84 92.19 4.37 
17 7.91 9.08 0.98 97.81 -8.56 -7.92 121.22 7.91 
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Table 2-15 F200Y Template Based Docking 
Pose S rmsd rmsd_refine E_conf E_place E_score1 E_refine E_score2 
1 20.28 2.98 2.46 96.63 -12.96 -6.26 215.64 20.28 
2 20.86 3.23 2.17 79.13 -15.25 -7.43 219.28 20.86 
3 21.11 2.65 2.31 96.37 -15.06 -6.30 223.52 21.11 
4 21.78 2.94 2.18 80.39 -12.75 -6.18 227.54 21.78 
5 29.35 6.07 1.24 101.64 -12.47 -6.44 292.03 29.35 
6 30.39 5.90 0.69 107.12 -10.82 -6.32 300.17 30.39 
7 31.85 6.14 1.14 96.91 -11.64 -6.68 313.67 31.85 
8 32.80 5.96 0.88 105.49 -13.39 -6.63 321.02 32.80 
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Figure 2-18: Yeast F200Y 3D Model and 2D Contact Map 
 
 
  
Figure 2-18. Left, F200Y yeast β-tubulin superimposed with TBZ.  Clashing residues shown in cyan. Right, 2-D contact 
map.  Constriction of the pocket leads to 27.6 kcal/mol of clashing energy to TBZ. 
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Table 2-16: TBZ contact energy and binding predictions to tubulin variants 
Model Contacts Predicted Binding 
nda_3 -9.9 +++ 
nda_3 F200Y 27.6 - 
hTubb1 -1.8 + 
hTubb2a 38.3 - 
hTubb2b 8.8 - 
hTubb3 11.4 - 
hTubb4a 2.6 - 
hTubb4b 18.3 - 
hTubb5 10.7 - 
hTubb6 12.3 - 
hTubb8 -8.3 +++ 
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Figure 2-19: Human Tubb1 3D Model and 2D Contact Map 
 
Figure 2-20: Human Tubb2A 3D Model and 2D Contact Map 
 
 
 
  
Figure 2-19. Left, Tubb1 bound to TBZ. Right, 2-D contact map. Contacts contribute -3.8 kcal/mol 
  
Figure 2-20. Left, Tubb2a superimposed with TBZ.  Clashing residues shown in cyan. Right, 2-D contact map. 
Constriction of the pocket leads to 38.3 kcal/mol of clashing energy to TBZ. 
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Figure 2-21: Human Tubb2b 3D Model and 2D Contact Map 
 
Figure 2-22: Human Tubb3 3D Model and 2D Contact Map 
 
 
  
Figure 2-21. Left, Tubb2b superimposed with TBZ.  Clashing residues shown in cyan. Right, 2-D contact map.  
Constriction of the pocket leads to 8.8 kcal/mol of clashing energy to TBZ. 
  
Figure 2-22. Left, Tubb3  superimposed with  TBZ.  Clashing residues shown in cyan. Right, 2-D contact map.  Constriction 
of the pocket leads to 11.4 kcal/mol of clashing energy to TBZ. 
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Figure 2-23: Human Tubb4a 3D Model and 2D Contact Map 
 
Figure 2-24: Human Tubb4b 3D Model and 2D Contact Map 
 
  
Figure 2-23. Left, Tubb4a  superimposed with  TBZ.  Clashing residues shown in cyan. Right, 2-D contact map.  Constriction 
of the pocket leads to 2.6 kcal/mol of clashing energy to TBZ. 
  
 Left, Tubb4b  superimposed with  TBZ. Clashing residues shown in cyan. Right, 2-D contact map. 
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Figure 2-25: Human Tubb5 3D Model and 2D Contact Map 
 
Figure 2-26: Human Tubb63D Model and 2D Contact Map 
 
 
 
Figure 2-25. Left, Tubb5 superimposed with TBZ. Clashing residues shown in cyan. Right, 2-D contact map.  Constriction of 
the pocket leads to 10.7 kcal/mol of clashing energy to TBZ. 
  
Figure 2-26. Left, human Tubb6 superimposed with TBZ. Clashing residues shown in cyan. Right, 2-D contact map. 
Constriction of the pocket leads to 12.3 kcal/mol of clashing energy to TBZ. 
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Figure 2-27: Human Tubb8 3D Model and 2D Contact Map 
 
 
  
 
  
Figure 2-27. Left, human Tubb8 bound to TBZ. Right, 2-D contact map. Polar contacts contribute -8.3 kcal/mol to TBZ 
binding. 
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Chapter 3: Resurfacing β-Glucuronidase Leads to Thermoswitchable 
Phenotypes in Bulk and Single-Molecule Experiments 
 
ABSTRACT 
In this chapter, we sought to employ the Rosetta suite of protein design tools to redesign the 
surface of β-glucuornidase (GUS), a model enzyme, to include only one solvent exposed cysteine 
per active monomer in order to site-specifically label the enzyme or attach it to surfaces using thiol 
chemistry. While comparing the activity and stability of resurfaced designs to the wild-type enzyme 
and serine controls in bulk assays at room temperature and 37˚C, we found a pronounced 
thermoswitchable phenotype in the resurfaced variants. We also show that the activity of the 
redesigned variants could be modulated with temperature in single molecule assays using a novel 
platform (SiMoA) developed at Tufts University. One rationally designed serine variant (C262) 
was shown to be completely inactive at room temperature but had near wildtype levels of activity at 
37˚C in both SiMoA and bulk reaction conditions. We show that Rosetta redesign variants are more 
prone to accessing inactive conformations after thermal pulsing, while serine containing variants 
retain elevated activities after a short temperature pulse. Taken together, we propose that the serine 
controls access the active conformation in an ‘irreversible’ manner, while the energy barrier 
between conformations in the Rosetta redesigns seems to favor the inactive state. This study 
highlights the significance of surface mutations on conformational dynamics and the activity of 
enzymes  
INTRODUCTION 
It is difficult to overstate the significance of enzymology in the last half century. The study 
of nature’s biological catalysts has contributed profoundly to our understanding of how life works 
at the molecular level and given us tools to probe deeper than early biochemists and biologists 
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could have possibly imagined (Zalatan and Herschlag, 2009). A profoundly important enzyme in 
this regard has been β-D-glucuronidase (EC 3.2.1.31). Though it catalyzes a seemingly simple 
reaction, the hydrolysis of a glycosidic bond, it has been used as a work horse in: plant molecular 
biology, microbiology, diagnostics, therapeutic design, and protein engineering for use in 
biotechnology. Perhaps now overshadowed by DNA/RNA polymerases(Broll, 2010), CRISPR/cas 
systems (Barrangou et al., 2007; Brouns et al., 2008), restriction enzymes, and green fluorescent 
protein (GFP), still β-glucuronidase (GUS) has been cited in over 10,000 PubMed articles. The 
impact this enzyme has had on molecular biology and biochemistry has been profound.  
GUS is a member of family 2 in the glycoside hydrolase-A clan and is found over an 
enormous range of taxa (Jain et al., 1996). In humans, β-glucuronidase (hGUS) is localized in the 
lysosome and is produced from the gusB gene. Its primary purpose is to degrade sulfated 
glycosaminoglycans, namely chondroitin sulfate and hyaluronic acid. Loss of function or 
significantly reduced production of the enzyme leads to Sly syndrome, a buildup of 
mucopolysaccharides throughout the body (Sly et al., 1973). In some disease states, it can be found 
in the cytosol. Escherichia coli also possess a GUS form, encoded by gusA. Although the purpose 
of the enzyme differs drastically, it shares 50% sequence homology with hGUS. The bacterial form 
is used to breakdown glucronidated carbohydrates, which are then shuttled into central metabolism 
for carbon source utilization (Arul et al., 2008). It is the bacterial form of the enzyme that has been 
widely used in molecular biology and biotechnology. 
The Chemistry 
GUS catalyzes the generic reaction shown in Figure 3-1. Upon binding of a β-D-
glucuronoside and water to the active site, the glucuronic acid moiety is cleaved, and an alcohol is 
produced. Products of the reaction retain their anomeric configuration (Wong et al., 1998). The two 
highly conserved glutamates participate in the reaction by a general acid/nucleophile mechanism. A 
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conserved tyrosine is suggested to recognize the carboxylic acid of the glucuronic acid through a 
hydrogen bonding network (Wallace et al., 2010). Early efforts of enzymologists to elucidate the 
reaction mechanism were thwarted by the lack of modern recombinant technologies and protein 
purification methods. However, these studies were not all in vein. 
Wang and Touster, as early as 1971, were able to show that a general acid-nucleophile 
mechanism was in operation by studying electronic effects of substituted substrates using Hammett 
plots and comparing reaction rates in deuterated water (Wang and Touster, 1972a). In a follow-up 
study in the same year, the authors studied the pH dependence of the reaction. They were able to 
accurately determine pH 5.1 as the optimum of the liver lysosomal isoform. Wang and Touster also 
correctly identified carboxylate groups as the functional groups partly responsible for catalysis. 
However, their model was not entirely accurate. They suggested that an histidine was responsible 
for the nucleophilic attack of the substrate (Wang and Touster, 1972b). 
In the modern era, sequence alignments of known hydrolases pointed to the conserved core 
as the catalytic residues (Henrissat and Bairoch, 1996). X-ray crystal structures(Jain et al., 1996; 
Wallace et al., 2010) and inhibition studies (Gebler et al., 1992) have also aided in our 
understanding of the two-step reaction mechanism (Figure 3-2). It has also been shown that an 
intact tetramer must be present in order for the enzyme to be active (Jain et al., 1996). 
 
Structural Characterization 
The first GUS structure solved was the human variant of the enzyme to 2.6 Å resolution 
(PDB 3LPF), using the multiple isomorphous replacement method (Jain et al., 1996). The structure 
was recently refined by Anumula to 1.7 Å (Figure 3-3). The initial structure revealed that human 
β-D-glucuronidase (hGUS) is a homotetramer, comprised of 4 identical 651 amino acid monomers, 
and exhibits ellipsoidal or asymmetric symmetry. The monomers of the enzyme are arranged in 
three recognizable domains: a barrel like structure with a jelly roll motif (22-223), an 
immunoglobulin-like domain (224-342), and the TIM barrel domain or (α/β)8.  
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The TIM barrel contains the active site of the enzyme, which is housed at the interface of 
opposing monomers. Each monomer of the enzyme has the catalytic core, meaning there are 4 
active sites in each functional tetramer. hGUS also has a lysosomal targeting domain (179-199), 
which is thought to help localize the enzyme in the lysosome. Another feature of the structure, 
supporting lysosomal targeting, is the β-hairpin found between residues 184-204 (Jain et al., 1996).  
In a study designed to probe the effects of glucuronidase inhibitors to alleviate toxicity from 
chemotherapeutic agents, Redinbo and coworkers solved the crystal structures of native and 
inhibitor-bound enzyme to 2.39 Å resolution (Figure 3-4) (Wallace et al., 2010).  
Like hGUS, the E. coli’s version has the three recognizable domains (TIM barrel, immunoglobulin-
like domain, and jelly roll motif). Workers used molecular replacement,  
based on hGUS to solve the structure. The bacterial and human forms of the enzyme share an 
astonishing 50% identity, including the catalytic core (2 glutamates and a tyrosine). A minor 
difference between the two forms is that each monomer of bacterial GUS is 603 amino acids in 
length, rather than 651. Another important distinction is that bacterial GUS lacks the lysosomal 
targeting domain.  
Structural studies can aid in the understanding of underlying reaction methods. Careful 
examination of bound and unbound structures can give mechanistic insight in cases where 
mutagenic studies fail or rate constants are too fast or elusive to measure by direct methods. In 
bacterial GUS, we see a very small change in the structure of the enzyme upon substrate binding 
(Figure 3-4). Only careful analysis of the structure reveals any fluidity or change in the enzyme’s 
conformation. The most drastic effects can be seen with the tyrosine residues in the active site. 
Beyond the ~14 Å shift of these residues, a mild shift (~7 Å) can be seen in a β-sheet distal from 
the active site. These small structural changes upon substrate binding may dampen signals 
generated in modern enzymological techniques. 
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Molecular Biology & Biotechnology 
Gus Reporter System 
A landmark in the field of plant molecular biology was the use of GUS as a reporter gene in 
higher plants. The GUS-fusion system, developed by Jefferson during his tenure as a graduate 
student (Jefferson et al., 1987), has been the most utilized tool in transgenic plant research to date 
(Miki and McHugh, 2004). Due to GUS’s stability and relatively low toxicity levels, it has been a 
tried and true tool for plant molecular biologists since its inception. While other reporters have been 
developed, GUS-fusions remain in use today. A major advantage to the GUS system is that it does 
not require any specialized equipment. Instead, once GUS is co-expressed with its target promoter, 
a colorimetric substrate (5-bromo-4-chloro-3-indolyl-β-D-glucuronic acid) can be seen with the 
naked eye (Xiong et al., 2012). 
A major disadvantage to the GUS-fusion system is that, unlike previously thought, not all 
higher-ordered plants lack an active glucuronidase. This challenge has partly been overcome by 
engineering a GUS variant to withstand temperatures outside of the host’s enzyme thermal 
tolerance (Xiong et al., 2011a).  Unfortunately, this system cannot be used in most vertebrates or 
molluscs because these organisms have fully functional GUS forms (Jefferson, 1993). 
 
Therapeutics 
hGUS has been involved in many studies involving therapeutic strategies for several 
diseases. Antibody dependent enzyme pro-drug therapy (ADEPT) is one example of an avenue that 
has been explored with the enzyme (Carter, 2001). This method involves the fusion of a 
monoclonal antibody to a recombinant form of GUS. Once the antibody has found its target, the 
attached enzyme is able to cleave the glucuronidated pro-drug into an active form (Haisma et al., 
1998). In this approaches, the drug is inactive until the glucuronic acid is cleaved. 
Another therapeutic strategy involving a similar mechanism is to use localized host hGUS 
at the site of a tumor. Due to hGUS’s overproduction in some forms of cancers, which leads to it 
leaking out of the lysosome, again glucuronidated pro-drugs have been employed. This novel 
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method takes advantage of the overproduction because healthy cells do not generally have hGUS in 
the cytosol. An apparent advantage is that toxicity effects, generally seen in the parent drug, are 
largely nullified by the near target-specific manner in which the drug is delivered. Epirubicin-
glucuronide was > 10,000 times less toxicity by glucuronidating a chemotherapeutic agent. 
However, there are limitations to this strategy. With some pro-drugs, including 9-amino-
camptothecin, the pro-drug is cleaved by E. coli in the gut and toxicity levels increase to parent 
drug levels (Graaf et al., 2002). 
  
Diagnostics 
Bacterial GUS has been fused to monoclonal antibodies for use in enzyme-linked immuno 
sorbent assays (ELISA). In an ELISA colorimetric or fluorigenic substrates are used to determine 
whether or not the antibody is attached to its antigen. In several commercially available kits, GUS 
is used as the enzyme for the reaction. In others, GUS is the target, due to the increased GUS 
activity in several disease states. Falk and coworkers developed a GUS-based ELISA for the 
detection of 2-hydroxyesterone/16α-hydroxyesterone (Falk et al., 2000). Mackenzie also used GUS 
to develop an urinary immunoassay to detect a metabolite of chlorpyrifos (MacKenzie et al., 2000). 
 
Protein Engineering 
Directed evolution has proven to a useful tool for an array of biotechnological applications 
(Dalby, 2003; Tobin et al., 2000; Xiong et al., 2012). Once again, GUS has been utilized as a model 
enzyme in this regard. A significant portion of solved structures and known sequences of enzymes 
are built on the TIM barrel motif. Enzyme engineers have used GUS as a starting point to overcome 
various user-defined challenges by incrementally selecting variants from a library of mutants 
(typically  ~108) in as little as weeks (Rowe et al., 2003). Protein engineers have evolved GUS to: 
be thermostable (Flores and Ellington, 2002; Xiong et al., 2011b); change its surface chemistry to 
resist glutaraldehyde and formaldehyde (Matsumura et al., 1999); and shift its pH profile and 
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change its substrate specificity (Geddie and Matsumura, 2004; Matsumura and Ellington, 2001). In 
the current work, we resurfaced GUS to allow for single-site conjugation using thiol chemistry. 
 
RESURFACING GUS FOR CONJUGATION TO SURFACES 
In order to direct the orientation of bacterial GUS relative to surfaces, we sought to come up 
with a general method for identifying a single conjugation site in the enzyme.  Thiol chemistry is 
well-known for site-specific labeling of proteins for use in a variety of downstream applications (1–
3).  The introduction of single cysteines into the surfaces of proteins has previously been largely 
empirical.  To develop a more generalized method for generating single-cysteine variants, we 
sought to use the Rosetta suite of protein design tools (4) to remove all but one cysteine from the 
surface of a commonly used reporter protein, beta-glucuronidase (5).  This was an especially 
interesting problem as there are six cysteines per monomer within the GUS tetramer. Additionally, 
serine only controls were constructed, expressed, and assayed for activity. When the variants were 
tested for activity at RT and 37°C, several variants demonstrated a significant increase in activity at 
37°C in bulk and at the single molecule level. Single molecule experiments revealed reversible or 
irreversible thermal switching properties of a fraction of the population for these variants. 
 
RESULTS & DISCUSSION 
Rosetta computational resurfacing of β-glucuronidase 
All six of the surface-exposed cysteines were identified by visual inspection of apo- and 
inhibitor-bound structures (PDBs: 3K4D & 3K46).  Thus, in order to limit surface reactivity, five 
cysteines had to be removed.  The systematic removal of the surface-exposed residues was 
accomplished by employing a fixed backbone design methodology using the Rosetta 3.4 protein 
modeling and structure prediction software package. The program was used to assess the impact of 
altering these residues on the overall stability of the enzyme.  First, the crystal structure was 
relaxed, and sequence optimization simulations were performed on five of the six solvent-exposed 
cysteine residues at once to determine the most favorable residues to mutate. All combinations of 
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cysteine replacement were evaluated 100 times. We identified mutations at positions C133 and 
C262 to be the most destabilizing. Thus, designs were optimized using these two positions as single 
attachment points with all other residues allowed to adopt alternative identities and rotamer 
conformations during energy minimization. Designs were scored for their overall structural stability 
using the Rosetta all atom score function. Four of the designs exhibiting the most stable properties 
were chosen for expression and analysis (D1-D4).  
In three of the four Rosetta designed GUS variants (Designs 1-3), Cys28, Cys133, Cys197, 
Cys253, and Cys527 were mutated while Cys262 was conserved in order to enable chemical 
conjugation (Figures 3-5 and 3-6). In the fourth re-designed GUS variant (Design 4), Cys28, 
Cys197, Cys253, Cys262, and Cys527 were mutated while Cys133 was maintained (Fig. 1C). 
Residues Cys443, Cys449, and Cys464 were deemed to be buried or mostly buried within GUS, 
and not considered to be able to undergo cysteine conjugation chemistry, so were therefore not 
candidates for mutation (Table 3-1).  
Mutations in all four Rosetta re-designs were chosen to optimize overall GUS protein 
stability, as measured by the Rosetta energy score. All re-designs were predicted to be more stable 
than the wildtype GUS enzyme, and furthermore mutations in the designs were compatible with the 
overall surface properties of the GUS enzyme. In Designs 1 and 4, C28 was mutated to Lys, while 
in Designs 2 and 3 the residue was mutated to Leu. Both of these mutations extend existing patches 
of either positive charges or hydrophobic atoms that are adjacent to residue 28 on the GUS surface. 
In all designs where C133 and C197 were allowed to mutate, both residues were mutated to Asp, 
connecting to a slightly negative patch adjacent to each residue. (Fig 1E-F). Lastly, residues C252 
and C527 were mutated to match a small, slightly hydrophobic surface patch in each Rosetta re-
design.  
 
Bulk characterization of GUS variants reveals temperature switching activity 
We tested these designs for bulk activity using four commercially available substrates in 
endpoint assays (Figure 3-7). Activity was observed using each of the substrates with 4-
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methylumbelliferylglucuronide (4-MUG) giving the most robust results.  In each case, D4 was 
found to be the most active of the variants. Using 4-MUG, D4 exhibited nearly 60% of activity 
when compared to the wildtype enzyme, and we therefore decided to use 4-MUG in subsequent 
bulk characterization of the enzyme variants.  
We next examined timecourse kinetics and observed a lag in activity of the Rosetta-
designed variants at 22˚C (RT) (Figure 3-8). We hypothesized that this lag may be overcome by 
thermally perturbing the enzyme as it was unlikely that the resurfaced enzyme would now adopt a 
cooperative mechanism. Our rationale was that the designed enzymes may need kinetic energy to 
surmount an energetically unfavorable or slow conformation caused by the resurfacing mutations. 
Consistent with this prediction, we found that increasing the temperature abolished the lag in 
temperatures above 30˚C (Figure 3-9). We found that the optimal temperature for each of the 
designed variants matched the wildtype thermal preference (between 35-40˚C) (Figure 3-10).  
We then compared these properties to a “dumb” all-Serine replacement re-design (S1-GUS) 
and two single cysteine variants, C133 and C262. S1-GUS is a rational re-design of the GUS 
enzyme surface, wherein all surface cysteine residues were mutated to serine, a rational re-design 
choice for cysteine replacement on the surface of a protein. C133 and C262 are also serine variants 
where a single cysteine is incorporated at the given position. Thus, we were able to compare GUS 
enzyme thermostability and activity (Figure 3-11) between computational re-designs and “rational” 
re-designs. All resurfaced GUS variants showed a decrease in thermostability of ~8˚C (Table 3-2). 
Looking at initial rates, we found that the wildtype exhibited a normal rate vs substrate curve that 
could be fit the Michaelis-Menten equation at 22˚C or 37˚C. Rosetta designs displayed a lag at 
22˚C, but could be fit to the Hill equation. Suprisingly, C133 and C262 were both almost 
completely inactive at 22˚C but regained near wildtype activity at 37˚C (Figure 3-12). This 
suggests that the serine controls are more destabilized at room temperature, but are capable of 
surpassing an energy barrier to productive catalysis at the elevated temperature. 
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Single-molecule experiments confirm temperature switching activity 
The Walt laboratory at Tufts University has pioneered the use of single-molecule arrays 
(SiMoA) in femtoliter reaction chambers (Figure 3-13). In these assays, low concentrations of 
enzyme and substrate are sealed and monitored with a detector through a fiber optic bundle. 
Product is incapable of diffusing through the sealant, and thus, through use of a Poisson distribution 
of enzyme, single enzyme activities can be measured. This technology has been applied to a 
number of single-molecule enzyme studies (Gorris and Walt, 2009; Rissin and Walt, 2006; Rissin 
et al., 2008). 
The Walt laboratory then performed single molecule experiments for all of the GUS 
variants at 22˚C and 37˚C. Each enzyme was diluted to 1 pM and sealed within the optical fiber 
wells. Resorufin-glucuronide was used in these studies because the optical properties of SiMoA do 
no accommodate the use of 4-MUG, the substrate used in bulk experiments in the previous section. 
In each of these single-molecule experiments, 250 µM substrate was used in order to reduce 
background fluorescence of this molecule and determine reaction rates. Histograms of typical 
single molecule velocities at room temperature and 37˚C are shown in Figure 3-14. The single 
molecule velocities were largely in agreement with observations from bulk experiments. For each 
variant, a velocity increase of ~3-6 fold was observed at 37˚C with the exception of C262. For this 
variant, we observed roughly a 206-fold increase in the rate of the reaction (Table 3-3). This result 
was consistent with our bulk measurements using 4-MUG as a substrate in our initial rate 
experiments where we did not observe any activity over background with this variant. 
We next sought to compare activities of individual enzymes at room temperature and 37˚C 
in the context of shifting the temperature or briefly pulsing the enzymes with an elevated 
temperature (Figure 3-15). In the temperature shift experiments, activities of variants could be 
measured before and again after the target temperature of 37˚C was reached. Activity was measured 
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for 5 minutes at room temperature before ramping. We observed that the rates of individual 
enzymes increases for single molecules of the wildtype enzyme, although a significant correlation 
could not be determined (Spearman coefficient = 0.3, p<0.005) (Figure 3-16). We interpret these 
data to suggest that conformational changes were not needed to access a productive catalytic state 
as the number of active enzymes did not change after shifting the temperature.  
In contrast, Rosetta designed variants showed a significant increase in activity after the shit 
as well as an increase in number of active enzymes. In particular, D2 and D4 increase single-
molecule activities by 13.2 and 10.9-fold, respectively (Figure 3-17). For these variants, several 
inactive enzymes at room temperature also gained activity after the shift (plotted as <0 on the x-
axis). Nearly 20% of D2 and D4 enzymes gain activity at the elevated temperature. This effect was 
more pronounced in the C133 and C262 controls where over 90% of enzymes gained activity after 
the temperature shift. We interpret these results in a framework that supports our conformational 
shift hypothesis from the lab observed in our single trace bulk experiments. 
In order to determine if the temperature switchable phenotypes observed in our studies were 
reversible, we conducted thermal pulse experiments. Here, the increase to 37˚C is transient, lasting 
only 2 seconds. After the pulse, the temperature is cooled and  held constant at room temperature. 
Measurements are made before and after the pulse. Surprisingly, many of the Rosetta enzymes lost 
activity after the heat pulse, which resulted in a reduced average activity. On the other hand, C133 
and C262 gained and sustained activity after the pulse (Figure 3-18). These data suggest that the 
thermal switch behavior may be irreversible, or functionally so, in the timescales tested here. It 
could also be that once the active conformation of the enzyme is reached, it is energetically 
unfavorable to traverse back down the less active conformation.  
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Transition state modeling of GUS variants reveals differences in complex stability 
In an effort to understand the rational and Rosetta designed mutations, we attempted to 
model the transition state with MOE using PDB: 3K4D, the wild-type GUS:inhibitor bound 
structure, as a starting point. We simulated the effects of mutations on the tetramer. In total 44 
structural issues were identified and corrected in the initial structure file from the Protein Data 
Bank. These included: 2 alternate occupancy issues, 8 termini breaks or gaps, 24 atom clashes and 
4 cis-amide issues. The break between residues 362 and 370 was built by homology modeling. The 
final prepared structure was protonated at pH 7.4 and 310K. A total of 1304 ionizable groups were 
protonated for optimal hydrogen bonding in the tetrameric structure. Inspection of the Phi-Psi plot 
indicated proper geometry without any outliers present, and all atom clashing was relieved upon 
minimization with the Amber10:EHT forcefield to an RMS gradient of 0.001 kcal/mol/Å2. Mild 
perturbation from the uncorrected structure could be seen in the RMSD between structures with 
surface mutations present in the Rosetta and rational designs.  
To model the transition state, we docked resorufin glucuronide into the active site of each 
monomer and formed a covalent adduct with the catalytic glutamate. A total of 100 poses were 
generated and evaluated with the binding of the inhibitor present in the wild-type structure. Final 
geometries were calculated using an all-atom QM minimization with Guassian09. The structure 
was then subjected to 10 ns of molecular dynamics using NAMD 2.9. The lowest energy structure 
was then used as a basis for in silica mutational analysis (Figure 3-19). In silica measurements of 
stability were then made by saturating each surface-exposed cysteine with all 20 canonical amino 
acids (Table 3-4). We summed each stability score for each of the variants. Interestingly, the all-
serine mutant was shown to be the least stable (-46.1 kcal/mol), consistent with our thermal melt 
measurements in bulk. The wildtype enzyme was shown to have a sum of -61.7 kcal/mol of 
stability. Rosetta designed mutants were less stable (-52.6 to -53.4 kcal/mol) than the wildtype, but 
more stable than the all serine control. C133 was more stable than all of the Rosetta designs and 
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serine controls but less stable than the wildtype (Table 3-5). It may prove useful to build variants 
predicted by MOE to be the most stabilizing at each of the positions using the transition state model 
presented here. 
Conclusions 
Here we observed the effects of temperature on activity of resurfaced β-glucuronidase 
variants in bulk reactions as well as at the single molecule level using SiMoA, a novel platform 
developed by the Walt laboratory. Using two methodologies with two different fluorescent 
substrates, we were able to observe thermally switchable phenotypes in Rosetta and serine 
resurfaced mutants. The most pronounced changes in activity were observed with C262, the variant 
with a single cysteine on the surface at position 262 whereby all other cysteines had been mutated 
to serine. For the two serine variants, C133 and C262, the temperature switching in activity 
appeared to be irreversible on the timescales tested here. That is, the activity was sustained after 
pulsing. The Rosetta variants did not display this behavior. In fact, many of the Rosetta enzymes 
lost activity after the pulse.  
These results suggest that the enzymes tested here occupy at least two distinct, thermally 
accessible states, active and inactive conformations—though a continuum of these extremes is 
likely. More detailed kinetic studies could potentially elucidate which of the steps along the 
reaction coordinate are affected by the surface mutations. This study also highlights the fact that 
amino acids at the surface of proteins contribute more than just a hydrophilic shell with which to 
interact with an aqueous environment. While substrate channeling on surfaces has been shown, we 
are unaware of any studies that have shown resurfacing to drastically change bulk and single-
molecule activities of enzymes at moderate temperature changes. Single cysteine replacements may 
point to key positions that lead to the thermoswitchable phenotype. Further, it will be interesting to 
test if this is a general phenomenon within structurally-related enzymes. For example, β-
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galactosidase (lacZ) is a closely related enzyme that has a comparable number of cysteines on the 
surface.  
MATERIALS AND METHODS 
Cloning and purification of GUS variants 
Escherichia coli TOP10 and BL21 (DE3) (Invitrogen) strains were used for cloning and 
expression, respectively. Strains were maintained on either LB or 2XYT growth media. WtGUS, 
Rosetta-designed variants (D1-D4), an all-serine variant (S1), C133, and C262 were cloned into the 
pET28+ vector using the Gibson Assembly method. An N-terminal His6-tag was fused to all 
enzymes for affinity purification. Overnight cultures of BL21 (DE3) harboring each of the GUS 
variants were grown in LB at 37°C. Cells were then diluted into Terrific broth. Protein production 
was induced with 1 mM IPTG at 18°C for 20 hrs. Cells were lysed in 50 mM phosphate, 20 mM 
imidazole, 500 mM NaCl, pH 7.4 and cleared cell lysate were purified over NiNTA resin (GE 
Healthcare). Proteins were eluted with 50 mM phosphate, 500 mM imidazole, 500 mM NaCl, pH 
7.4 and further purified over a Sephadex 16/60 size exclusion column (GE Healthcare), 
concentrated, and dialyzed against 50 mM phosphate, 1 mM DTT, pH 7.4. Aliquots of each 
enzyme were flash-frozen in liquid nitrogen for downstream testing. Enzyme concentration was 
determined by the BCA method (Pierce). 
Rosetta protein redesign  
The structure of the E. coli  β-Glucoronidase protein (PDB code 3K4D) was analyzed for 
number and placement of surface cysteine residues, both visually and computationally using a 
nearest-neighbor count of the number of atoms surrounding each cysteine residue sidechain atom 
(reference supercharge paper). Six solvent- exposed, potentially reactive, surface cysteine residues 
were identified. Mutations to surface cysteine residues on GUS were probed using the Rosetta 3.4 
protein modeling and structure prediction software package.  The program was used to assess the 
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impact of altering these residues on the overall stability of the enzyme.  The crystal structure was 
relaxed, and sequence optimization simulations were performed on five of the six solvent-exposed 
cysteine residues at once, with amino acid sidechains allowed to adopt alternative identities and 
neighboring side chains free to adopt new sidechain conformations. All sidechains were energy 
minimized. All combinations of five groups of cysteines redesigned at a time with one cysteine 
remaining unchanged were attempted 100 times. Designs were scored for their overall structural 
stability using the Rosetta all atom score function. Four of the designs exhibiting the most stable 
properties were chosen for expression and analysis. Rosetta flags: Rosetta relax flags: 
./relax.[version][release] -database <path>/rosetta_database -in:file:s  3K4D.pdb -in:file:fullatom -
relax:fast -nstruct 100 -ex1 -ex2 Rosetta fixed backbone design flags: ./fixbb.[version][release] -
database <path>/rosetta_database -s <3K4D.pdb> -resfile <resfile> -ex1 -ex2 -nstruct 100 -
minimize_sidechains 
Enzyme activity measurements 
Enzyme activities were measured in 96-well plate format in GUS buffer at 37°C in a Tecan 
M200 Pro plate reader. Initial rates of enzyme with varying concentration of 4-methylumbelliferyl 
glucuronide) were plotted using SigmaPlot to determine kcat, Km and kcat/Km. Product formation 
was monitored by fluorescence (ex. 365/em. 455) and compared to a 4-MUG standard curve. 
Activity was also measured on a temperature controlled fluorimeter in 1 mL volumes from 15-65°C 
in 5°C increments and in pH increments of one unit (5 nM enzyme, 400 µM 4-MUG) to determine 
thermal and pH optima. To assess potential differences in glucuronide substrates, activities were 
also measured using pNP-glucuronide and resorufin-glucuronide (Sigma). 
 
Thermal melt measurements 
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Thermal stability of each enzyme was assessed by incubating 2 𝝁M enzyme in GUS buffer 
with TexasRed dye (Invitrogen). Enzyme/dye mixtures were heated rate of 1°C/s to 95°C using a 
LightCycler 96 thermocycler, while fluorescence was monitored. Data were analysed using Roche 
thermocycler software.  
Bulk experiments using resorufin-glucuronide  
Bulk experiments were performed on a microtiter plate reader to test for enzymatic activity. 
100 µM of substrate solution was prepared in the reaction buffer (50 mM Na2PO4, 0.1% Triton X-
100, 10 mM EDTA), and then 10 µL of 2 nM enzyme was mixed with 90 µL of 100 µM substrate 
solution. The fluorescence intensity (λex=558 nm, λem=590 nm) was measured in the plate reader at 
30 second intervals for 0.5 hours.  All of the experiments were performed both at room temperature 
and at 37°C.  
SiMoA Assays 
Time lapse imaging of the fluorescent product generated as a result of enzyme catalysis, 
was performed with an upright Olympus BX61 microscope equipped with a short arc mercury lamp 
(Ushio, Tokyo, Japan) and a CMOS camera (ORCA-Flash 4.0, Hamamatsu, Japan), and a custom 
built automated sealing stage. A filter set with λex = 558 nm and λem  = 577 nm (Semrock, 
Rochester, NY) was used for imaging the resorufin product. Images of the distal end of the fiber 
were captured every 30 seconds for a period of 30 minutes or less. The images were analyzed using 
the MATLAB software Image Processing Toolbox. 
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Figure 3-1: β-glucuronidase reaction 
 
Figure 3-1. β-glucuronidase reaction. Depiction of the reaction catalyzed by β-glucuornidase. A β-D-
glucuronoside is hydrolyzed by the enzyme to form a D-glucuronic acid and an alcohol. Figure created in 
ChemDraw Pro. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2: Two step reaction mechanism of GUS 
 
Figure 2: Two Step Reaction Mechanism. Proposed reaction mechanism for hGUS. Theoretical 
transition states have been omitted for clarity. Two conserved glutamate residues act as the 
nucleophile and electrophile, respectively. The conserved tyrosine is proposed to stabilize the 
carboxylic acid through a hydrogen bonding interaction. In the first step of the sequence, the OR 
group deprotonates E451, and E540 attacks the substrate. Next, E451 deprotonates a water 
molecule in the active site. The hydroxyl group attacks the anomeric carbon, releasing E540 from 
the substrate. 
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Figure 3-3: Human β-glucuronidase structure 
 
Figure 3-3. Human β-glucuronidase structure. (PDB: 3HN3) with EVA bound ((2S,3R,4S,5R)-3,4,5-
trihydroxy-6-oxopiperidine-2-carboxylic acid). Each monomer is depicted in a distinct color. 
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Figure 3-4: Overlay of Free and Inhibitor-Bound Bacterial GUS 
 
 
Figure 3-4. Overlay of Free and Inhibitor-Bound Bacterial GUS. A. Overlay. Native and inhibitor-
bound structures with space-filling model of (2S,3R,4S,5R)-3,4,5-trihydroxy-6-oxopiperidine-2-
carboxylic acid. The native structure is grey. B. Active Site Pertubation. Panel B shows one of the 
most obvious differences between the bound and unbound structures. Y472 moves drastically upon 
binding (~14 Å). C. Distal Pertubation. Depiction of a distal movement of a beta sheet. The 
measured shift in V206 is 7.4 Å. Figures generated in Pymol (PDBs 3K46 and 3K4D). 
 
 
 
 
 
 
 
 
 
A 
B C 
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Figure 3-5: Bacterial GUS tetramer with position of cysteines highlighted 
 
Figure 3-5: Bacterial GUS tetramer with position of cysteines highlighted. 3D representation of the 
GUS tetramer. Surface cysteines are highlighted in yellow. One active site is shown in the structure 
(blue sticks) for reference. None of the cysteines are near or involved in oligomerization, substrate 
binding, or catalysis. 
 
 
Figure 3-6: Monomeric GUS with positions of cysteines highlighted 
 
Figure 3-6: Monomeric GUS with positions of cysteines highlighted. Substrate is depicted in 
orange. Blue residues indicate substrate binding or catalytic residues. 
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Table 3-1: Rosetta and rational design mutations 
Variant Mutations 
D1 28K, 133D, 197D, 253V, 527M 
D2 28L, 133D, 197D, 253V, 527M 
D3 28L, 133D, 197D, 253I, 527M 
D4 28K, 197D, 253I, 262Y, 527M 
C133 28S, 197S, 253S, 262S, 527S 
C262 28S, 133S, 197S, 253S, 527S 
 
 
 
 
 
 
 
Figure 3-7: Substrate optimization of GUS variants 
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Figure 3-8: Timecourse kinetics of GUS variants 
 
Figure 3-8: Timecourse kinetics of GUS variants. Variants were monitored for 300s. A lag in 
activity can be seen in each of the resurfaced variants. wtGUS (gray) displays normal activity, 
denoted by the hyperbolic rise in product. 
 
 
 
 
Figure 3-9: Initial lag is overcome with temperature 
 
 
Figure 3-9: Initial lag is overcome with temperature. Representative traces of activity of resurfaced 
variants at various temperatures. The lag observed at room temperature is overcome at temperatures 
> 30˚C. 
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Figure 3-10: Thermal profile of D1 
 
Figure 3-10: Thermal profile of D1. Representative plot to determine thermal optimum. Rosetta D1 
is shown here. The optimal temperature for this and other variants was found to be between 35-
40˚C, consistent with wtGUS. 
 
 
Figure 3-11: Rosetta vs rational design endpoint assay 
 
Figure 3-11: Rosetta vs rational design endpoint assay. Endpoint assay showing relative activities 
of the Rosetta and rational designs to wtGUS at 37˚C. Single cysteine controls display activity 
comparable to wtGUS. 
 
 
Table 3-2: Thermal melt measurements of GUS variants 
Variant wt D1 D4 S1 C133 C262 
Tm 68.1 60.7 60.8 55.4 62.4 61.5 
StdDev 0.7 0.9 1.0 2.0 0.8 2.8 
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Figure 3-12: Initial rates of C133 and C262 
 
Figure 3-12: Initial rates of C133 and C262. Initial rates of C133 (left) and C262 (right) were 
compared at various substrate concentrations. Remarkably, both of the enzymes are essentially 
inactive at room temperature but regain robust activity at 37˚C. 
 
Figure 3-13: SiMoA platform 
 
Figure 3-13: SiMoA plaform. 46 fL optical fiber microwells are generated at the distal end of the 
fiber bundle by etching the fibers for 115 seconds with 0.025 M HCl. The enzyme is diluted into a 
solution containing excess of the substrate (REG) such that the final concentration of the enzyme is 
2 pM. This solution is immediately sealed into the array of 46fL wells. Using the Poisson 
distribution statistics   where  gives the probability  of finding x 
molecules per well, μ being the mean number of molecules per well, it can be determined that for a 
concentration of 2 pM,  there is a very low probability of finding more than one enzyme per well. 
Hence every well contains either one or zero enzyme molecules. The turnover of REG to resorufin 
is used to detect the presence of the active species, as shown in the figure. 
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Figure 3-14: Histograms of single molecule activities at room temperature and 37˚C 
 
 
Figure 3-14: Histograms of single molecule activities at room temperature and 37˚C for WT, D2 
and D4 (a, b and c respectively). 
 
 
 
 
 
 
Table 3-3: Single molecule rates of GUS variants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a b c 
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Figure 3-15: Temperature profiles in SiMoA assays 
 
  
Figure 3-15: Temperature profiles in SiMoA assays. Temperature shift (a) and pulse (b) 
experiments. 
 
 
 
Figure 3-16: wtGUS temperature shift experiment 
 
Figure 3-16: wtGUS temperature shift experiment (a) Fold increase in activity for single enzyme 
molecules (b) Scatter plot of the activities of the WT at RT and 37°C. 
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Figure 3-17: Temperature shift results of Rosetta resurfaced GUS variants 
 
Figure 3-17: Temperature shift results of Rosetta resurfaced GUS variants. SiMoA assays were 
performed at RT and 37°C for D2 and D4. Several enzymes that were inactive at RT gain activity 
at 37°C. 
 
Figure 3-18: Temperature pulse experiment of C133 
 
Figure 3-18: Temperature pulse experiment of C133. Enzymes were monitored at RT for 50 
seconds and then pulsed to 37˚C for 2 seconds. Activities were measured for over 300 seconds 
following the pulse. Enzymes retained increased activity after the pulse. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-19: Transition state model of GUS 
a b 
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Figure 3-19: Transition state model of GUS. (Left) Using MOE and Guassian09, we made a 
transition state model in order to assess the effects of surface mutations on the tetrameric 
biomolecule. (Right) 2D contact map of resorufin glucuronide transition state model. 
 
 
 
Table 3-4: In silica mutational analysis at surface-exposed cysteines 
 C28 C133 C197 C253 C262 C443 C527 
Mutation Stability Mutation Stability Mutation Stability Mutation Stability Mutation Stability Mutation Stability Mutation Stability 
1:C28C -8.1 1:C133I -11.4 1:C197Y -5.4 1:C253C -10.6 1:C262C -7.1 1:C443C -10.9 1:C527C -10.6 
1:C28Y -7.1 1:C133C -11.1 1:C197S -4.9 1:C253Y -10.4 1:C262L -6.7 1:C443I -10.6 1:C527I -9.7 
1:C28P -7.1 1:C133L -10.4 1:C197N -4.0 1:C253V -10.1 1:C262Y -6.3 1:C443M -10.0 1:C527L -9.2 
1:C28R -7.0 1:C133Y -10.1 1:C197W -3.8 1:C253I -9.6 1:C262N -6.1 1:C443V -10.0 1:C527M -9.1 
1:C28V -6.9 1:C133V -10.0 1:C197L -3.8 1:C253L -9.4 1:C262V -6.1 1:C443L -9.7 1:C527Y -8.9 
1:C28L -6.8 1:C133P -9.6 1:C197V -3.6 1:C253P -9.1 1:C262S -5.8 1:C443H -9.3 1:C527V -8.8 
1:C28S -6.5 1:C133M -9.2 1:C197Q -3.6 1:C253M -9.1 1:C262E -5.7 1:C443Y -9.0 1:C527R -8.5 
1:C28N -6.3 1:C133W -9.1 1:C197R -3.2 1:C253W -8.8 1:C262R -5.7 1:C443P -9.0 1:C527N -8.1 
1:C28I -5.8 1:C133N -8.7 1:C197C -3.2 1:C253F -8.4 1:C262M -5.4 1:C443R -8.5 1:C527W -8.0 
1:C28A -5.8 1:C133R -8.7 1:C197K -3.1 1:C253T -8.1 1:C262D -5.2 1:C443N -8.1 1:C527P -7.9 
1:C28T -5.5 1:C133F -8.6 1:C197M -2.8 1:C253R -7.7 1:C262T -5.2 1:C443T -8.1 1:C527S -7.4 
1:C28M -5.5 1:C133T -8.1 1:C197D -2.8 1:C253N -7.7 1:C262I -5.1 1:C443F -7.9 1:C527T -7.3 
1:C28F -5.5 1:C133H -7.9 1:C197G -2.7 1:C253A -7.5 1:C262Q -5.1 1:C443W -7.9 1:C527A -7.2 
1:C28W -5.4 1:C133A -7.6 1:C197E -2.6 1:C253S -7.2 1:C262K -4.9 1:C443K -7.5 1:C527K -7.0 
1:C28K -5.2 1:C133K -7.6 1:C197P -2.4 1:C253H -7.2 1:C262W -4.1 1:C443A -7.3 1:C527F -7.0 
1:C28Q -5.0 1:C133E -7.6 1:C197I -2.3 1:C253Q -6.7 1:C262A -4.1 1:C443S -7.2 1:C527Q -6.8 
1:C28E -4.9 1:C133S -7.2 1:C197T -2.2 1:C253E -6.7 1:C262F -3.9 1:C443E -7.0 1:C527E -6.7 
1:C28D -4.4 1:C133D -7.0 1:C197A -1.9 1:C253K -6.7 1:C262P -3.8 1:C443Q -7.0 1:C527D -6.5 
1:C28H -3.9 1:C133Q -6.8 1:C197F -1.4 1:C253D -6.7 1:C262G -3.5 1:C443D -6.2 1:C527H -5.3 
1:C28G -3.5 1:C133G -4.6 1:C197H 0.4 1:C253G -4.4 1:C262H -1.1 1:C443G -3.9 1:C527G -4.2 
 
 
 
Table 3-5: Transition state stabilization scores 
Enzyme 
Stability 
(kcal/mol) ΔStability 
Wildtype -61.7 0.0 
Serine -46.1 15.6 
Rosetta -52.6 9.1 
Rosetta 3.4  -53.4 8.3 
MOE -61.3 0.4 
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Chapter 4:  Rational Design of Fusion Proteins for Diagnostic Applications 
ABSTRACT 
The theme for this chapter is the rational design of fusion proteins. In the first section, we 
discuss a couple of proof-of-concepts where we fuse human and archaeal O6-alklylguanine-DNA-
alkyltransferases (AGTs) to antibodies. Doing so allows us to covalently and stoichiometrically 
label antibodies with oligonucleotides. In our first example, we attach a 93 base pair single-
stranded DNA to an antibody, which then in turn serves as a template in an immunoPCR reaction. 
Using an immunosandwich assay, this strategy allows us to detect as little as 35 attomoles of 
interferon-gamma in a milliliter binding assay. Our second oligo-antibody fusion enables the use of 
DNA hybridization to programmably attach antibodies to surfaces. In collaboration with the Crooks 
laboratory at the University of Texas at Austin, we show electrochemical detection of human 
chorionic gonadotropin using oligo-antibody-silver nanoparticle fusions using their oSlip 
technology. In the second section, we extend the use of AGT fusions to pregnancy test strips. The 
use of an engineered hCG–SNAP fusion reporter protein (hCG-SNAP: human chorionic 
gonadotropin-O6- alkylguanine-DNA alkyltransferase) enabled loop-mediated amplification 
(LAMP)-to-hCG signal transduction on commercially available pregnancy test strips. Our novel 
diagnostic method reliably detected as little as 20 copies of Ebola virus templates in human serum 
and saliva. Further, we show that our strategy could be used to diagnose a common melanoma SNP 
allele (BRAF V600E) from the wild-type sequence. In the final section, we rationally design split 
nanoluciferase (nLuc) variants, which are then fused to AGTs to enable luminescent LAMP (Lumi-
LAMP). We show the specific detection of HSV1 and β-actin using Lumi-LAMP and smartphones. 
We believe the methods described in this chapter are generalizable and will show great utility 
across a number of diagnostic applications. 
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4.1 SNAP-TAG LABELING OF ANTIBODIES ENABLES A PANOPLY OF DIAGNOSTIC TOOLS 
Introduction 
The SNAP-tag protein labeling system allows specific, covalent attachment of virtually any 
molecule to a protein of interest. It is a two-step process requiring cloning and expression of the 
protein as a SNAP-tag fusion, and labeling of the fusion with the SNAP-tag probe of choice. 
SNAP-tag fusion proteins have been used extensively over a wide range of biotechnological 
applications. By expressing a single fusion, proteins can be functionalized to: fluorophores, 
surface-coupling linkers, biotin, oligonucleotides, and other molecules of interest (Kampmeier et 
al., 2009). The 20 kDa recombinant human O6-alklylguanine-DNA-alkyltransferase (hAGT) has 
been engineered to use modified benzyl purine and pyrimidine derivatives for covalent attachment 
of molecules that can then be functionalized with a number of commercially available linkers 
(Keppler et al., 2004). For example, benzyl guanine (BG) with a NHS ester can be used to to allow 
for specific conjugation with 5’ amine modified oligonucleotides (Gu et al., 2013), resulting in 
covalent attachment of oligonucleotides to proteins.  The system has also been further optimized 
for both bacterial and mammalian expression systems, widening the range of potential protein 
fusions (Kampmeier et al., 2009). In addition to the commercially available SNAP-tag, an archael 
thermostable AGT from Sulfolobus solfataricus has also been shown to be functionalizable with 
commercial SNAP-tag substrates (Perugino et al., 2012). 
Here we discuss a number of proof-of-concepts with fusing the human and archael AGTs to 
antibodies. We begin with the development of immunoPCR reagents, whereby a PCR template is 
attached to an antibody. ImmunoPCR is the combination of two powerful diagnostics: PCR and 
immunodetection of analytes. For a full review on the power of immunoPCR, see references 
(Assumpção and da Silva, 2016; Chang et al., 2016; Ryazantsev et al., 2016). Using an 
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immunosandwich assay, we were able to detect as little as 35 attomoles of interferon-gamma, a 
cytokine used in the diagnosis of some cancers. 
Next, we extend our use of oligo-tagged antibodies to the DNA-addressed attachment to 
silver nanoparticles. We found that an antibody that was incapable of binding antigen after passive 
adsorption to nanoparticles could be attached to the nanoparticle through nucleic acid hybridization 
while retaining binding to the target analyte using our fusions. This antibody-DNA conjugate was 
then used in the electrochemical detection of human chorionic gonadotropin. The limit of detection 
in this assay was 31.5 ng/mL. Together, these projects extend the many uses of SNAP-tag 
technology and allowed us to develop the techniques needed to design fusions for novel diagnostic 
strategies discussed in sections 2 and 3. 
  
Results & Discussion 
Development of immunoPCR reagents 
In order to carry out immunoPCR, antibodies must be conjugated to DNA (Figure 4-1), 
which is then in turn used as the template in a standard PCR or qPCR reaction.  The use of SNAP-
tag technology enables convenient, site-specific conjugation at a defined stoichiometry of 1 
DNA/SNAP-tag. For example, an scFv-SNAP-tag fusion is labelled once, while a full-length IgG 
fusion to either the light or heavy chain is labeled twice, due to the dimeric nature of full-length 
antibodies. The SNAP-tag reacts specifically with a synthetic derivative of guanine, benzylguanine 
(BG),which then leads to irreversible covalent labeling of the SNAP-tag (Engin et al., 2010).  
 SNAP-tagged oligonucleotide labeling of antibodies is a two-step process that first requires 
cloning and expression of an antibody-AGT fusion, followed by labeling of the fusion with an 
appropriately modified DNA oligonucleotide. As a proof of concept, we engineered a construct in 
which the coding sequence of an anti-ricin single-chain fragment variable (scFv) antibody that 
binds specifically to ricin A chain was genetically fused to the SNAP-tag cassette, which allowed 
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site-specific conjugation of BG-modified substrates to the antibody, in this case an oligonucleotide. 
The fusion antibody was purified by nickel affinity and size exclusion chromatography before 
being used for site specific oligonucleotide conjugation. Binding assays indicated that SNAP fusion 
did not alter the binding of anti-ricin antibody (Figure 4-2). To attach the PCR template to the 
antibody, an oligonucleotide probe was first modified by conjugating BG-GLA-NHS (New 
England Biolabs, Ipswich, MA), an amine-reactive building block, with an amine functionalized 
oligonucleotide. Unreacted BG-GLA-NHS was removed by using NAP-5 desalting column (GE 
Healthcare life sciences, Piscataway, NJ). BG functionalized oligonucleotide were then mixed with 
SNAP-fusion anti-ricin antibodies in 3:1 ratio respectively, and final purification was carried out by 
using Hi-trap-Q sepharose anion exchange column (GE Healthcare life sciences, Piscataway, NJ). 
The formation of conjugate was validated by separating the products in a SDS polyacrylamide gel 
(Figure 4-2C).  
Similarly, a preliminary sandwich-immunoPCR reaction, targeting IFN-ϒ, was performed 
using SNAP-tagged antibodies for both capture and detection. In this scheme, capture antibodies 
were covalently attached to benzylguanine-functionalized beads (NEB) via the SNAP-tag. Varying 
concentrations of antigen were then incubated with 20 μL beads in a 1 mL binding volume. We 
found that blocking the antibody-SNAP-tagged magnetic beads with tRNA greatly reduced 
nonspecific binding and background. After 3 washes by magnetic separation, a qPCR was initiated 
where the detection antibody was covalently attached to a 93mer oligonucleotide and subsequently 
used as the template in the PCR reaction. The lowest amount of antigen added (35 attomoles) was 
clearly detected in the assay (Table 4-1).  
Functionalization of silver nanoparticles with an oligonucleotide-conjugated antibody enables 
facile detection of a protein analyte 
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The Crooks laboratory has previously published their oSlip PAD protocol, which has been 
used for paper-based immunoassay development using an electrochemical readout (Cite 
Josephine). The quantitative immunosandwich assay relies on detection of an analyte using 
antibodies on magnetic beads for capture, and antibody-coated silver nanoparticles (AgNPs) for 
electrochemical detection. In an effort to adapt the platform to pregnancy testing, we entertained 
the idea of using antibody-SNAPtag-Oligo fusions to programmably attach antibodies to AgNP 
surfaces via nucleic acid hybridization. This provided an interesting case because the detection 
antibody used in this reaction could not be passively adsorbed to AgNPs and remain functional. To 
determine oligo-antibody-AgNP coupling was possible, we expressed full-length IgG1 anti-human 
chorionic gonadotropin (hCG) antibody fusions and labeled them with short 22 base single-
stranded DNA. Using thiolated oligos, we then functionalized silver nanoparticles (AgNPs) with 
the reverse compliment of this sequence. Oligo hybridization was then used to attach the antibodies 
to the AgNPs. 
As the Figure 4-3 shows, we were able to successfully attach the detection antibody to the 
AgNPs using oligo hybridization. Further, our unoptimized limit-of-detection was found to be near 
the 5 week mark of  pregnancy (31.5 ng/mL). This project was abandoned due to the need to use 
KMnO4 in the oxidation step, which made this incompatible with a new NoSlip variation of the 
technology.  While we were not able to compete with commercial tests using this technology, we 
believe that attaching antibodies to surfaces using oligonucleotides will be of great utility that could 
be extended to a variety of surfaces that require antibody/protein adherence.  
Conclusions 
In addition to the antibodies shown above, we were able to show this to be generalizable to 
a number of other antibodies (Table 4-2). Over the course of these experiments, we learned a few 
lessons. First, while full-length IgG light-chain fusions did not appear to hinder binding, the SNAP-
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tag did make the purification more difficult when expressed in the commercial pSNAPf vector. For 
full-length IgGs, we normally purify with Protein-A resin, typically a one-step process. However, 
the addition of the SNAP-tag, human or archael, prevented binding to the resin, resulting in lower 
yields. We were able to purify the light-chain fusions with nickel-NTA chromatography, using a 
histidine (6x) tag, followed by ion-exchange chromatography. Heavy-chain fusions did not suffer 
from this problem, and yields were typically much higher. Next, we learned that fusions in bacterial 
cells were problematic. In many cases, the fusions would express but contained truncations (Figure 
4-4) that were difficult to purify out. We attributed the truncations to cryptic ribosomal binding and 
initiation sites. To mitigate truncations, it was much easier to express the fusions in yeast or 
mammalian cells (Figure XXX). Subsequently, we moved all of our expression of AGT-fusions to 
Expi293s, a common mammalian expression system. We also found that antibody fusion 
expression in pcDNA3.4 (Invitrogen) was far more robust and gave much higher yields, typically 
10-20 mg from a 30 mL culture of Expi293s.The work here laid the foundation to what we call the 
“Antibody Production Pipeline” (Figure 4-4), which we used to supply reagents to a number of 
collaborators. 
Methods & Materials 
Synthesis, expression, and purification of Antibody-SNAP fusion proteins. 
 
The DNA corresponding to antibody fragments were fused with the gene encoding either 
the human or thermophilic O6-alkyl-guanine-DNA alkyltransferase from the thermophilic Archaea 
Sulfolobus solfataricus (SsOGT) (Perugino et al., 2012).  Geneblocks were purchased from IDT. 
For mammalian expression, fusions were cloned into the pcDNA™ 3.4 vector from Invitrogen 
(Grand Island, NY, USA), which contains the human cytomegalovirus (CMV) immediate-early 
promoter/enhancer for high level gene expression (Gibson et al., 2009). Proteins were then either 
purified using Protein A, NiNTA, or ion-exchange chromatography. For bacterial expression, 
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fusions were cloned into modified pET21 vectors. Binding affinity was characterized by Enzyme-
Linked Immunosorbent Assays (ELISA). 
Synthesis and purification of hCG-oligo probes  
Benzylguanine (BG) was conjugated to amine-functionalized oligonucleotides via the 
compound BG-GLA-NHS. Non aqueous DMSO was added to the BG-GLA-NHS vial (2 mg) with 
the help of a syringe to yield a final concentration of 20 mM. Amine- functionalized 
oligonucleotides were dissolved in water to a final concentration of 2 mM. Some 4 μL of 
oligonucleotide was mixed with 12 μL of BG-GLA-NHS along with 8 μL of 200 mM HEPES 
buffer (pH 8.3), and the mixture was shaken and incubated at room temperature for 2 h. 
Unconjugated BG was removed using a NAP-5 desalting column (GE Life Sciences, Pittsburgh, 
PA, USA). BG-conjugated oligonucleotides were stored at -20 oC for further use. The conjugated 
probes were generated by combining BG-conjugated oligonucleotides with the purified hCG-stable 
SNAP in a 1:2.5 molar ratio in 1× TBS buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.5) followed 
by incubation at room temperature for 15-18 h. The unconjugated oligonucleotides and proteins 
were removed and the probes purified via fast protein liquid chromatography (FPLC) with a high 
trap Q Sepharose column (GE Life Sciences, Pittsburgh, PA, USA). Purified probes were 
concentrated on Amicon Ultra spin columns (Billerica, MA, USA) and purity was checked on a 
SDS-PAGE gel. 
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Figure 4-1: scFv:Snap Fusion 
 
  
Figure 4-1: scFv:Snap Fusion. Variable domains of the antibody  are depicted in cyan and purple. 
L1 & L2 represent flexible linkers, shown in orange. Together these components are expressed as a 
single fusion protein. BG-functionalized oligonucleotides are then used to covalently modify the 
fusion protein with an oligonucleotide tag. 
 
 
 
Figure 4-2: Binding profiles of anti-Ricin scFv and anti-Ricin-SNAP-tag fusion 
 
Figure 4-2: Binding profiles of anti-Ricin scFv and anti-Ricin-SNAP-tag fusion. Left, ELISA showing binding of scFv. 
A non-linear regression fit revealed a Kd of 1.58 ± 0.2 nM. Middle, ELISA data of RCA43-SNAP-tag fusion. The Kd 
of the fusion was found to be 1.42 ± 0.3 nM and was within error of the scFv alone. Right, SDS-PAGE of anti-Ricin-
pSNAP conjugated with 93mer oligonucleotide and purified by Hi-trap Q column. Control is unconjugated anti-ricin-
SNAP fusion antibody. 
 
 
 
 
 
Table 4-1: IFN-ϒ immunoPCR results 
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Table 4-2: Constructed antibody fusions and Kd values 
Antibody Type Modifications Kd (nM) 
Ricin IgG StableSNAP 1.52 
IFN-ϒ IgG StableSNAP 0.13 
GM-CSF IgG StableSNAP 0.10 
TNF-α IgG StableSNAP 0.03 
EpCAM IgG StableSNAP 7.0 
P24 IgG StableSNAP 30 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample Cq Error Slope 
NTC 17.16 0.07 2.25 
No Antigen 16.56 0.11 2.22 
35 picomoles 2.54 0.02 0.11 
3.5 picomoles 5.73 0.15 2.31 
350 attomoles 10.98 0.27 2.24 
35 attomoles 12.31 0.30 2.21 
 139 
Figure 4-3: oSLip electrochemical detection of anti-hCG-SNAP fusions 
 
 
 
 
Figure 4-3: oSlip electrochemical detection of anti-hCG-SNAP fusions. (Left) Immunosandwich 
setup. Red ball indicates magnetic bead coupled to capture antibody. AgNPs are functionalized 
with a thiolated oligo, which contains the reverse compliment to an oligo attached to the antibody-
SNAP fusion. (Right) Data collected using oSlip technology. Limit of detection (bottom right) was 
shown to be 31.25 ng/mL. 
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Figure 4-4: Antibody-oligo conjugation pipeline 
 
Figure 4-4: Antibody-oligo conjugation pipeline. Overview of the antibody production pipeline 
generated during this work. 
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4.2 COUPLING SENSITIVE NUCLEIC ACID AMPLIFICATION WITH COMMERCIAL PREGNANCY 
TEST STRIPS 
INTRODUCTION 
With recent advancements in medical diagnostics, it has become increasingly more possible 
to quickly and accurately diagnose a variety of disease states using nucleic acid or protein 
biomarkers (Cheng et al., 2006; Vo-Dinh and Cullum, 2000; Wong, 2006). In order to increase the 
sensitivity of these methods, assays have been improved by the incorporation of target-based or 
signal-based amplification strategies (Giljohann and Mirkin, 2009). However, these methods are 
generally restricted to medical diagnostic laboratories, which require complex instrumentation and 
are geographically constrained. Low-cost assay methods that are accurate, reliable, and can be used 
in diverse or resource-limited locations are attractive alternatives for the early identification of 
disease causing agents (Urdea et al., 2006).  
Point-of-care (POC) devices are low-cost and appropriate as a first line of defense against 
chemical and biological threats where rapid identification of exposure is essential (Daar et al., 
2002; Tram et al., 2014; Yager et al., 2008; Zhu et al., 2014b). Despite many years of research, a 
limited number of POC products are commercially available. The most successful of these devices 
has been the personal glucose meter (PGM) (Clark and Lyons, 1962; Montagnana et al., 2009). 
Recently, the PGM was modified to quantify non-glucose targets by nucleic acid mediated release 
of invertase, which converts sucrose to glucose, from a functional DNA-invertase conjugate (Xiang 
and Lu, 2011). The PGM has also been adapted for aptamer- or DNAzyme-based detection of 
analytes (Gu et al., 2013; Lan et al., 2016; Wang et al., 2016b; Zhu et al., 2014a). Previously, our 
laboratory coupled the PGM to a loop-mediated isothermal amplification (LAMP), strand exchange 
signal transduction scheme for pathogen detection (Du et al., 2015; Jiang et al., 2015). However, 
usage of a glucometer in POC diagnostics is problematic for many biomarkers because targets exist 
in glucose-rich blood or urine samples. These limitations and other efforts (Liao and Li, 2014; 
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Wang et al., 2014) inspired our more generalizable approach to molecular diagnostics by 
transducing LAMP-mediated amplification to commercially available pregnancy test strips. 
Utilizing pregnancy test strips in POC diagnostics is an attractive alternative, due to their 
low cost and ease of signal interpretation by end users (Marks et al., 2007). Here, we report the 
conversion of LAMP amplicons to commercially available pregnancy test strips, thereby combining 
molecular genomic diagnostics with a proven off-the-shelf device. This novel and modular 
technique is based on an hCG-SNAP-DNA fusion reporter protein that enables LAMP-induced 
signal transduction. The simplicity of our direct hybridization strategy ultimately resulted in a limit 
of detection of 20 copies of pathogenic Zaire Ebolavirus (ZEBOV), even in 10% human serum or 
15% human saliva samples.  To overcome the limitation of non-specific products of LAMP, we 
turned to strand exchange nucleic acid chemistry, which has been shown to mitigate false positives 
and can be used to probe and distinguish between highly similar amplicons (Du et al., 2015; Jiang 
et al., 2015). The toehold-mediated strand exchange reaction, termed one-step strand displacement 
(OSD), accurately distinguished single nucleotide polymorphisms (SNPs) in “YES-or-NO” 
detection of a mutant melanoma related biomarker BRAF allele (V600E) against the wild-type 
(WT) BRAF gene. Moreover, the novel toehold-mediated three-way junction strand exchange 
(3way-SE) strategy employed here can be readily adapted for signal-on detection of other nucleic 
acid biomarkers using pregnancy test strips and has great potential for use as a general signal 
transducer in other nucleic acid circuits. 
Results 
Design of the hCG-SNAP:DNA fusion reporter  
In order to produce functional hCG-SNAP-tag fusions, capable of binding to pregnancy test 
strips, we first designed a series of N- and C-terminal hCGα- and hCGβ-thermostable SNAP-tag 
fusion proteins, expressed them in Expi293 cells, and tested their ability to bind a panel of 
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commercial pregnancy test strips. The C-terminal fusion of the thermostable SNAP-tag to hCGβ 
provided the most robust signal in our initial screening, and all further assay optimizations were 
conducted with this fusion (hCGβ-SNAP). Given that our hCGβ-SNAP fusion protein gave a 
robust signal during our initial pregnancy test strip screening, we wanted to determine if our fusion 
protein was negatively impacting binding to hCG antibodies.  We used a standard ELISA and 
compared binding of our fusions against a commercially available preparation of hCG. Our hCG-
SNAP protein had EC50 value of  1.0 nM , while the EC50 for the commercially obtained 
unmodified hCG was 45.5 nM, indicating that our hCG fusion did not negatively affect antibody 
binding (Figure 4-5). Next, we optimized conditions to label hCGβ-SNAP with a benzylguanine-
labeled oligonucleotide, which would later serve as our LAMP probe, and found that we were able 
to label > 95% of hCGβ-SNAP. Further purification using anion exchange chromatography 
eliminated unlabeled fusions in our protein preparations for downstream testing (Figure 4-6).  
 
Adapting LAMP to a pregnancy test strip by direct hybridization 
The process of adapting LAMP to pregnancy test strips can be divided into three steps 
(Figure 4-7): (1) LAMP amplification; (2) direct hybridization of the LAMP amplicons and the 
specific hCG-DNA probe; (3) readout via a pregnancy strip. In this scheme, the LAMP reaction is 
carried out to produce complex, double-stranded concatameric amplicons, including four kinds of 
single strand loops positioning between F2-F1 (F-target), F2c-F1c (F-probe), B2-B1 (B-probe), and 
B2c-B1c (B-target), respectively. The LAMP amplicons are allowed to directly hybridize to the 
hCG-DNA probe that specifically recognizes one of the loop regions (here, the loop positioning 
between F2c-F1c) of the LAMP product. The hybridized products are then applied to the pregnancy 
strip. Preliminary experiments revealed that after the hCG-DNA probe hybridized with the large 
molecular weight LAMP amplicon, the complex was unable to flow up the strip, shown by a loss of 
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signal in the positive control and experimental lines. For the free loop regions that originated from 
off-target sequences, amplicons would not hybridize with the hCG-DNA probes or form 
complexes, allowing the hCG-DNA probe to migrate and produce a positive signal on the test strip. 
Together these results suggested that we were able to generate signal in the absence of the target 
sequence, thus creating a ‘signal-off’ detection method.  
Encouraged by the results of our initial attempts at transducing LAMP products to 
pregnancy test strips, we then determined if we were able to reliably generate ‘signal-off’ detection 
of Zaire Ebolavirus (ZEBOV) and wilde-type BRAF sequences. Using our direct hybridization 
strategy, we were able to definitively detect each of the synthetic templates (Figure 4-8). Further, 
we were able to detect as few as 20 copies of the ZEBOV templates and 2,000 copies of WT-BRAF 
templates within 1.5 hrs. The reproducibility of the direct hybridization method developed here 
provided very sensitive YES-or-NO answers for both targets. Due to the high selectivity for both 
LAMP primers, we were also able to demonstrate that non-relevant LAMP products did not 
produce false positive responses. Next, we tested the stability of the hCG-SNAP-DNA probes. Ten 
aliquots of the probe were lyophilized,stored at room temperature, and assayed in 30 day intervals. 
The hCG-Ebola probe was robust and could be stored for at least 90 days without large signal 
deviations (Figure 4-9). 
Further demonstration of the performance of our diagnostic platform was shown by directly 
detecting ZEBOV template spiked into human saliva and human serum (Figure 4-10). The fresh 
collected human saliva and serum were used directly without any pre-treatments. The LAMP to 
pregnancy test strip method with the direct hybridization strategy showed true positives in both 
15% saliva and 10% serum sample without signal or sensitivity loss. 
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Adapting LAMP and OSD to pregnancy strip transduction to discriminate the WT- and SNP-
BRAF gene. 
Detecting mutations that predispose or diagnose an individual to a specific cancer is of 
particular importance, and nucleic acid circuitry can be used to probe and distinguish between 
mutant and wild-type alleles. In previous work, we were able to demonstrate the utility of 
oligonucleotide-strand displacement (OSD) probes in SNP detection (Jiang et al., 2015). Here, we 
extend OSD probes to our newly developed pregnancy test strip assay (Figure 4-7). To do so, we 
rationally designed the OSD probes with a single-mismatch located in the toehold region. The 
hybridization of the reporter to the correct target loop is initiated at the toehold, which then 
proceeds by branch migration. This process ultimately leads to the release of the shorter signal 
strand.  
It has been shown that the V600E mutation of the BRAF gene is one of the melanoma-
associated nucleic acid biomarkers. We generated LAMP primers and hCG-labeled OSD reporters 
for both wild-type and V600E BRAF alleles. LAMP-OSD to hCG strip transduction was carried 
out with 0 and 2x106 copies of both the WT- BRAF gene and SNP-BRAF gene (T to A 
transversion). When the hCG-B-WT reporter was introduced, no band appeared on test line for the 
WT-BRAF LAMP amplicons, as expected. Conversely, when the hCG-B-SNP reporter specific for 
the V600E allele was used, the mutant gene could be detected (Figure 4-11). These results 
successfully validated that our method could accurately distinguish SNP- and WT-BRAF gene in 
LAMP amplicons with high signal amplitude (ΔI).  
Three-way junction strand exchange (3way-SE) allows for ‘Signal-on’ transduction 
To produce “signal-on” detection of target sequences using pregnancy test strips (target 
indicated by typical positive pregnancy-test result), we designed a new three-way junction strand 
exchange (3way-SE) probe and immobilized it on streptavidin-modified magnetic beads (See 
Figures 4-7 and 4-12 for details). To detect LAMP amplicons of ZEBOV and WT-BRAF using 
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this strategy, samples (30 μL) were mixed with 1 μL 3waySE-modified magnetic beads (0.5 
mg/mL) and incubated for 30 min prior to magnetic separation. The supernatant was then run on 
individual pregnancy test strips (Figure 4-12). Using 3waySE, we were clearly able to distinguish 
between positive and negative signals on the test-strips. That is, typical positive signals on the test 
strips corresponded to the correct targeted amplicons. Astonishingly, as little as 20 copies of 
surrogate ZEBOV template produced easy-to-read positive signals on the test line of the pregnancy 
test strips. We were also able to repeat this process in LAMP reactions in 5% human serum (Figure 
4-12).  
Discussion 
The detection of nucleic acid biomarkers for point-of-care (POC) diagnostics is currently 
limited by technical complexity, cost, and time constraints. To overcome these shortcomings, we 
developed a new nucleic acid detection method--combining loop-mediated isothermal amplification 
(LAMP), programmable nucleic acid circuitry (i.e. toehold-mediated strand exchange reaction), and 
standard pregnancy test strips. The incorporation an engineered hCG-SNAP fusion reporter protein 
has allowed for “LAMP-to-hCG” singal transduction, thus enabling the detection of nucleic acid 
biomarkers on low-cost, commercially available pregnancy test strips. Our assay reliably detected 
as little as 20 copies of ZEBOV-VP30 templates and was adapted to distinguish a common 
melanoma-associated SNP allele BRAF (V600E) from the wild-type sequence in both human 
serum and saliva. 
The commercially available hCG strips we used here are 20 fold less expensive compared to 
custom made LFD strips, typically used in new fluorescence-based assays. Additionally, the DNA-
hCG-SNAP fusion reporter, developed here, is stable at room temperature for months. This assay 
method is particularly amenable to further development for point-of-care applications and should 
be easily applicable to the detection of virtually any nucleic acid targets. These advances were 
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made possible through protein-engineering efforts that site-specifically and stoichiometrically 
labeled oligonucleotide probes to hCG. By focusing on molecular transduction, rather than on the 
development of a novel diagnostic platform, we were able to develop diverse assays that could be 
used to monitor public health issues. 
Methods & Materials 
Chemicals and materials  
Commercial human chorionic gonadotropin (hCG) was obtained from Fitzgerald Industries 
International (Acton, MA, USA). BG-GLA-NHS, E.coli Strains DH-10B and Top 10, Gibson 
cloning master mix and all enzymes including Bst 2.0 DNA polymerase were obtained from New 
England Biolabs (Ipswich, MA, USA). The cloning vector pCDNA3.4 and Expi293™ expression 
system were from Invitrogen (Grand Island, NY, USA). Streptavidin-coated magnetic beads (1.5 
μm in average diameter) were purchased from Bangs Laboratories Inc. (Fishers, IN, USA). The 
Amicon Ultra-2 mL 10 K was from Millipore Inc. (Billerica, MA, USA). Nickel affinity resin for 
affinity purification of the hCG-stable SNAP fusion protein was purchased from Thermo Fisher 
Scientific (Rockford, IL, USA). Prepacked High trap Q columns for hCG-oligo probe purification 
were from GE Life Sciences (Pittsburgh, PA, USA). The hCG protein standards were provided by 
Fitzgerald Industries International (Acton, MA, USA). All oligonucleotides used in these studies 
were purchased from Integrated DNA Technologies, Inc. (Coralville, IA, USA) and their sequences 
are listed in Table 4-3. The concentrations of DNA suspensions of oligonucleotides were measured 
by UV spectrophotometry using a NanoDrop 1000 spectrophotometer (Thermo Scientific, 
Wilmington, DE, USA). Human serum was obtained from Sigma-Aldrich (St. Louis, MO, USA). 
To collect human saliva, a 1 mL sterile syringe (BD, Franklin Lakes, NJ, USA) with no needle was 
inserted under the tongue. Saliva was used immediately following collection. All other chemicals 
and solvents were purchased from Sigma-Aldrich, Inc. (St. Louis, MO, USA). The Blue Cross One 
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Step hCG Urine Pregnancy Test Strips (Blue Cross Bio-Medical Co, Ltd., Beijing, China) were 
obtained from Amazon.com.  
Synthesis, expression, and purification of hCG-stable SNAP fusion protein. 
 
The sequences of the alpha and beta subunits of hCG were synthesized by IDT (Morgan et 
al., 1975). The DNA corresponding to the hCG beta (hCGβ) chain was fused with the gene 
encoding a thermophilic O6-alkyl-guanine-DNA alkyltransferase from the thermophilic Archaea 
Sulfolobus solfataricus (SsOGT); we refer to this herein as “stable  SNAP” (Perugino et al., 2012)  
Geneblocks were purchased from IDT for the hCG alpha (hCGα) gene and the hCG beta (hCGβ)-
stable SNAP fusion gene, with an intervening glycine serine rich linker (GGGGS GGGGS 
GGGGS). The beta fusions were constructed with an export tag (MEMFQGLLLLLLLS) at the N-
terminus, and a 6xhistidine tag at the C-terminus. Both the hCGα gene and hCG beta (hCGβ)-stable 
SNAP fusion gene were inserted via Gibson cloning methods into the pcDNA™ 3.4 vector from 
Invitrogen (Grand Island, NY, USA), which contains the human cytomegalovirus (CMV) 
immediate-early promoter/enhancer for high level gene expression (Gibson et al., 2009). Sequence-
verified expression constructs of both hCGα and hCGβ-stable SNAP were transiently transfected at 
a 1:1 ratio into suspension- adapted cells Expi293F™ cells. The hCGα:hCGβ-stable SNAP fusion 
protein was secreted into the media and purified via nickel affinity column chromatography. The 
typical yield of the full fusion protein was about 8 mg/30 mL culture, and its purity was routinely 
characterized by denaturing gel electrophoresis. Binding affinity was characterized by Enzyme-
Linked Immunosorbent Assays (ELISA) (Bhadra et al., 2015) using anti-hCG IgG as the primary 
antibody and Goat Anti-Human IgG (Fcγ fragment specific) as the secondary antibody (Jackson 
ImmunoResearch Laboratpories Inc., West Grove, PA, USA). 
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Synthesis and purification of hCG-oligo probe.  
Benzylguanine (BG) was conjugated to amine-functionalized oligonucleotides via the 
compound BG-GLA-NHS. Non aqueous DMSO was added to the BG-GLA-NHS vial (2 mg) 
with the help of a syringe to yield a final concentration of 20 mM. Amine- functionalized 
oligonucleotides were dissolved in water to a final concentration of 2 mM. Some 4 μL of 
oligonucleotide was mixed with 12 μL of BG-GLA-NHS along with 8 μL of 200 mM HEPES 
buffer (pH 8.3), and the mixture was shaken and incubated at room temperature for 2 h. 
Unconjugated BG was removed using a NAP-5 desalting column (GE Life Sciences, Pittsburgh, 
PA, USA). BG-conjugated oligonucleotides were stored at -20 oC for further use. The conjugated 
probes hCG-P1, hCG-P2, hCG-P3, hCG-P4 and hCG-P6 were generated by combining BG-
conjugated oligonucleotides with the purified hCG-stable SNAP in a 1:2.5 molar ratio in 1× TBS 
buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.5) followed by incubation at room temperature for 
15-18 h. The unconjugated oligonucleotides and proteins were removed and the probes purified 
via fast protein liquid chromatography (FPLC) with a high trap Q Sepharose column (GE Life 
Sciences, Pittsburgh, PA, USA). Purified probes were concentrated on Amicon Ultra spin 
columns (Billerica, MA, USA) and purity was checked on a SDS-PAGE gel. 
Cloning of Zaire Ebolavirus VP30 and human v-raf murine sarcoma viral oncogene homolog 
B1 (BRAF) gBlocks and PCR amplification of transcription templates. 
The ZEBOV, wild-type BRAF (WT-BRAF) and V600E mutant single nucleotide 
polymorphisms (a T to A transversion) BRAF (SNP-BRAF) gBlocks were designed to include a T7 
RNA polymerase promoter at their 5’-ends to enable subsequent transcription. The DNA 
polymerase chain reaction (PCR) amplification reactions were performed using AccuPrime™ Pfx 
DNA Polymerase (Thermo Scientific, Wilmington, DE, USA). The PCR products were purified 
from agarose gels using the Wizard SV gel and PCR purification system (Promega, Madison, WI, 
USA). The ZEBOV gBlocks were cloned into the pCR2.1-TOPO vector (Life Technologies, 
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Carlsbad, CA, USA) by Gibson assembly using the 2x mastermix (NEB) according to the 
manufacturer’s instructions. Cloned plasmids were selected and maintained in an E. coli Top10 
strain. Plasmid minipreps were prepared from these strains using the Qiagen miniprep kit (Qiagen, 
Valencia, CA, USA). All gBlock inserts were verified by sequencing at the Institute of Cellular and 
Molecular Biology Core DNA Sequencing Facility. 
 
Standard LAMP reaction 
The LAMP primers, composed of the outer primers F3 and B3 and the inner primers FIP 
and BIP, were generated by PrimerExplorer 4 (Eiken). Primer design was constrained to include at  
least a 30 bp  gap between the F1 and F2 as well as between the B1 and B2 priming sites. Mixtures 
containing different copies of template (ZEBOV DNA plasmid or BRAF PCR products),1.6 μM 
each BIP and FIP, 0.4 μM each B3 and F3, 1 M betaine, 2 mM MgCl2, and 0.8 mM dNTPs in a 
total volume of 29 μL 1 × isothermal amplification buffer (20 mM Tris- HCl, 10 mM (NH4)2SO4, 
10 mM KCl, 2 mM MgSO4, 0.1% Triton X-100, pH 8.8) were heated to 95°C and maintained for 2 
min, followed by chilling on ice for 2 min. Then, 1µL (8 U) of Bst DNA polymerase 2.0 was added 
to initiate the LAMP reaction. The reactions (with a final volume of 30 µL) were incubated for 1.5 
hour in a thermal cycler maintained at 65 oC. A 3.5 µL aliquot of the reaction mixed with 1.5 µL of 
6 × DNA loading dye was then analyzed by electrophoresis through a 1% agarose gel containing 
ethidium bromide. 
End-point LAMP-hCG to pregnancy test strip transduction  
A series of tubes containing 10 μL aliquots of hCG-Ebola (18 nM) or hCG-Braf (8 nM) 
were mixed with 30 μL standard LAMP products with different starting concentration of templates. 
The hybridization reactions were allowed to proceed for 35 min at 25 °C. Subsequently, the 
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pregnancy testing strips were dipped into the reaction solutions and the pictures were taken after 2 
min by using a cell phone (iphone 6 plus, Apple, CA, USA).  
 
Standard LAMP reaction in human serum and human saliva.  
Mixtures containing different copies of ZEBOV template, 1.6 μM each BIP and FIP, 0.4 
μM each B3 and F3, 1 M betaine, 2 mM MgCl2, 0.8 mM dNTPs and 10% human serum (or 15% 
human saliva) in a total volume of 29 μL 1 × isothermal amplification buffer were heated to 95°C 
for 7 min, followed by chilling on ice for 2 min. Then, 1 µL (8 U) of Bst DNA polymerase 2.0 was 
added to initiate the LAMP reaction. The reactions (with a final volume of 30 µL) were incubated 
for 1.5 hour in a thermal cycler maintained at 65 oC. 
Stability tests for the lyophilized hCG-oligo probe (hCG-Ebola).  
15 µL of 18 nM hCG-Ebola probe was added into each 1.5 mL tubes and was lyophilized 
by using a freeze dryer (SP Scientific, NY, USA). The lyophilized probe was stocked at room 
temperature (about 25 oC). The stability test was carried out every 30 days for a total of 90 days. 
Sixty µL ZEBOV negative and positive samples (2E4 copies) were added into the lyophilized 
hCG-Ebola probes, respectively. After 35 min hybridization reactions at 25 °C, the pregnancy 
testing strips were dipped into the reaction solutions and the pictures were taken after 2 min by 
using a cell phone (iphone 6 plus, Apple, CA, USA). 
 
Single nucleotide polymorphisms (SNP) test for WT- and SNP-BRAF genes through strand 
displacement (OSD) probe.  
BRAF OSD reporter, WT-reporter (or SNP-reporter), were prepared by mixing hCG-B-
WT-P1 (or hCG-B-SNP-P1) and B-P2 with 1:1 molar ratio (final concentration of 200 nM) in 1× 
TBS buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.4) and incubating at 25 oC for 1 h 
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hybridization. Then, 30 µL WT-BRAF (or SNP-BRAF) LAMP products negative and positive 
samples (2E6 copies) were added into 2 µL 200 nM hCG-B-WT reporter (or 3.5 µL 200 nM hCG-
B-SNP reporter) and the mixture were incubated for 40 min at 25 oC. The pregnancy testing strips 
were dipped into the final reaction solutions and the pictures were taken after 2 min by using a cell 
phone (iphone 6 plus, Apple, CA, USA). 
Signal-on strategy for detection of Ebola through three-way junction strand exchange (3way-SE) 
probe.   
Preparation of the 3way-SE/MB conjugate: Fifteen µL mixture of 30 µM biotinylated E-P2 
and 31 µM E-P3 was heated to 95 oC for 5 min, then cooled slowly to 25 oC at a rate of 0.1 oC /s. 
Two hundreds µL of 1 mg/mL streptavidin coated MBs were washed three times with 1× 
isothermal amplification buffer by using the magnetic rack and resuspended in 85 µL isothermal 
amplification buffer. Fifteen µL pre-hybridized E-P2-E-P3 was added into the 85 µL washed MBs 
and incubated on a vertical rotator for 30 min. The unbound E-P2/E-P3 was removed by washing 
the E-P2/E-P3/MBs in 200 µL 1× isothermal amplification buffer at least three times. Then the E-
P2/E-P3/MBs were suspended in 70 µL 1× isothermal amplification buffer and incubated with 30 
µL 1.56 mg/mL hCG-E-P1 on a vertical rotator for 1.5 h at 25 oC. After eight times washes with 
200 µL 1× isothermal amplification buffer, the hCG-E-P1/E-P2/E-P3/MBs (i.e. 3way-SE/MBs) 
were suspended in 200 µL SuperBlock™ (PBS) Blocking Buffer (Thermo Scientific, Wilmington, 
DE, USA) and incubated on a vertical rotator over night at 4 oC. Finally, the hCG-E-P1/E-P2/E-
P3/MBs were washed with 200 µL 1× isothermal amplification buffer at least eight times, 
suspended in 400 µL 1× isothermal amplification buffer with the final concentration of 0.5 mg/mL, 
and stored at 4 oC for further use.  
Detection of Ebola LAMP products with 3way-SE-to-prengncy test strip transduction: 1 µL 
aliquots of the 0.5 mg/mL 3way-SE/MB conjugates were incubated with 30 µL of standard LAMP 
(or LAMP in 10% human serum) products with different starting concentration of templates. The 
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3way-SE reactions were allowed to proceed for 30 min on a vertical rotator at 25 °C. The MBs 
were separated using a magnetic rack and the resulting supernatant was transferred into separate 
tubes for pregnancy strips test. The pictures were taken after 2 min by using a cell phone (iphone 6 
plus, Apple, CA, USA). 
Data analysis.  
The analysis of relative signal intensities was carried out using Adobe Photoshop CS5.1 
(Adobe Systems Incorporated, CA, USA) and Image J.[8] The relative intensities were measured as 
follows by opening the image in Photoshop CS5.1; and converting it to greyscale, then transferring 
the image to Image J, where background subtractions were carried out. The relative intensity of 
signal response could be quantitatively calculated as: Relative Intensity = [intensity of the test 
band]/[intensity of control band]. The bar-graphs in maunscript present the quantification of inset 
picture using software, Image J. The error bars of the bar-graphs represent standard deviations 
obtained from two parallel assays. All the figures are fabricated likewise unless otherwise noted. 
 
Contributions 
J Gollihar designed and built the fusion proteins, aided in experimental design, analyzed data, and 
wrote the manuscript. A Pothukuchy and Y Du designed and performed all experiments and wrote 
the manuscript.
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Figure 4-5. ELISA comparison of commercial and oligonucleotide-conjugated hCG to 
pregnancy test antibodies 
 
Figure 4-5. ELISA comparison of commercial and oligonucleotide-conjugated hCG to pregnancy 
test antibodies. Dose response curves were generated for the in-house hCG-oligonucleotide 
conjugate (A) and a commercially purchased hCG sample (B). The corresponding EC50 values 
were 1.0 nM and 46 nM, respectively. 
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Figure 4-6 hCG-SNAP fusion design and purification   
 
Figure 4-6 hCG-SNAP fusion design and purification  (A) SDS PAGE of hCG-SNAP fusion 
protein and  hCG-oligo conjugate; (B) The structure of hCG-SNAP fusion protein.   
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Figure 4-7. Three strategies for detection of ZEBOV or wild-type BRAF (WT-BRAF) LAMP 
amplicons using pregnancy test strips 
 
Figure 4-7. Three strategies for detection of ZEBOV or wild-type BRAF (WT-BRAF) LAMP 
amplicons using pregnancy test strips. A) “Signal-off” direct hybridization strategy. B) 
“Signal-off” OSD strategy for discriminating mismatches. C) “Signal-on” 3way-SE strategy. 
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Figure 4-8 Sensitive and specific detection of synthetic ZEBOV and WT-BRAF 
 
 
Figure 4-8 Sensitive and specific detection of synthetic ZEBOV (ZEBOV-VP30) and WT-BRAF 
DNA using LAMP to-hCG transduction. The LAMP reaction was carried out at 65 oC for 1.5 hours. 
(A) Agarose gel electrophoretic characterization of LAMP amplicons using ZEBOV-VP30 as a 
template. Lane 1: Negative control without template; lane 2: template 20 copies; lane 3: template 
200 copies; lane 4: template 2,000 copies; lane 5: template 20,000 copies; lane 6: template 200,000 
copies; lane 7: side products; lane 8: Non-target with WT-BRAF lamp products. (B) The hCG strip 
(inset) responses to both non-target (WT-BRAF) and different amounts of target (ZEBOV-VP30) 
templates, as mentioned in A. Strip 0 is hCG-E19 in 1X Iso buffer. (C) Agarose gel electrophoretic 
characterization of LAMP amplicons using WT-BRAF as a template. Lane 1: Negative control 
without template; lane 2: template 2,000 copies; lane 3: template 20,000 copies; lane 4: template 
200,000 copies; lane 5: side products; lane 6: Non-target with ZEBOV-VP30 lamp products. (D) 
The hCG strip (inset) responses to both non-target (ZEBOV-VP30) and different amounts of target 
(WT-BRAF) templates, as mentioned in A. Strip 0 is hCG-Braf in 1X Iso buffer. The error bars 
represent standard deviations calculated from two parallel assays. 
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Figure 4-9. Time dependence of hCG strip responses to LAMP amplicons 
 
Figure 4-9. Time dependence of hCG strip responses to LAMP amplicons. Data generated from 2x104 
copies of ZEBOV-VP30 using the lyophilized hCG-Ebola probe. The bar-graph presents the quantification of 
inset pictures using Image J. The error bars represent standard deviations calculated from three parallel 
assays. 
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Figure 4-10 10 Sensitive and selectivity of synthetic ZEBOV DNA 
 
 
Figure 4-10 Sensitive and selectivity of synthetic ZEBOV DNA (ZEBOV-VP30) in 15% human 
saliva (A) and in 10% human serum (B) using LAMP to-hCG transduction. The hCG strip (inset) 
responses to different amounts of target (ZEBOV-VP30) templates and off-target Braf templates. 
Strip 1: negative control; strip 2: 20 copies; strips 3: 200 copies; strip 4: 2,000 copies; strip 5: 
20,000 copies; strip 6: 2,000,000 copies of Braf template. 2. The bar-graph presents the 
quantification of inset picture using software, Image J. The error bars represent standard deviations 
calculated from two parallel assays. 
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Figure 4-11 Detection of single nucleotide polymorphisms (SNPs) using strand displacement 
(OSD) probes. 
 
Figure 4-11 Detection of single nucleotide polymorphisms (SNPs) using strand displacement 
(OSD) probes. (A) Sequence interactions between LAMP amplicons that represent either the wild-
type (WT) BRAF gene or the allele V600E (SNP, which contains a single nucleotide difference) 
and the OSD probes. The discriminating nucleotide position is shown in red in both amplicons and 
the OSD probes (where it is found in the toehold region). (B) The hCG strip responses to both WT 
and SNP-Braf templates with either WT-hCG or SNP-hCG probe. (C) The bar-graph presents the 
quantification of (B) using Image J. The error bars represent standard deviations calculated from 
two parallel assays. 
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Figure 4-12: 3way-SE detection of ZEBOV and BRAF 
 
Figure 4-12: 3way-SE detection of ZEBOV and BRAF (A) The scheme of “signal on” 3way-SE 
strategy for detecting of ZEBOV VP30 LAMP amplicons using LAMP to-hCG transduction. 
Sensitive and selectivity of synthetic ZEBOV DNA (ZEBOV-VP30) in buffer (B and C) and in 5% 
human serum (D and E) through  (B) and (D) The hCG strip responses to different amounts of 
target (ZEBOV-VP30) templates, off-target Braf template, and non-target of Braf LAMP product. 
Strip 1: negative control; strip 2: 20 copies; strips 3: 200 copies; strip 4: 2,000 copies; strip 5: 
20,000 copies; strip 6: 5,000,000 copies of Braf template with Ebola primers; strip 7: 5,000,000 
copies of BRAF LAMP product. (C) and (E) The bar-graph presents the quantification of pictures 
B and D, respectively, using Image J. The error bars represent standard deviations calculated from 
two parallel assays. 
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Table 4-3. Sequence of oligonucleotides used for Pregnancy Lamp. 
Name Sequence  5’-3’ 
ZEBOV. 
3.3 primer 
set  
F3  AGACAGCATTCAAGGGATG 
B3 CCTTTTTTCAAGGTCGGACA 
FIP CTCCTTGATTGACGGTACTCACCGACACGACCACCATGTTC 
BIP CTCACAAGTGCGCGTTCCTAATGTCTTTAGGTGCTGGAG 
BRAF 
primer set 
F3  CCACAGAGACCTCAAGAGT 
B3 ACAGAACAATTCCAAATGCATAT 
FIP ACTGATGGGACCCACTCCATAAGACCTCACAGTAAAAATA 
BIP AACAGTTGTCTGGATCCATTTTGTGACATCTGACTGAAAGCTGTA 
hCG-Ebola probe /5AmMC6/AATTCTCTCTGGATGATGA 
hCG-Braf probe /5AmMC6/TAGGTGATTTTGGTCTAGC 
Braf OSD 
reporter set 
(for SNP 
detection) 
hCG-B-
WT-P1 
/5AmMC6/GATTTCACTGTAGCTAGACCAAAATACAAGAA 
hCG-B-
SNP-P1 
/5AmMC6/GATTTCTCTGTAGCTAGACCAAAATACAAGAA 
B-P2 TTCTTGTATTTTGGTCTAGCT 
Ebola 3 
way 
junction 
reporter set 
(for signal 
on strategy) 
hCG-E-
P1 
/5AmMC12/ CTCTGCACAGTCGGAC 
E-P2 GAGCACGATCATCATCCAGAGAGAATTATCGAGGTGCAGAGA   
AAAAAAAAAA /3BiodT/ 
E-P3 GTCCGACTCTCGATAATTCTCTCTGGATGAT 
 Mimic-T TGCACCTCGATAATTCTCTCTGGATGATGATCGTGCTC 
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4.3 RATIONAL DESIGN OF SPLIT NANOLUCIFERASE FUSIONS ENABLES LUMINISCENT LAMP (LUMI-
LAMP) AND POINT-OF-CARE SMARTPHONE DIAGNOSTICS 
Introduction 
Loop-mediated isothermal amplification (LAMP) is a powerful sequence amplification 
technology that relies on strand displacement DNA synthesis to generate 109 to 1010 copies of 
nucleic acid targets within 1-2 hours (Notomi et al., 2000). Isothermal operation is ideally suited for 
adaptation to point-of-care diagnostic devices, as it does not require complex devices capable of 
thermal cycling (Yager et al., 2008).  There are four primers in a typical LAMP reaction: two inner 
primers (FIP and BIP) and two outer primers (F3 and B3). These primers are specific to six 
consecutive blocks of target sequences designated in their order of appearance from the 5’-end as 
B3, B2, B1, F1c, F2c and F3c. The final LAMP product is comprised of large molecular weight 
concatemers that contain free loops between the F1 and F2, B1 and B2, F1c and F2c, and B1c and 
B2c regions that can be further exploited for detection and for speeding up amplification. 
LAMP has frequently been limited by the accumulation of non-specific products and by the 
lack of versatile methods for unambiguous sequence distinction.  To overcome this, we have 
engineered LAMP signal transduction modules called oligonucleotide strand displacement (OSD) 
probes that are triggered by LAMP loop sequences and that are essentially the equivalent of 
TaqMan probes for isothermal amplification.  OSD probes are comprised of short DNA partial 
duplexes that undergo strand exchange reactions in the presence of specific loop sequences that 
terminate LAMP concatamers. The longer strand of the OSD probe duplex is complementary to the 
target-derived sequence in one of the LAMP loops.  
Because of the versatility of OSD probes, we were recently able to transduce LAMP 
amplicons into glucose for detection by a commercial glucometer. For LAMP-to-glucose 
conversion the toehold-bearing OSD strand is immobilized on magnetic beads and pre-hybridized 
to the shorter, complementary strand that is covalently coupled to an in-house engineered 
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thermostable invertase. Specific LAMP amplicons initiate toehold-mediated strand displacement 
resulting in the release of invertase-bearing strands into the solution. Catalytic conversion of 
sucrose to glucose by isolated solution-phase invertase is quantified with a commercial glucometer. 
By combining the nucleic acid transducer circuit with a thermostable invertase we can use this high 
temperature isothermal amplification method in a one-tube format to directly transduce analytes 
such as ebolavirus templates into glucose signals, with a sensitivity to detect as few as 20-100 
copies per microliter (Du et al., 2015). Moreover, as mentioned in the previous section, we were 
able to transduce LAMP amplicons to pregnancy test strips using an hCG-AGT fusion with an 
OSD reporter (Du et al., 2017). 
In an effort to expand our use of OSD probes to commonly used devices, we endeavored to 
develop a smartphone-based point-of-care diagnostic. By engineering a split thermostable 
nanoluciferase (NLuc) into a sequence-dependent bioluminescent probe for LAMP amplicons, we 
were able to transduce LAMP amplicons to smartphones using a free application on an iPhone after 
30 seconds of exposure. We believe that the preliminary experiments shown here will be of great 
utility in developing a panel of point-of-care diagnostics using our split nLuc. 
Results & Discussion 
nLuc is a small (19 kDa), single subunit, ATP-independent luciferase that produces a high 
intensity glow-type luminescence with a half-life >2 h (He et al., 2014). The specific activity of 
nLuc has been reported to be up to 150-fold greater than the commonly used firefly luciferases. 
nLuc does not possess disulfide bonds or any known post-translational modifications. The enzyme 
is stable and active at elevated temperatures. nLuc is also active over a wide pH range (5-9) and has 
been shown to remain active after being challenged with 8 M urea. Together these properties render 
nLuc an ideal candidate for engineering. 
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To minimize background luminescence and obviate the need to physically separate unused 
LAMP reporters, we sought to split nLuc into two non-luminescent fragments that would regain 
luminescence only upon proximity-dependent association. By utilizing LAMP loop sequences as 
scaffolds to facilitate split nLuc reconstitution, LAMP amplicons can be specifically transduced 
into bioluminescence (Figure 4-13). 
Several split sites were selected based on the predicted NLuc structure (Figure 4-14). N- 
and C-terminal halves were fused with the SNAP-tag (Figure 4-15) and expressed in E. coli.  
Fusion proteins were purified using Ni-affinity chromatography and conjugated with 
benzylguanine-labeled oligonucleotides. The split reporters were then either incubated alone or in 
various equimolar combinations at 55 °C for 1 h. Luminescence upon adding Nano-Glo substrate 
was measured on a plate reader to measure background reconstitution. Duplicate fusion protein sets 
were incubated with equimolar amount of non-specific or a complementary target strand to foster 
adjacent hybridization of the oligonucleotides linked to the N and C-terminal halves of nLuc. 
Luminescence was measured after 1 h at 55 °C and compared to the activity in the absence of 
oligonucleotide hybridization. Our results demonstrate that a 122 amino acid N-terminal fragment 
(NNLuc) and a 49 amino acid C-terminal fragment (CNLuc) (N3:C3 pair in Figure 4-16 reconstitute 
more efficiently in the presence of oligonucleotide hybridization (Figure 4-17).  
Therefore we selected this pair of split proteins to create reporters for LAMP amplicons. 
We covalently conjugated the thermostable SNAP-tag of NnLuc fusion protein via benzylguanine to 
the 3’-end of single stranded oligonucleotide probe 1 (P1-NNLuc) while the CnLuc fragment was 
conjugated to the 5’-end of the 3’-end blocked oligonucleotide probe 2 (P2-CNLuc). A portion of the 
single stranded probes in P1-NnLuc and P2-CnLuc were subsequently converted to the OSD format 
(OSD1-NnLuc and OSD2-CnLuc) by hybridization to the shorter complementary oligonucleotides. 
Probes: OSD 1 and 2 are designed to hybridize with adjacent sequences in target-derived LAMP 
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loop regions, thus juxtaposing the 3’-end NnLuc of probe 1 and the 5’-end CnLuc of probe 2. The 
ensuing split reporter reconstitution can be quantitated by applying its substrate furimazine 
(Promega) and measuring luminescence using a plate reader (Figure 4-18). In the absence of 
specific LAMP amplicons, the split NLuc reporter displays minimal reconstitution and 
luminescence. The bioluminescence triggered by the correct LAMP amplicons can also be visually 
distinguished from background (Figure 4-19) and can also be imaged using a smartphone camera 
without employing additional hardware (Figure 4-20). 
Conclusions 
To our knowledge, this work represents the first functional split of nanoluciferase. 
Additionally, we believe this to be the first example of oligo-mediated functionalization of this 
class of enzymes. Our rational design of nLuc enabled the facile detection of 2 LAMP amplicons in 
a sequence specific manner. This approach should prove generalizable to other targets and enable 
the use of smartphone in point-of-care diagnostics. 
 
Methods & Materials 
Synthesis, expression, and purification of split nLuc-SNAPtag fusions 
The sequences of split nLuc designs were synthesized by IDT and ligated into a modified 
bacterial pET expression vector (Figure 4-15). Sequence-verified expression constructs of both 
were expressed in BL21 DE3 and purified via NiNTA column chromatography.  
 
Oligo-mediated activity check 
A total of 0.6 µM of each nLuc probe (N-nLuc and C-nLuc; Table 4-4) and a LAMP mimic 
were incubated in isothermal buffer (20 mM Tris-HCl, 10 mM ammonium sulfate, 50 mM KCl, 2 
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mM MgSO4, 0.1% Tween20, pH 8.8) at 55˚C for 1 hour. 0.5 µL of Nano-Glo substrate was used in 
each reaction. Endpoint luminescence measurements were taken with a TECAN F500 platereader. 
 
Standard LAMP reaction 
The LAMP primers, composed of the outer primers F3 and B3 and the inner primers FIP 
and BIP, were generated by PrimerExplorer 4 (Eiken). Primer design was constrained to include at  
least a 30 bp  gap between the F1 and F2 as well as between the B1 and B2 priming sites. Mixtures 
containing 10 pg template, 1.6 μM each BIP and FIP, 0.4 μM each B3 and F3, 1 M betaine, 2 mM 
MgCl2, and 0.8 mM dNTPs in a total volume of 29 μL 1 × isothermal amplification buffer (20 mM 
Tris- HCl, 10 mM (NH4)2SO4, 10 mM KCl, 2 mM MgSO4, 0.1% Triton X-100, pH 8.8) were 
heated to 95°C and maintained for 2 min, followed by chilling on ice for 2 min. Then, 1µL (8 U) of 
Bst DNA polymerase 2.0 was added to initiate the LAMP reaction. The reactions (with a final 
volume of 30 µL) were incubated for 1.5 hour in a thermal cycler maintained at 65 oC. A 3.5 µL 
aliquot of the reaction mixed with 1.5 µL of 6 × DNA loading dye was then analyzed by 
electrophoresis through a 1% agarose gel containing ethidium bromide. 
 
Synthesis and purification of nLuc-OSD probes 
Benzylguanine (BG) was conjugated to amine-functionalized oligonucleotides via the 
compound BG-GLA-NHS. Non aqueous DMSO was added to the BG-GLA-NHS vial (2 mg) with 
the help of a syringe to yield a final concentration of 20 mM. Amine- functionalized 
oligonucleotides were dissolved in water to a final concentration of 2 mM. Some 4 μL of 
oligonucleotide was mixed with 12 μL of BG-GLA-NHS along with 8 μL of 200 mM HEPES 
buffer (pH 8.3), and the mixture was shaken and incubated at room temperature for 2 h. 
Unconjugated BG was removed using a NAP-5 desalting column (GE Life Sciences, Pittsburgh, 
PA, USA). BG-conjugated oligonucleotides were stored at -20 oC for further use. The conjugated 
probes generated by combining BG-conjugated oligonucleotides with the purified nLuc-stable 
SNAP in a 1:2.5 molar ratio in 1× TBS buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.5) followed 
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by incubation at room temperature for 15-18 h. The unconjugated oligonucleotides and proteins 
were removed and the probes purified via fast protein liquid chromatography (FPLC) with a high 
trap Q Sepharose column (GE Life Sciences, Pittsburgh, PA, USA). Purified probes were 
concentrated on Amicon Ultra spin columns (Billerica, MA, USA) and purity was checked on a 
SDS-PAGE gel. 
Real-time measurement of Lumi-LAMP 
LAMP reactions were incubated at 65˚C for 1 hr. Polymerase was then inactivated with a 
heating step of 80˚C for 20 minutes. Split nLuc probes were then added at 0.2 µM or 0.12 µM. A 
1:100 dilution of Nano-Glo substrated was added, and the reaction was held at 55˚C. Measurements 
were taken at 2 minute intervals. For smartphone measurements, reactions were incabed for 15 
minutes and exposed for 30 s using LongExpo, a freeware application found in the Apple App 
Store. 
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Figure 4-13: Split nLuc reporter (Lumi-LAMP) concept 
 
Figure 4-13: Split nLuc reporter (Lumi-LAMP) concept. In Lumi-LAMP, a split nanoluciferase 
becomes active via oligonucleotide hybridization. Functional nLuc is only produced by targeting a 
specific amplicon generated in a standard LAMP reaction.  
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Figure 4-14: Rational design of split nanoluciferase variants 
 
Figure 4-14: Rational design of split nanoluciferase variants. Four sites were chosen based on a 
homology model of nLuc. Sites were chosen based on secondary structure. Sites marked in green 
were shown to be functional in oligonucleotide-dependent activity assays. Site N4:C4, shown in 
red, was not functional. 
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Figure 4-15: nLuc primary sequence and AGT fusion strategy for split reporters. 
 
Figure 4-15: nLuc primary sequence and AGT fusion strategy for split reporters. Top, primary 
amino acid sequence of nLuc. Sites for split reporter are highlighted in purple. Bottom, fusion 
strategy for N- and C-termini of split nLuc variatns. In each case, the SNAPtag was fused to the N-
terminus of each end of the split enzyme. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 172 
Figure 4-16: Reaction scheme for Lumi-LAMP proof-of-concept. 
 
Figure 4-16: Reaction scheme for Lumi-LAMP proof-of-concept. The relative position of each of 
the split nLuc is shown at the top. For the reaction, 0.6 µM of each portion of the split nLuc was 
incubated with and without an equimolar amount of the LAMP probe mimic. Reactions are carried 
out at 55˚C. 
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Figure 4-17: Oligo-dependent activity of designed split nLucs. 
 
Figure 4-17: Oligo-dependent activity of designed split nLucs. Activity of split designs was 
measured using luminescence. In each case, oligo-dependent activity was observed with the 
addition of an equimolar amount of the LAMP mimic. Individual pieces of split enzymes were not 
reactive, and activity was dependent on the correct partner being present (not shown). C4:N4 as the 
only design that did not show oligo-dependent activity. 
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Figure 4-18: Real-time measurement of Lumi-LAMP products. 
 
Figure 4-18: Real-time measurement of Lumi-LAMP product. Split nLuc variants with actin probes 
were incubated with actin LAMP products. Luminescence was measured every 2 minutes, 
revealing a large increase when both probes and LAMP product for actin were present. 
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Figure 4-19: Split nLuc OSD probes can distinguish between target and non-target LAMP 
amplicons. 
 
Figure 4-19: Split nLuc OSD probes can distinguish between target and non-target LAMP 
amplicons. Left, agarose gel of LAMP amplicons targeting β-actin or HSV1. Right, correct 
detection of HSV1 using HSV1 template and nLuc probes. 
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Figure 4-20: Lumi-LAMP to smartphone readout. 
 
Figure 4-20: Lumi-LAMP to smartphone readout. Top left, assay conditions. Bottom, quantitative 
measurements of 0.2 µM vs 0.12 µM probes. LAMP reactions and controls are shown. Both actin 
and HSV1 could be distinguished on a smartphone (iPhone) after 30 seconds of exposure (bottom 
right). 
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Table 4-4: nLuc probe sequences 
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Chapter 5:  Expanding the Reach of Compartmentalized Self-Replication 
ABSTRACT 
The theme for this chapter is Compartmentalized Self-Replication. This directed evolution 
technique has been used by the scientific community to engineer thermostable DNA polymerases 
with a number of novel properties and functions. In the first section, we use DNA shuffling to 
create libraries of chimeric archaeal Family B DNA polymerases that we ultimately use in proof-of-
concept selections. We find that shuffled polymerases are more active than parental enzymes. 
Further, we develop screening techniques that would allow us to perform multiple CSR directed 
evolution experiments in parallel. In the second section of this chapter, we develop a modified 
version of CSR, termed Reverse-Transcription Compartmentalized Self-Replication (RT-CSR). 
This novel selection strategy enables us to engineer the first known high-fidelity reverse 
transcriptase using a commonly used Family B DNA polymerase. With the aid of deep sequencing 
and modeling, we were able to halve the number of mutations needed to impart reverse 
transcriptase activity and re-engineered the polymerase to proofread mismatches on both DNA and 
RNA templates. Our selections at this point all produced error-prone polymerases. To combat this 
problem, we develop high-fidelity Compartmentalized Self-Replication  (hifiCSR) in the third 
section. We also characterize inhibition of a model Family B DNA polymerase by chaotropes, 
heme, melanin, and lipoteichoic acids. We discuss the initiation of selections against these common 
inhibitors and provide sequencing data from each selection. Strong convergence is seen in many of 
the sequenced libraries after only five rounds of selection. In the final section, we extend the reach 
of CSR to a eukaryotic organism. The process by which we were able to perform CSR in 
Saccharomyces cerevisiae is discussed in detail. The ability to perform CSR in yeast provides the 
core technology needed to perform the more sophisticated directed evolution technique, 
Compartmentalized Partnered Replication (CPR), in a eukaryotic organism. 
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5.1 PRELIMINARY COMPARTMENTALIZED SELF-REPLICATION DIRECTED EVOLUTION 
EXPERIMENTS 
Introduction 
Compartmentalized Self-Replication (CSR) is a powerful directed evolution technique, 
originally developed in Phil Holliger’s laboratory (Ghadessy et al., 2001b). In CSR, bacteria 
expressing individual polymerase variants are emulsified into individual water-in-oil emulsion 
bubbles. These bubbles can be thought of as individual reaction chambers or PCR ‘tubes’. In the 
ideal case, the bubbles do not merge or mix with one another once they are formed. Emulsion PCR 
within these compartments in the presence of primers specific for the polymerase gene results in 
self-amplification of those genes that produce the most active polymerases. Amplified gene 
products are then re-cloned into plasmids for subsequent rounds of selection and amplification 
(Figure 5-1).  
Using this selection strategy, thermostable DNA polymerases have been engineered to have 
novel functional properties using a variety of selection pressures. For example, heparin-resistant 
Taq variants were isolated in the first demonstration of CSR (Ghadessy et al., 2001b). Later, 
shuffling of Taq and other Family A polymerases led to variants that were resistant other 
environmental PCR inhibitors (Baar et al., 2011). Others have used CSR to train polymerases to use 
modified or unnatural bases during polymerization (Brown and Suo, 2011; Laos et al., 2014).  
Our lab became interested in using CSR for the directed evolution of archaeal Family B 
polymerases. Thermostable family B polymerases are the high-fidelity enzymes commonly used in 
PCR reactions. In this section, we describe the shuffling of two commonly used Family B DNA 
polymerases and our first directed evolution experiments utilizing CSR. After only two round of 
selection, we identified two variants that were far more active than either of the parental enzymes.  
 We also describe novel screening techniques that we developed in order to streamline CSR 
selections. The experiments described below would lay the foundation of future directed evolution 
experiments of DNA polymerases discussed in detail in later sections of this chapter. 
 180 
Results & Discussion 
Library generation of DNA polymerases using gene shuffling 
To generate library diversity for selection of DNA polymerases with enhanced properties, 
two Family B DNA polymerases were chosen from thermostable archaeal organisms and shuffled. 
We chose KOD (Thermococcus kodakaraensis) and Pfu (Pyrococcus furiosus) because of their 
high level of fidelity and distinct functional properties. For example, KOD is more processive and 
faster (Takagi et al., 1997), and Pfu has been shown to generate longer amplicons in routine PCR 
reactions (Wang et al., 2004). We hypothesized that properties of each of these enzymes could be 
melded together to create novel, robust enzymes that would prove useful in a variety of 
biotechnological applications. To generate the libraries, the enzymes were codon optimized for 
both increased crossing-over during shuffling and expression in Escherichia coli. We reasoned that 
optimizing conditions for enhanced crossover would potentially lead to novel mutations not present 
in any of the parental enzymes. The polymerases were then synthesized in-house, fragmented by 
DNaseI digestion, and shuffled with equimolar ratios of fragments from each parental enzyme to 
reduce potential bias (Meyer et al., 2014b). 
Selection of DNA polymerases using Compartmentalized Self-Replication 
In order to select novel polymerases, two independently created libraries (> 107) were 
subjected to two rounds of compartmentalized self-replication (CSR) (Figure 5-1). We chose 
minimal selective pressure in each round (1 min/kb) in an effort to decrease stringency and carry 
forward functional polymerases. We hypothesized that under these conditions, enhanced 
polymerases would begin to dominate the population over several cycles of PCR. To test for 
enhanced functionality after only two rounds of selection, the top variants were assayed again in 
emulsion PCR and purified to homogeneity for assays in bulk reactions. Target amplicons of 2.7 kb 
and 7 kb were amplified with each variant alongside wild-type controls. Two variants, A12 and 
PK6, were consistently better than KOD and Pfu under all conditions tested (Figure 5-2). 
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Additionally, A12 and PK6 were shown to be functional in qPCR using intercalating dyes, where a 
1 second extension time was sufficient to amplify a 100 bp target (Figure 5-3). Moreover, A12 was 
able to amplify a 3 kbp target with only 15 seconds per kbp of extention time (Figure 5-4). We 
interpreted these results to mean that the evolved enzymes were indeed faster than the parental 
enzymes. 
To elucidate possible mutations responsible for enhanced functionality in A12 and PK6, the 
polymerases were sequenced by the Sanger method and aligned. Interestingly, both variants greatly 
favored KOD, each sharing 94.5% identity with the parental enzyme (Figure 5-5). KOD and PK6 
are both one amino acid shorter in length, highlighted by a gap at position 381. Each of the evolved 
polymerases acquired mutations that were not present in either of the wild-type enzymes (A12: 
E306G & V647A; PK6: E150G), possibly demarking sites of crossover. Homology modeling of 
these enzymes did not show any drastic changes in structure (Figure 5-6). 
Given that we could select for polymerases with enhanced activity, we initiated selections 
under a variety of additional selection pressures: speed, processivity, and heme resistance (Table 5-
1). To better address the need for faster, more robust DNA polymerases, we completed four 
additional rounds of CSR, using KOD, Pfu and Deep Vent as parental enzymes. We created 
libraries by shuffling random sequences generated from DNaseI treatment of the intact parental 
genes. The independently created libraries were then subjected to increasing amounts of selection 
pressure in three separate selections. To select for speed, the extension time was decreased in the 
CSR reaction from round to round. We started by allowing 1 min/kbp for the elongation step (~2.5 
kb amplicon) in the emulsion PCR. This is a relatively small amount of selection pressure, and we 
anticipated only moving functional polymerases into the next round. The polymerases were only 
allowed 30 s/kbp in the second round, 10 s/kbp in round three, and 5 s/kbp in round 4. After 
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recovery of the 4th round, we sequenced the N- and C-termini (~420 AA of 776) to gauge the 
amount of diversity present in the population (Figures 5-7 & 5-10) 
Processivity in polymerases generally refers to the number of bases polymerized after 
binding a primed target before the polymerase is released or “falls” off (Wang et al., 2004). 
Typically, Family B polymerases exhibit processivities between 20-200 bp in the absence of the 
proliferating cell nuclear antigen (PCNA) clamp, which allows these polymerases to processively 
synthesize tens of thousands of bases (Kitabayashi et al., 2002). In an attempt to select for more 
processive polymerases, we lowered the expression of the polymerase and extension time. Further, 
we forced the polymerase to ampify the full 7 kbp plasmid during the CSR reaction. After four 
rounds of selection, the survivors were able to elongate 7 kbp with only a 2.5 minute extension time 
per PCR cycle. Sequencing revealed that the populations were converging (Figures 5-8 & 5-10). 
Heme-resistnace provided an interesting challenge. In initial testing, we found that parental 
enzymes were inhibited by heme (IC50 = ~1-5 µM). Due to the large concentration of heme found 
in blood (~10 mM), we reasoned that evolving polymerases for heme-resistance would be a 
necessary first step in creating a polymerase to work in whole-blood (Akane et al., 1994; Al-Soud 
and R\a adström, 2001). We started at 10 µM heme and increased the concentration by an order of 
magnitude with each round. After round four, polymerases capable of handling physiologically 
relevant concentrations of heme (10 mM) were sequenced from the two starting libraries (Figures 
5-9 & 5-10). 
Convergence for each of these libraries was observed after only 4 rounds of selection 
(Figure 5-11), giving us confidence that our selections were producing fully functional polymerase. 
However, it became apparent that hybrid polymerases would be difficult to tease apart 
mechanistically. Further, it was found that A12 and PK6 were error-prone, with error rates as high 
as 0.1%. This came as somewhat of a surprise because sequencing of these variants revealed that 
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the exonuclease, or proof-reading domain, was still intact. At this stage, we began to think about 
ways to do multiple selections in parallel and develop screening methodologies that would allow 
for multiplex selections. Given that KOD was the most robust Family B polymerase in emulsions 
and exhibited the highest fidelity, we turned our attention to evolving this polymerase in all 
subsequent selections. 
Development of screening technologies for CSR selections 
During our proofs-of-concept, we found that it took up to two weeks before a particular 
variant could be assayed after the selection was completed. The variant needed to be isolated and 
cloned into a suitable expression vector and then sequenced before purifying the enzyme using 
standard methods. The original pAK vector used for CSR selections did not produce enough 
polymerase for bulk assays using manageable volumes of culture (Ghadessy and Holliger, 2007). In 
fact, it required at least 500 mL of culture to produce enough enzyme to properly purify. For 
example, 25 mL of culture was not enough to reliably purify using NiNTA resin. However, once a 
variant was moved into a T7-based pET vector, 25 mL of culture was more than enough to purify 
usable quantities of polymerase (Figure 5-12). While this greatly reduced the cost and time of 
assaying a variant, this methodology was still slow. Fortunately, once a variant was cloned into the 
expression vector, we found that 0.5 µL of induced cells was enough to use in a typical PCR 
reaction (Figure 5-12). Further, cells could be stored as pellets at -20˚C or -80˚C before 
resuspension and testing. This allowed us to grow sub-milliliter quantities of cells in 96-well grow 
blocks. Further, cells could be screened in bulk using qPCR (Figure 5-13). This would allow us to 
screen up to 96 variants at once without having to run gels. We were also able to assay rounds 
within a day, rather than 6-8 variants over the course of two weeks. 
 
Conclusions 
The early experiments described above were important for a number of reasons. First, our 
laboratory learned how to perform rounds of Compartmentalized Self-Replication. Our first attempt 
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at CSR identified two highly active polymerases in A12 and PK6, and we would later use their 
apparent low-fidelity as a means to create error-prone libraries for future CSR and CPR evolution 
experiments. Many of the laboratories at the University of Texas at Austin still use A12 as a means 
of generating library diversity for directed evolution experiments. Secondly, we learned that we 
could change selection pressures and see convergence in our libraries. This gave us quite a bit of 
confidence in the technology. Finally, we streamlined the process of screening our libraries. Rather 
than waiting weeks for small numbers of active polymerases, we could screen hundreds in a single 
day. The techniques developed here would inform and shape selections described below. 
 
Methods & Materials 
CSR selections and emulsion PCR 
Libraries were cloned into the pAK vector (Ghadessy and Holliger, 2007) and transformed 
into BL21s. Overnight library cultures were seeded at a 1:20 ratio into fresh 2xYT media 
supplemented with ampicillin and grown for 2 hours at 37◦C. Polymerases were induced with IPTG 
and incubated at 37◦C for  4 hours. Induced cells (400 µL total) were spun in a tabletop centrifuge 
at 3,000 x g for 8 minutes. The supernatant was discarded and the cell pellet was resuspended in 
300 µL CSR mix: 1x Selection buffer (50 mM Tris-HCl (pH8.8), 10 mM (NH4)2SO4, 10 mM KCl, 
2 mM MgSO4), 260 µM dNTPs, 530 nM of each of the forward and reverse primers, and 10-300 
µM TMAC. The resuspended cells were placed into a 2 mL tube with a 1mL rubber syringe 
plunger and 1200 µL of oil mix (73% Tegosoft DEC, 7% AbilWE09 (Evonik), and 20% mineral oil 
(Sigma-Aldrich)). The emulsion was created by placing the cell and oil mix on a TissueLyser  LT  
(Qiagen) with  a program  of 42Hz  for 4  minutes.  The emulsified  cells  were thermal-cycled for 
20-25 cycles. 
Emulsions were broken by spinning the reaction (20,000xg) for 15 minutes, removing the 
top oil  phase, adding 750 µL chloroform, vortexing vigorously, and finally phase separating in a 
phase lock tube (5Prime). The aqueous phase was cleaned using a Promega PCR purification 
column. Overnight treatment with DpnI mitigated plasmid carryover. Subamplification with 
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recovery primers ensures that only polymerases were functional in the emulsion PCR amplified. 
Selection pressures are shown in Table 5-1. A representative CSR mastermix setup is shown in 
Table 5-2. A detailed protocol can be found in Appendix I. 
 
Purification of polymerase variants 
Overnight cultures of BL21 (DE3) harboring each of the variants were grown overnight in 
Superior broth at 37°C.  Cells were then diluted 1:250, and protein production was induced with 1 
mM IPTG during mid- log at 18°C for 20 hrs. Harvested cells were flash-frozen and lysed by 
sonication in 10 mM phosphate, 100 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 10% glycerol, pH 7 
(Buffer A). Cleared cell lysates were heated at 85˚C for 25 min, cooled on ice for 20 minutes, and 
filtered (0.2 μm). The filtrate was then passed over a NiNTA column and eluted with imidazole. 
Pooled fractions were then applied to a heparin column (GE Healthcare), concentrated, and 
dialyzed into storage buffer (50 mM Tris- HCl, 50 mM KCl, 0.1 mM EDTA, 1 mM DTT, 0.1% 
Non-idet P40, 0.1% Tween20, 50% glycerol, pH 8.0). Working stocks were made at 0.2 mg/mL. 
 
Homology modeling of polymerase variants 
Homology models of the DNA polymerase variants A12 and PK6 were constructed using 
the parental enzymes, KOD and Pfu, as reference structures (PDBs: 4K8Z and 2JGU). To create the 
models, sequence identities were calculated, and RMS deviation values were used as guideposts in 
manipulating potential structures. Using the Amber12EHT force field with R-Field treatment of 
solvation electrostatics, an average of the 100 lowest energy conformations was used in the 
workup. Once the final homology model was complete, it was superimposed against the reference 
structures. Further evaluation of the models was checked by calculating Phi-Psi angles (Figure 6). 
Finally, the homology models were refined using fine grain energy minimization. 
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Small scale purification for screening 
Overnight cultures of BL21 DE3 harboring polymerase variants in a pET21-derived 
expression vector were diluted 1:20 into 25 mL of 2XYT growth medium. Cells were grown for an 
additional 2 hours before inducing expression with 1 mM IPTG for 4 hours. Cells were then 
collected by centrifugation, washed in TBS, and resuspended in 2 mL of B-PER II cell lysis buffer 
(Thermo). The cells were then incubated at 80˚C for 20 min on a thermal block with light agitation. 
Debris was cleared by centriguation (20,000xg) for 15 minutes. Lysate was then incubated with 25 
uL NiNTA resin and step eluted with imidazole. Purified protein was dialyzed into 50 mM Tris-
HCl, 50 mM KCl, 0.1% Tween20, pH 8.0.  
 
Whole-cell PCR and qPCR screening 
Overnight cultures of BL21 DE3 harboring polymerase variants in a pET21-derived 
expression vector were diluted 1:20 into 500 µL or 4 mL of superior growth medium. Cells were 
grown for an additional 2 hours before inducing expression with IPTG (1 mM) for 4 hours. Cells 
were then collected by centrifugation, washed in TBS, and resuspended in 1X PCR buffer 
(Accuprime). Next, 0.5-10 µL cells were incubated with primers specific to a 550 bp piece of the 
pET21 vector. EvaGreen intercalating dye was used to monitor fluorescence in standard 30 µL 
reactions using a LightCycler96. 
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Figure 5-1: General CSR cycle 
 
Figure 5-1: General CSR cycle. Depiction of the in vivo and in vitro stages selection using CSR. 
Once protein has been expressed within a cell, it is compartmentalized in a water-in-oil emulsion 
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Figure 5-2. Emulsion and Bulk PCR Results 
 
Figure 5-2. Emulsion and Bulk PCR Results. The left pane shows the initial 
screening of polymerases after 2 rounds of CSR. On the right, emulsion and bulk 
PCR results are shown. Evolved variants (A12 and PK6) are compared with their 
parental enzymes. 
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Figure 5-3: A12 and PK6 qPCR results 
 
Figure 5-3: A12 and PK6 qPCR results. qPCR results using a 1 second extension time for a 100 bp 
amplicon are shown. Cq values are shown in table. A12 and PK6 were both shown to be faster than 
either of the parental enzymes or the commonly used Taq polymerase. 
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Figure 5-4: A12 15s per kbp extension 
 
Figure 5-4: A12 15s per kbp extension. Replicates of a 3 kbp product are shown. A12 could 
robustly amplify DNA using a much shorter extension time than either of the parental enzymes, Pfu 
or KOD. 
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Figure 5-5: Sequence alignment and identity heat map of A12 and PK6 
 
 
Figure 5-5: Sequence alignment and identity heat map of A12 & PK6. 
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Figure 5-6. Homology models and calculated Phi-Psi plots of A12 and PK6 
 
 
 
 
 
 
 
Figure 5-6. Homology models and calculated Phi-Psi plots of A12 and PK6. A.,C. Best-fit homology 
models of A12 and PK6, respectively. Final structures are overlaid with KOD, one of two parental 
enzymes used. B., D. Phi-Psi plots of A12 and PK6. A12 shows only one residue in the outlier region, 
while PK6 has two. 
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Table 5-1: Selection conditions for shuffled polymerases 
 
 
 
 
 
 
Selection  Rd 1 Rd 2 Rd 3 Rd 4 
Speed  1 min/kb 30 s/kb 15 s/kb 7.5 s/kb 
Heme  10 µM 100 µM 1 mM 10 mM 
Length  1 min/kb 45 s/kb 30 s/kb 20 s/kb 
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Figure 5-7. N- and C-terminal heat maps of round 4 extension (speed) library variants 
 
Figure 5-7: N- and C-terminal heat maps of round 4 extension (speed) library variants. Heat map shows relationship 
of sequencing results of the polymerases through round four with the ancestral polymerases. 
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Figure 5-9: N- and C-terminal heat maps of round 4 length (processivity) library variants 
 
 
Figure 5-9: N- and C-terminal heat maps of round 4 length (processivity) library variants. Heat map shows 
relationship of sequencing results of the polymerases through round four with the ancestral polymerases. 
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Figure 5-10: N- and C-terminal heat maps of round 4 heme library variants 
 
 
 
Figure 5-10: N- and C-terminal heat maps of round 4 heme library variants. Heat map shows relationship of 
sequencing results of the polymerases through round four with the ancestral polymerases. 
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Figure 5-10: Round 4 recovery of shuffled rounds 
 
Figure 5-10: Round 4 recovery of shuffled rounds. After four rounds of selection, each round was 
recovered and recloned for sequencing analysis. 
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Figure 5-11: Round 4 convergence of processivity library 
 
 
 
 
Figure 5-11: Round 4 convergence of processivity library. Convergence is shown by highlighting 
differences from the reference sequence. Parental enzymes are shown at the top for reference. A 
and D in the legends refer to the segment sequenced. A is the amino terminus, and D is the carboxy 
terminus. 
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Figure 5-12. Change in expression and activity in pET vector 
 
 
Figure 5-12. Change in expression and activity in pET vector. Left, 25 mL cultures of KOD were 
induced for 4 hrs and purified by Ni-NTA chromatography. Lane 1 is a protein standard. Lane 2 
shows production in pET28. Lane 3 is the pAK vector. No visible amount of polymerase could be 
seen when induced from pAK. Middle, varying amounts of cells (0.5-20 µL) were used in a 30 µL 
reaction using the original pAK selection vector for expression. Amplicons could not be seen in any 
of the lanes. Right, 1 µL of induced cells harboring the pET vector (biological replicates).  
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Figure 5-13. qPCR-based screen proof-of-concept 
 
Figure 5-13. qPCR-based screen proof-of-concept. 1 µL of induced cells harboring the polymerase 
in a pET vector was used to detect 2.5 ng of an exogenous plasmid. Three independent clones were 
tested in triplicate (9 total). Cq values were all within error.  
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Table 5-2: Representative CSR reaction mix 
Component Volume (µL) 
Buffer (10X) 37.5 
dNTPS (4 mM) 18.75 
F (20 μM) 7.5 
R (20 µM) 7.5 
RNase (0.5 U/µL) 1.875 
TMAC (10 mM) 3.75 
H2O 298.125 
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5.2 DIRECTED EVOLUTION OF A THERMOSTABLE, PROOF-READING REVERSE TRANSCRIPTASE 
Introduction 
In the previous section, we learned how to perform selections with Compartmentalized Self-
Replication. We also developed methods to screen libraries, enabling us to perform multiple 
directed evolution experiments in parallel (see Section 3). Having these tools in our hands enabled 
us to pursue more ambitious projects. At this time, Dr. Jared Ellefson came up with the idea to 
evolve KOD into a thermostable reverse transcriptase using a novel selection platform. The 
technique employed here, Reverse-Transcription Compartmentalized Self-Replication (RT-CSR), 
is a modified version of CSR where hybrid primers, containing both RNA and DNA bases (Figure 
5-14), are used in the CSR reaction. By forcing library variants to reverse transcribe the end of the 
selection primers, we were able to engineer KOD to function as both a DNA polymerase and a 
reverse transcriptase. 
KOD was chosen as a scaffold for engineering due to its superior functional properties in 
standard and emulsion PCR reactions. In the previous section, we found that KOD was the only 
natural Family B polymerase that we tested capable of robustly amplifying DNA in water-in-oil 
emulsions. Moreover, our shuffled libraries almost always converged on sequences containing 
more KOD sequence than the other parental enzymes. Further, KOD is one of the most highly 
processive Family B polymerases known, and displays superior fidelity. Preliminary experiments 
using KOD and Pfu revealed that neither polymerase was capable of extending a template 
containing as little as 5 RNA bases. Modeling of these polymerases with DNA:RNA 
heteroduplexes revealed a vast number of contacts, and we thought it impractical to create focused 
or targeted libraries. Over 50 contacts were observed between the polymerase and duplex. Instead, 
we chose to create error-prone libraries of KOD with A12, the error-prone polymerase discovered 
in Section 1. Dr. Ellefson carried out 18 rounds of RT-CSR utilizing increasing selection pressure 
(10-176 RNA bases) and found a variant that was capable of robustly reverse-transcribing RNA. 
Further modeling and engineering led to the production of the first known high-fidelity, 
 203 
thermostable reverse transcriptase (RTX). Here, we describe the modeling, engineering, and 
characterization of RTX. 
 
Results & Discussion 
Selection of a thermostable reverse transcriptase 
At round 18, variants were challenged with 176 RNA bases during each thermal-cycle. 
Sequencing of random clones from the survivors of the final revealed a large number of mutations 
throughout the polymerase. We attributed the increased number of mutations to: (1) variants error-
proning themselves during the selection and (2) over 1000 cycles of PCR having been performed 
throughout the course of the evolution experiment. Using techniques described in Section 1, we 
found one clone (B11) that was capable of reverse-transcribing 500 bp of RNA. Sequencing of this 
clone also indicated that the proofreading domain was nonfunctional, supporting our hypothesis 
that polymerases may be capable of mutating their sequences during RT-CSR. Transplantation of 
the exonuclease domain from the wildtype sequence restored a small amount proofreading activity 
(Figure 5-15). This led us to believe that a minimal set of mutations may be accessible that would 
retain reverse transcriptase activity and increase the fidelity of the enzyme by improving its 
proofreading ability. Thus, we sought to rationally design polymerase variants with a core, minimal 
set of mutations using deep sequencing and molecular modeling. 
 
Deep sequencing and modeling provide molecular insight into RT activity 
In an effort to understand how KOD evolved to use RNA templates, rounds of RT-CSR 
were deep sequenced (Ellefson et al., 2016). A large number of mutations were identified along the 
polymerase-duplex interface. However, the most conserved mutations were found at the point 
where the polymerase encounters template bases. We believe that these mutations were part of 
molecular checkpoints that the wildtype enzyme uses to enforce strict DNA template utilization. 
We modeled these interactions using MOE (Figures 5-16). 
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Position R97 was identified near the entry site of the template-polymerase structure. 
Mutations at this position are known to affect ‘uracil scanning’ of template strands by Family B 
polymerases. A specialized pocket near this position has been shown to bind tightly to uracil, which 
arises from cytosine deamination, and stalls the polymerase until the base can be repaired 
(Connolly et al., 2003; Fogg et al., 2002). A number of mutations to R97 were observed in the 
sequencing data (>10%), which modeling predicted to abolish polar contacts between the residue 
and phosphate backbone of the template. This interaction is presumably used to ‘flip’ the template 
base into the checkpoint site. 
Next, we rationalized the most conserved mutation from our RT-CSR evolution experiment, 
Y384H. This mutation appears to disrupt a hydrogen bonding network between the 2’ hydroxyl of 
the RNA template and residues Y384 and Y494. The next most prevalent mutations (E664K, 
G711V, and E735K) appear to enhance binding to homo- and heteroduplexes in both A- and B-
form duplex conformations. Our modeling is surprisingly supported by a previous study in which 
E664K was shown to greatly increase binding to RNA:DNA heteroduplexes (Cozens et al., 2012). 
We then modeled a number of other conserved mutations along the polymerase-template 
interface (Figure 5-17). K118I appears to break a potential hydrogen bond on a RNA template, 
which may be involved in the checkpoint disrupted by R97M. Y493L is poised to allow for packing 
within the hydrophobic core adjacent to the heteroduplex. This movement may be necessary for 
binding to both A- and B-form duplexes. V389I adds a methyl group and pushes the neighboring 
beta sheet towards the heteroduplex to better orient the hydrogen-bonding network of T541 and 
D540 to both primer-template duplexes. G711V pushes two α-helices away from each other in the 
thumb domain, likely allowing for geometry differences in DNA:DNA and DNA:RNA duplexes 
(B- and A-form, respectively). N735K displays stronger binding by ~8 kcal/mol to the backbone of 
the template strand by making contact to the phosphate backbone.  
Using our sequencing and modeling as guideposts, we then rationally designed four 
potential variants and tested their ability to perform reverse transcription and high-fidelity PCR. All 
four of the variants were capable of high-fidelity PCR. However, only two were shown to be robust 
in reverse transcription of a 1 kbp amplicon (Figure 5-18). The most promising variant, RTX, had 
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less than half of the mutations of the selected polymerase B11 without sacrificing catalytic 
efficiency or the Michaelis constant in single-nucleotide kinetics experiment (Figure 5-19). We 
next determined if RTX was capable of single-enzyme RT-PCR, where RTX performs reverse 
transcription and PCR in the same reaction. Using several RNA templates from both bacterial and 
human samples, RTX was capable of performing single-enzyme RT-PCR on RNAs over 5 kbp, 
potentially highlighting its processivity (Figure 5-20).  
Modeling of RTX showed a preference for DNA templates to RNA templates (contact 
energies of -221.7 kcal/mol vs -204.8 kcal/mol). For KOD, our modeling predicted much less 
binding to both DNA and RNA templates, -182.62 kcal/mol and -167.28 kcal/mol, respectively 
(Figure 5-21). In vitro characterization of the binding of these enzymes to homo- and 
heteroduplexes  was in excellent agreement with these predictions. RTX was shown to have a 2.3 ±  
0.4 nM Kd with DNA duplexes and a 46.0 ± 8.2 nM Kd with DNA:RNA heteroduplexes. KOD 
displayed similar binding to both duplexes (25.5 ± 4.7 nM vs 33.0 ± 7.8 nM) (Table 5-3). These 
results gave us confidence that our modeling predictions were valid. 
 
RTX can proofread on DNA and RNA templates 
While our high-fidelity PCR results showed that RTX still had the ability to proofread 
mismatches, we were unsure if the enzyme would be able to proofread mismatches on a DNA-
primed RNA template due to the A-form helical nature of heteroduplexes (Wang et al., 1982). 
Using primer extension analysis using matched and 3’-dideoxy mismatched primers, RTX was 
shown to elongate on mismatches using both RNA and DNA as templates. As expected, KOD was 
only able to extend on DNA templates. Interestingly though, KOD was shown to excise several 
bases in the primer when RNA was used as a template, presumably triggering proofreading due to 
the unique conformation of the heteroduplex. As expected, exonuclease deficient versions of RTX 
and KOD were unable to excise mismatches and extend the primer (Figure 5-22). To our 
knowledge, this marked the first demonstration of proofreading activity by a reverse transcriptase. 
Subsequent experiments revealed that RTX was capable of high-fidelity reverse transcription in a 
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novel fidelity assay. Interestingly, RTX was found to have a slightly altered mutational bias. This 
may be a result of RTX’s ability to use DNA and RNA templates, which when primed with DNA 
are geometrically and structurally distinct. 
 
Conclusions 
Using KOD as a scaffold, we were able to engineer the first known thermostable, high-
fidelity reverse transcriptase. We believe that the mutations discovered here unlocked molecular 
checkpoints that the wildtype enzyme used to discriminate between templates. Throughout the 
course of RT-CSR, polymerases accumulated mutations that not only gave rise to RNA template 
utilization, but also mutations that inactivated the proofreading domain. This is a common feature 
of CSR type reactions because inactivating the proofreading domain typically increases the speed 
of polymerization. Our initial attempts to engineer proofreading into B11 were met with modest 
results, giving credence to the notion that other deleterious mutations were present—more than 
likely due to variants increasing mutational load throughout rounds of selection. By combining 
deep sequencing analysis of individual rounds and molecular modeling, we were able to rationally 
design variants with less than half of the mutations present in B11, the original reverse transcriptase 
found during our screening process. RTX was found to proofread on DNA and RNA templates, 
which was unexpected due to RNA:DNA heteroduplex geometry. This increase in fidelity should 
enable higher precision RNA-seq experiments in the future.  
 
Materials and Methods 
Initial reverse transcription test for polymerases 
 
30 pmol of 5' fluorescein labeled primer (25FAM) were annealed with 30 pmol of template 
(TEMP.A.DNA/1RNA/5RNA) and 0.4 µg of polymerase by heat denaturation at 90
◦
C for 1 minute 
and allowing to cool to room temperature. Reactions were initiated by the addition of "start" mix 
which contained (50mM Tris-HCl (pH8.4), 10 mM (NH4)2SO4, 10 mM KCl, 2 mM MgSO4  and  
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200  µM  dNTPs.  MMLV  polymerase  was  treated  according  to    manufacturer’s 
recommendations (New England Biolabs). Reactions were incubated for 2 minutes at 68
◦
C   until 
terminated by the addition of EDTA to a final concentration of 25 mM. The labeled primer was 
removed from the template strand by heating sample at 75
◦
C for 5 minutes in 1x dye (47.5% 
formamide, 0.01% SDS) and 1 nmol of unlabeled BLOCKER oligonucleotide (to competitively 
bind the template strand). Samples were run on a 20% (7 M urea) acrylamide gel. 
Reverse Transcription CSR (RT-CSR) 
 
 
Library generation and RT-CSR 
KOD polymerase libraries were created through error prone PCR to have a mutation rate of 
~1-2 amino acid mutations per gene. Libraries were cloned into tetracycline inducible vector and 
electroporated into DH10B E. coli. Library sizes were maintained with a transformation efficiency 
of at least 10
6
, but more typically 10
7
-10
8
. Overnight library cultures were seeded at a 1:20 ratio 
into fresh 2xYT media supplemented with 100 µg / mL ampicillin and grown for 1 hour at 37
◦
C. 
Cells were subsequently induced by the addition of anhydrotetracycline (typically at a final 
concentration of 200 ng / mL) and incubated at 37
◦
C for  4 hours. Induced cells (200 µL total) were 
spun in a tabletop centrifuge at 3,000 x g for 8 minutes. The supernatant was discarded and the cell 
pellet was resuspended in RTCSR mix: 1x Selection buffer (50 mM Tris-HCl (pH8.4), 10 mM 
(NH4)2SO4, 10 mM KCl, 2 mM MgSO4), 260 µM dNTPs, 530 nM forward and reverse RNA 
containing primers. The resuspended cells were placed into a 2 mL tube with a 1mL rubber syringe 
plunger and 600 µL of oil mix (73% Tegosoft DEC, 7% AbilWE09 (Evonik), and 20% mineral oil 
(Sigma-Aldrich)). The emulsion was created by placing the cell and oil mix on a TissueLyser  LT  
(Qiagen) with  a program  of 42Hz  for 4  minutes.  The emulsified cells w e r e  t h e r m a l -
cycled with the program: 95
◦
C - 3min, 20x (95
◦
C- 30 sec, 62
◦
C- 30 sec, 68
◦
C- 2 min). Emulsions 
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were broken by spinning the reaction (10,000 x g - 5 min), removing the top oil  phase, adding 150 
µL of H2O and 750 µL chloroform, vortexing vigorously, and finally phase separating in a phase 
lock tube (5Prime). The aqueous phase was cleaned using a PCR purification column which results 
in purified DNA, including PCR products as well as plasmid DNA. Subamplification with 
corresponding outnested recovery primers ensures that only polymerases that reverse transcribed 
are PCR amplified. Typically this is achieved by addition of 1/10 the total purified emulsion using 
Accuprime Pfx (ThermoFisher) in a 20 cycle PCR, however challenging rounds of selection could 
require increasing the input DNA or  cycle number to achieve desired amplification. 
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Molecular Modeling of RT-CSR Mutations 
 
The wild-type structures of the family B polymerases from Thermococcus kodakaraensis 
(KOD) (PDB: 4K8Z) and Thermococcus gorgonarius (PDB: 2VWJ) were prepared for mutational 
analyses using the Molecular Operating Environment (MOE.10.2015) software package from 
Chemical Computing Group. The structures were inspected for anomalies and protonated/charged 
with the Protonate3D subroutine (341K, pH 8.0, 0.1 M salt). The protonated structures were then 
lightly tethered to reduce significant deviation from the empirically determined coordinates and 
minimized using the Amber12:EHT forcefield with Born    solvation model to an RMS gradient of 
0.1 kcal mol
-1 
Å
-1
.  These structures were then used as templates to build homology models of RT-
CSR mutations. Homology models of the variants were prepared by creating 25 main chain models 
with 25 sidechain samples at 341K (625 total) within MOE. Intermediates were refined to an RMS 
gradient of 1 kcal mol
-1 
Å
-1
, scored with the GB/VI methodology, minimized again to an RMS 
gradient of 0.5 kcal mol
-1 
Å
-1
, and protonated. The final model for each variant was further refined 
by placing the protein within a 6 Å water sphere and minimizing the solvent enclosed structure to 
an RMS gradient of 0.001 kcal mol
-1 
Å
-1
. Models were evaluated by calculating Phi-Psi angles and 
superimposed against the reference structures. RNA:DNA A-form duplexes were created and 
superimposed against the empirically derived coordinates for the DNA:DNA duplex. Models were 
then minimized and contact  energies measured within MOE. 
 
Cloning and purification of polymerase variants 
 
Escherichia coli DH10B and BL21 (DE3) strains were used for cloning and expression, 
respectively. Strains were maintained on either Superior or 2XYT growth media. Polymerases were 
cloned into a modified pET21 vector using NdeI and BamHI sites. Overnight cultures of BL21 
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(DE3) harboring each of the variants were grown overnight in Superior broth at 37°C.  Cells were 
then diluted 1:250, and protein production was induced with 1 mM IPTG during mid- log at 18°C 
for 20 hrs. Harvested cells were flash-frozen and lysed by sonication in 10 mM phosphate, 100 mM 
NaCl, 0.1 mM EDTA, 1 mM DTT, 10% glycerol, pH 7 (Buffer A). Cleared cell lysates were 
heated at 85˚C for 25 min, cooled on ice for 20 minutes, and filtered (0.2 μm). The filtrate was then 
passed over a DEAE column, immediately applied to an equilibrated heparin column, and eluted 
along a sodium chloride gradient. Polymerase fractions were collected and dialyzed into Buffer A. 
Enzymes were further purified using an SP column and again eluted along a salt gradient. Pooled 
fractions were then applied to a Sephadex 16/60 size exclusion column (GE Healthcare), 
concentrated, and dialyzed into storage buffer (50 mM Tris- HCl, 50 mM KCl, 0.1 mM EDTA, 
1 mM DTT, 0.1% Non-idet P40, 0.1% Tween20, 50% glycerol, pH 8.0). Working stocks were 
made at 0.2 mg/mL.  
PCR Proofreading Assay 
50 µL PCR reactions were set up with a final concentration of 1x Assay Buffer (60 mM 
Tris-HCl (pH8.4),  25  mM  (NH4)2SO4,  10  mM  KCl),  200  µM  dNTPs,  2  mM  MgSO4,  400  
nM (PCRTest.F/PCRTest.R) or (PCRTest.DiDe.F/PCRTest.DiDe.R) forward and reverse primers, 
20 ng of template plasmid and 0.2 µg polymerase. Reactions were thermal-cycled using the 
following program: 95
◦
C - 1min, 25x (95
◦
C- 30 sec, 55
◦
C- 30 sec, 68
◦
C- 2 min 30 sec). 
 
Primer Extension Assay 
 
10 pmol of 5' fluorescein labeled primer (RT.Probe or RT.Probe.3ddc) were annealed with 
50 pmol of template RNA or DNA (RT.RNA.TEMP and RT.DNA.TEMP, respectively) and 0.4 µg 
of polymerase by heat denaturation at 80
◦
C for 1 minute and allowing to cool to room temperature. 
Reactions were initiated by the addition of "start" mix which contained (1x Assay Buffer, 2 mM 
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MgSO4 and 200 µM dNTPs. Reactions were incubated for 10 minutes at 68
◦
C until terminated by 
the addition of EDTA to a final concentration of 25 mM. The labeled primer was removed from the 
template strand by heating sample at 75
◦
C for 5 minutes in 1x dye (47.5% formamide, 0.01% SDS) 
and 1 nmol of unlabeled RT.bigBlocker oligonucleotide (to competitively bind the template 
strand). Samples were run on a 20% (7 M urea) acrylamide gel. 
 
RT-PCR Assay 
 
50 µL reverse transcription PCR (RTPCR) reactions were set up on ice with the following 
reaction conditions: 1x Assay Buffer, 1 mM MgSO4, 1 M Betaine (Sigma-Aldrich), 200 µM 
dNTPs, 400 nM reverse primer, 400 nM forward primer, 40 units RNasin Plus (Promega), 0.2 µg 
polymerase and 1 µg of Total RNA from Jurkat, Human Spleen or E. coli (Ambion). Primer sets 
used: PolR2A (PolII.R, PolII.F1/F2/F4), p532 (p532.R, p532.F1/F2/F5), rpoC (rpoC.R, 
rpoC.F1/F2/F4). Reactions were thermal-cycled according to the following parameters: 68
◦
C - 30 
min, 25x (95
◦
C- 30 sec, 68
◦
C (63
◦
C for rpoC) - 30 sec, 68
◦
C - 30 s/kb).  
 
Single nucleotide incorporation kinetics 
 
Duplexes (DNA:DNA or DNA:RNA) were assembled by combining equimolar amounts of 
a DNA 25-mer (5’-CCCTCGCAGCCGTCCAACCAACTCA-3’) and DNA or RNA 36-mer (3’- 
GGGAGCGTCGGCAGGTTGGTTGAGTGCCTCTTGTTT-5’)  in  10  mM  Tris-HCl,  0.1 mM 
EDTA (pH 8.0). Solutions were heated to 95˚C for 5 min, slowly cooled to 60˚C for 10 min, and 
then cooled to room temperature for 15 minutes. Reactions (100 μL) consisting of assay buffer, 1 
mM MgSO4, and 500 nM duplex were initiated by variable amounts of α-P32-dCTP (0.003- 
400μM), which was diluted 1:400 in unlabeled dCTP. Reactions were allowed to proceed 3-14 
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minutes. 10 μL aliquots were quenched by the addition of EDTA (0.25 M final concentration) in 
15-120s intervals. Aliquots (2 μL) were spotted on DE81 filter paper and washed 6 times in 5% 
NaH2PO4 (pH 7), 2 times in ddH2O and finally in 95% EtOH. Dried filter paper was exposed for 
24 hrs and imaged on a STORM scanner. Initial rates were obtained by analysis using FiJi (Image 
J). Kinetic parameters were determined by non-linear regression using SigmaPlot10. 
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Figure 5-14: RT-CSR Scheme 
 
 
Figure 5-14: RT-CSR Scheme. Directed evolution of thermostable reverse transcriptase using 
reverse transcription compartmentalized self replication (RT-CSR). Libraries of polymerase 
variants are created, expressed in E. coli, and in vitro compartmentalized. During emulsion PCR, 
primers flanking the polymerase enable self-replication, but are designed with a variable number of 
RNA bases separating the plasmid annealing portion from the unique recovery tag. Outnested PCR 
ensures that only polymerases with reverse transcriptase activity are selective amplified. 
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Figure 5-15: Characterization of B11  
 
 
 
Figure 5-15: Characterization of B11. a, Mutations in the B11 polymerase (yellow) are mapped 
onto the KOD polymerase (grey with DNA primer:template duplex in blue). Thirty seven 
mutations were accumulated, many found in the proofreading domain. b, Examination of the 3'-5' 
exonuclease active site shows a mutation at glutamate 143 to glycine. c, Functional assays reveal 
B11 polymerase is capable of single enzyme RTPCR of a 500 base pair region of the HSPCB gene, 
as well as the B11 with grafted wildtype proofreading domain. Proofreading activity was 
qualitatively measured in a dideoxy-mismatch PCR, which requires removal of a 3' deoxy 
mismatch primer before polymerization occurs.  
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Figure 5-16: Molecular checkpoints involved in template recognition 
 
 
Figure 5-16: Molecular checkpoints involved in template recognition. (A) Structural heat map of 
mutated residues over the RT-CSR process found by deep sequencing. Conserved mutations are 
colored incrementally darker shades of red to indicate frequency in the polymerase pool. Amino 
acid residues that were mutated in over 50% of the population were labeled. Figure was adapted 
from KOD structure PDB 4K8Z. (B) Computer modeling of KOD (grey) and RTX mutations 
(orange) at checkpoints responsible for DNA and RNA template recognition at R97, Y384, and 
E664. Free energy changes between wild-type KOD and RTX mutations are inlet displayed. 
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Figure 5-17: Modeling of conserved mutations along polymerase-template duplex 
 
 
 
Figure 5-17: Modeling of conserved mutations along polymerase-template duplex. a, K118I breaks 
a potential hydrogen bond on a RNA template, which may be involved in the checkpoint disrupted 
by R97M. b. Y493L is poised to allow for packing within the hydrophobic core adjacent to the 
heteroduplex. This movement may be necessary for binding to both A- and B-form duplexes. c, 
V389I adds a methyl group and pushes the neighboring beta sheet towards the heteroduplex to 
better orient the hydrogen-bonding network of T541 and D540 to both primer-template duplexes. 
d, G711V pushes two α-helices away from each other in the thumb domain, likely allowing for 
geometry differences in DNA:DNA and DNA:RNA duplexes. e, N735K displays stronger binding 
by ~8 kcal/mol to the backbone of the template strand by making contact to the phosphate 
backbone. RTX mutations are shown in orange, and KOD wild- type residues are depicted in 
white. Models shown are in complex with a DNA:RNA heteroduplex.
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Figure 5-18:  Sequence- and model-driven designs of RT variants 
 
 
Figure 5-18:  Sequence- and model-driven designs of RT variants. The designed polymerases 
based on deep sequencing and modeling information were constructed and tested in an RTPCR 
assay (HSPCB loci) and proofreading assay. The mutations introduced into the wild-type KOD 
polymerase are shown for each of the designed reverse transcriptases. 
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Figure 5-19. Steady-state kinetics of polymerase variants 
 
Figure 5-19. Steady-state kinetics of polymerase variants. Initial rates of single nucleotide (dCTP) 
incorporation by exonuclease deficient polymerases were plotted against the concentration of dCTP 
using DNA (a) or RNA templates (b). c, Kinetic parameters were estimated by fitting the data to 
the Michaelis-Menten equation. Nucleotide addition could not be determined (nd) for KOD on 
RNA templates, due to low activity. 
 
 
 
 
 219 
 
Figure 5-20: RTX can perform single-enzyme RT-PCR reactions 
 
Figure 5-20: RTX can perform single-enzyme RT-PCR reactions. Reverse transcription PCR 
(RTPCR) was performed using KOD polymerase, RTX, and the proofreading deficient version of 
RTX (N210D; exo-). Various genes were amplified (red), two human genes, PolR2A and p532, 
and rpoC from E. coli from various RNA sources. Using gene specific forward and reverse 
primers, gene regions were amplified, demonstrating efficient single enzyme RTPCR. 
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Figure 5-21: RTX mutations are predicted to prefer DNA templates 
 
Figure 5-21: RTX mutations are predicted to prefer DNA templates. a, Positions of RTX 
mutations are depicted in orange. Surrounding residues are shown  in gray stick format. 
Contact analysis was performed within MOE by setting primer-template duplexes as the 
ligand. Potential contact sites are shown in purple. b, Contacts were measured on A-form 
heteroduplexes and B-form DNA duplexes. Positions making contact are shown in along 
the x-axis relative to the position of the duplexes along the y-axis. Individual 
contributions are depicted by an energy gradient. Overall contact energies are displayed 
within each frame. Consistent with our kinetic data, RT-CSR mutations were found to 
exhibit better binding to both duplexes, with a small preference for DNA duplexes. 
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Figure 5-22. RTX polymerase proofreads during reverse transcription 
 
 
Figure 5-22. RTX polymerase proofreads during reverse transcription. (A) Primer 
extension reactions of KOD and RTX polymerases and their proofreading deficient 
counterparts (exo-), on both DNA and RNA templates. Extension reactions were 
performed with matched 3' primer:templates (grey) or a 3' deoxy mismatch (orange), 
which must be excised before extension can proceed. The primer is denoted by a gray 
arrow, extended product in green, and exonuclease degraded primer in red. 
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5.3 METHODS FOR THE SELECTION OF HIGH-FIDELITY AND INHIBITOR-RESISTANT 
POLYMERASES  
Introduction 
 Our previous CSR evolution experiments taught us that polymerase variants that 
survived selection would often lack 3’-5’ exonuclease activity and become error-prone.  
Sequencing of individual clones would often lead us to find premature stop codons in 
polymerase sequences, which we attributed to errors generated by the polymerases 
themselves. Of course, the polymerases that survived the selection could not have too 
high of an error-rate. Error catastrophe would prevent those polymerases from 
dominating the population over prolonged selections. However, error-rates observed in 
variants isolated from our selections were several orders of magnitude higher than the 
parental enzymes. 
We wanted our polymerases to retain high fidelity amplification during the course 
of the selection. However, the solution was not immediately obvious. Early ideas 
involved putting mismatches in primers over restriction sites. In this scheme, if the 
incorrect base was not cleaved, then we could use restriction enzymes to eliminate 
variants that did not make the correction before self-amplification. This seemed possible 
but messy and difficult to enforce. After several months of thinking about this problem, 
Dr. Jared Ellefson suggested that we add 3’-dideoxy mismatches to the CSR primers. 
This would force polymerases to recognize the mismatch and cleave the incorrect base 
before continuing polymerization during the PCR reaction. Using a di-deoxy base at the 
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end of the primer ensures that polymerization cannot occur, which is the reason these 
bases are often used in chain termination reactions. 
 At this time, we also became interested in producing polymerases for specific 
diagnostic or forensic applications. DNA sample preparation often included the use of 
chaotropes (Nagy, 2007; Wirtz, 2014; Wolfe et al., 2002), and so we wanted to 
understand how KOD would behave when challenged with these molecules. Inhibitors 
found within biological samples were also of concern. Heme is the principle inhibitor 
found in blood (Akane et al., 1994). Melanin, a pigment found in human hair and skin, 
has also been shown to inhibit polymerases (Eckhart et al., 2000). Lipoteichoic acids are 
found in Gram positive cell walls and are thought to be the chief reason that ‘colony 
PCR’ does not work these bacterial species. Many common nosocomial infections arise 
from Gram positive bacteria, and their diagnosis is slow due to the need to culture these 
organisms (Khan et al., 2015; Obritsch et al., 2005). The engineering of polymerases that 
would be resistant to chaotropes and these inhibitors would be of great utility. The ability 
to amplify nucleic acids with high fidelity enzymes with little to no sample preparation 
would ensure accurate diagnostic and forensic analyses. Below we describe our work in 
initiating selections to create high-fidelity, inhibitor-resistant polymerases. 
Results & Discussion 
High-fidelity CSR 
Polymerases that do not contain active proofreading domains are incapable of 
exponential amplification of targets when using di-deoxy mismatches at the 3’ end of 
PCR primers (Figure 5-23). Thus, we hypothesized that using di-deoxy mismatch 
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primers in CSR evolution experiments would strictly enforce polymerase variants to not 
only recognize the geometries of misaligned bases, but that it would force the 3’-5’ 
exonuclease domain to remain intact and functional. To test this hypothesis, we 
constructed error-prone libraries of KOD and subjected them to 5 rounds of CSR using 
normal and mismatched primers. We added diversity between rounds using error-prone 
PCR and sequenced 8 survivors from each selection (Figure 5-24). The polymerase 
variants selected with normal primers were shown to have an average of 7.25 amino acid 
mutations after 5 rounds. In contrast, variants selected with 3’-dideoxy primers or ‘hi-fi’ 
primers had an average of 6.42 amino acid substitutions. While these numbers are not 
drastically different, this small difference after only 5 rounds of selection may support the 
notion that ‘hi-fi’ primers enforce functional exonuclease activity over the course of the 
evolution experiment. In the variants sequenced, we did not see the common mutations 
that lead to inactivation of the proofreading domain. Either our sample size was too 
small, or it may take more than 5 rounds to see clear differences in selection methods. A 
more rigorous test of this hypothesis is needed to before drawing too many conclusions. 
Deep sequencing of the final rounds or increasing the number of sequenced variants in 
the future will give a more accurate and detailed representation of the mutational load 
from each selection.  
Future rounds of selection, described below, were performed using ‘hifi’ primers 
for two reasons. First, we believe that it enforces the fidelity checkpoint by the 
polymerase. Secondly, by using Taq polymerase in the recovery round, we significantly 
lower any background that may come through the selection due to primer and plasmid 
carryover from the emulsion reaction. 
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Inhibitor and chaotrope screening to identify potential targets for selection 
 Given our ability to select for polymerases with novel function, we wanted to 
create polymerase variants that would be resistant to common PCR inhibitors and 
ultimately be used over a variety of diagnostic applications. Before initiating selections, 
we needed to assess the level of inhibition of each particular compound. To determine 
IC50 values of chaotropes and other inhibitors, we performed standard 50 µL PCR 
reactions using KOD. A summary of the results can be found in Table 5-3. For a 
representative gel and inhibition curve, see Figure 5-25.  
Consistent with earlier work, KOD was inhibited by heme, the chief inhibitor 
present in blood, with an IC50 of  5.3 µM. Lipoteichoic acid, a large component of Gram 
positive bacterial cell walls (Percy and Gründling, 2014), was also found to inhibit KOD 
(IC50 = 61 µg/mL). Melanin, found in human hair and skin, inhibited KOD with an IC50 
of 16.8 µM. Selections using these compounds are described below. Chaotropes inhibited 
KOD at varying concentrations hovering in the millimolar range. However, 20% SDS 
was unable to inhibit KOD, highlighting its potential use in sample preparation for point-
of-care diagnostics using PCR. We also identified Mg2+ as a strong inhibitor to KOD. 
While Mg2+ is needed for the reaction, typically 1-2 mM, strong inhibition is seen beyond 
2.3 mM Mg2+.  
 
Initiation of inhibitor selections 
To select for inhibitor-resistant versions of KOD, we initiated CSR directed 
evolution experiments with ‘hi-fi’ primers using varying levels of lipoteichoic acid and 
melanin. For the lipoteichoic acid selections, we performed 5 rounds of CSR. In the end, 
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survivors of this selection were able to amplify themselves in the CSR reaction at final 
concentration of 2.67 mg/mL lipoteichoic acid, far above the IC50 observed in our initial 
screening. Sequencing of 15 pre-screened clones from this selection revealed a number of 
strongly conserved mutations (Figure 5-26). Positions 97, 145, 228, 295, 468, 539, 580, 
664, 740, and 753 appear to be under selection in this evolution experiment. For melanin 
resistance, we again performed 5 rounds of CSR. In the final round of this selection, 
polymerases were challenged with 4.16 mg/mL melanin. Of the 20 clones screened, only 
6 were functional. In this selection, positions 28, 97, 256, 418, 539, 580, 664, and 759 
appear to be under selection (Figure 5-27). Given the mutational overlap at positions 97, 
539, 580, and 664 with our lipoteichic acid selection, we believe these mutations are 
general stabilizing mutations and do not affect resistance. Further characterization of 
these mutants is ongoing. 
We also initiated selections with increasing concentrations of heme. However, 
after 5 rounds of selection, we were unable to observe the same level of convergence 
described in the selections above—possibly due to multiple routes to heme resistance by 
KOD. In an effort to find optimal mutations that would lead to resistance in whole-blood, 
we carried two libraries forward for an additional 5 rounds of selection in the presence of 
human whole-blood. At the end of the 10th round of selection, survivors that were capable 
of amplification in 80% whole-blood during the selection were pooled and deep 
sequenced (Tables 5-4 & 5-5). As a control, we also deep sequenced a round 10 control 
selection where KOD was error-proned between rounds but was not challenged with an 
inhibitor (Table 5-6).  
In each of the 3 selections, we see a number of conserved mutations. Common to 
all 3, is the truncation of the protein at the C-terminus. This is more than likely due to the 
fact that the polymerase was fused to a 6x histidine tag for purification of variants. There 
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is an apparently strong selection pressure to free the polymerase from this affinity tag 
during CSR.  
There are also a number of silent mutations found across the libraries. We believe 
these may be present for 2 reasons. In the case of inhibitor selections, silent mutations 
may be beneficial if they codon optimize the polymerase for expression. Having more 
polymerase within a cell would increase the amount of inhibitor needed in the reaction. 
Secondly, silent mutations may be easier to amplify by reducing secondary structure of 
the template during amplification. KOD is not known to have strand-displacing activity, 
thus it is possible that reducing secondary structure may allow for faster, more robust 
amplification.  
We also see strong pressure to mutate positions 97 and 664. These mutations 
seem to crop up in all of our CSR experiments. E664K likely stabilizes protein-nucleic 
acid binding. The effects of this mutation were modeled in the previous section. 
Interestingly, we did not observe any mutations that would likely or are known to disable 
the proofreading domain of KOD. We interpret these results as support of our hypothesis 
that our ‘hi-fi’ selection primers are indeed functional and prevent the polymerase from 
becoming error-prone during evolution.  
Absent from the blood libraries are obvious mutations that lead to resistance. 
Again, this may be due to the likelihood of multiple mutational pathways to heme and 
blood resistance. More work is necessary to tease out necessary the necessary 
substitutions that ultimately allowed the variants to survive the selction. Highly 
functional variants have been isolated from whole-cell screening (Figure 5-28). 
However, these mutants have yet to be functionally validated with purified enzyme in the 
presence of whole-blood. The characterization of these and other variants is ongoing in 
our laboratory. 
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Conclusions 
We further expanded the reach of CSR in this section. By including di-deoxy 
mismatches in our selection primers, we no longer observed 3’-5’ exonuclease 
debilitating mutations in any of our selections. While more characterization is needed, 
these results are promising. Beyond the apparent increase in fidelity, using dideoxy 
primers lowers the amount of background or carryover from round to round during a CSR 
evolution experiment.  
We also characterized KOD in the presence of common chaotropes and inhibitors. 
Chaotropes generally inhibited KOD in the millimolar range. Future evolution 
experiments could attempt to increase resistance to these chemicals. Selections were 
initiated on lipoteichoic acids, melanin, and heme. These three inhibitors are immensely 
important for diagnostic and forensic applications. In each case, we were able to turn five 
rounds of selection. With the exception of the heme libraries, we observed convergence. 
Additional rounds of selection in whole blood did little to identify mutations that led to 
the resistant phenotype during the evolution experiment, possibly due to multiple 
mutational routes. Characterization of mutants identified here should shed light on 
optimal residues. It may also prove possible to combine mutations from each of the 
inhibitor selections and create a single polymerase that is resistant to all of the inhibitors.  
Methods & Materials 
Characterization of inhibitors 
Fifty microliter PCR reactions were setup using Accuprime Pfx buffer, 400 nM F 
and R primers, and 10 ng template plasmid. Initial range finding experiment narrowed the 
search for inhibition. We then chose 10 concentrations for the final experiments. After 25 
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cycles of PCR, the entire reaction was observed on a 0.8% agarose gel. Intensities of each 
band were then measure with ImageJ. Percent inhibition was then calculated and graphed. 
We then fit the data using SigmaPlot10 to determine IC50 values. 
 
CSR selections and emulsion PCR 
Libraries were cloned into pET21 vector and transformed into BL21 DE3 cells. 
Overnight library cultures were seeded at a 1:20 ratio into fresh 2xYT media 
supplemented with ampicillin and grown for 2 hours at 37◦C. Polymerases were induced 
with 1 mM IPTG and incubated at 37◦C for  4 hours. Induced cells (400 µL total) were 
spun in a tabletop centrifuge at 3,000 x g for 8 minutes. The supernatant was discarded 
and the cell pellet was washed in TBS and then resuspended in 300 µL CSR mix: 1x 
Selection buffer (50 mM Tris-HCl (pH8.8), 10 mM (NH4)2SO4, 10 mM KCl, 2 mM 
MgSO4), 260 µM dNTPs, 530 nM of each of the forward and reverse primers, 10-300 
µM TMAC, and varying ranges of inhibitor concentrations. The resuspended cells were 
placed into a 2 mL tube with a 1mL rubber syringe plunger and 1200 µL of oil mix (73% 
Tegosoft DEC, 7% AbilWE09 (Evonik), and 20% mineral oil (Sigma-Aldrich)). The 
emulsion was created by placing the cell and oil mix on a TissueLyser  LT  (Qiagen) with  
a program  of 42Hz  for 4  minutes.  The emulsified  cells  were thermal-cycled for 20-25 
cycles. 
Emulsions were broken by spinning the reaction (20,000xg) for 15 minutes, 
removing the top oil  phase, adding 750 µL chloroform, vortexing vigorously, and finally 
phase separating in a phase lock tube (5Prime). The aqueous phase was cleaned using a 
Promega PCR purification column. Overnight treatment with DpnI mitigated plasmid 
carryover. Subamplification with recovery primers ensures that only polymerases were 
functional in the emulsion PCR amplified.  
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Figure 5-23: Hifi PCR 
 
 
 
Figure 5-23: Hifi PCR. DNA polymerase activity was assessed by PCR using 
unmodified primers on a 2.5 kilobase fragment. Proofreading (3'-5' exonuclease 
activity) was assessed by use of 3' deoxy mismatch primers in the PCR. Inactivating 
the proofreading domain (N210D) in RTX prevents cleavage of the 3' deoxy primer 
and subsequently PCR. 
 
 
 232 
 
 
Figure 5-24: Hifi vs normal sequencing results 
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Table 5-3: Common chaotropes and PCR inhibitors 
Inhibitor IC50 Error 
SDS 0 0 
Urea 234.42 mM 1.15 
Magnesium 1.31 mM 1.07 
Lithium Acetate 10.69 mM 0.11 
Guanidinium-Cl 19.37 mM 0.22 
Heme 5.30 μM 0.01 
Melanin 5.35 ug/mL 0.05 
Teichoic Acid 60.98 ug/mL 7 
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Figure 5-25: Representative inhibition gel and curve 
 
 
Figure 5-25: Representative inhibition gel and curve. Left, agarose gel of urea inhibition. 
10 concentrations were tested (0-450 mM). Right, inhibition curve. Nonlinear regression 
was performed with SigmaPlot10. The IC50 was calculated to be 234.42 ± 1.15 mM urea. 
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Figure 5-26: Lipoteichoic acid round 5 sequencing results 
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Figure 5-27: Melanin round 5 sequencing results 
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Table 5-4: Blood-A deep sequencing results 
 
Codon Amino Acid  
Variant 
Frequency 
Change Coverage Protein Effect 
3 
 
99.70% A -> T 237,508 None 
778 
 
99.50% CC -> AG 239,293 Truncation 
2 
 
98.10% A -> T 234,416 None 
777 
 
97.60% GG -> TA 246,429 Truncation 
36 P -> L 41.30% C -> T 308,427 Substitution 
741 V -> A 29.60% T -> C 331,662 Substitution 
675 A -> V 28.60% C -> T 228,496 Substitution 
758 
 
28.50% C -> T 283,297 Truncation 
664 E -> K 22.10% G -> A 227,624 Substitution 
768 
 
17.60% G -> A 260,934 Truncation 
97 R -> C 14.10% C -> T 199,391 Substitution 
97 R -> H 13.70% G -> A 199,670 Substitution 
200 E -> G 11.10% A -> G 212,366 Substitution 
726 K -> E 11.00% A -> G 378,356 Substitution 
105 
 
10.40% G -> A 201,683 None 
97 R -> L 9.60% G -> T 199,670 Substitution 
155 G -> D 9.40% G -> A 208,301 Substitution 
742 E -> G 9.10% A -> G 327,780 Substitution 
59 H -> R 8.90% A -> G 363,891 Substitution 
270 
 
8.90% T -> C 229,356 None 
61 
 
8.80% A -> T 368,796 None 
664 E -> V 8.40% A -> T 227,590 Substitution 
46 S -> N 7.80% G -> A 330,271 Substitution 
164 D -> N 7.80% G -> A 208,885 Substitution 
632 K -> Q 7.70% A -> C 225,242 Substitution 
59 H -> Y 7.60% C -> T 363,002 Substitution 
743 
 
7.50% C -> T 323,101 None 
759 
 
7.40% A -> T 281,000 Truncation 
530 
 
7.40% G -> A 228,664 None 
379 R -> Q 7.40% G -> A 228,534 Substitution 
610 I -> V 7.20% A -> G 224,375 Substitution 
503 
 
7.10% G -> A 228,136 None 
343 D -> G 6.80% A -> G 237,152 Substitution 
512 
 
6.70% A -> G 229,348 None 
765 
 
6.60% (T)3 -> (T)2 266,067 Truncation 
27 K -> E 6.50% A -> G 284,044 Substitution 
85 
 
6.50% T -> C 192,825 None 
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658  
6.40% G -> A 225,426 None 
165 
 
6.40% A -> G 208,821 None 
97 R -> S 6.40% C -> A 199,391 Substitution 
373 D -> N 6.30% G -> A 229,628 Substitution 
595 
 
6.30% G -> T 222,825 None 
750 
 
6.20% T -> C 304,608 None 
347 
 
6.10% T -> C 236,250 None 
264 I -> V 6.00% A -> G 225,062 Substitution 
638 
 
6.00% A -> G 223,390 None 
753 E -> G 5.80% A -> G 294,827 Substitution 
348 
 
5.80% A -> G 236,121 None 
28 I -> V 5.70% A -> G 286,241 Substitution 
378 
 
5.70% T -> C 228,004 None 
644 K -> E 5.70% A -> G 224,499 Substitution 
754 D -> G 5.60% A -> G 291,136 Substitution 
242 Q -> R 5.60% A -> G 220,917 Substitution 
146 Y -> H 5.60% T -> C 204,713 Substitution 
524 
 
5.40% G -> A 228,603 None 
662 
 
5.40% T -> C 227,236 None 
522 
 
5.30% C -> A 228,478 None 
235 D -> N 5.30% G -> A 219,463 Substitution 
782 H -> D 5.30% C -> G 3,134 Substitution 
741 V -> G 5.20% T -> G 331,662 Substitution 
407 
 
5.10% T -> C 229,722 None 
455 D -> G 5.10% A -> G 225,297 Substitution 
237 
 
5.10% A -> G 219,732 None 
93 V -> A 5.10% T -> C 196,672 Substitution 
446 P -> Q 5.00% C -> A 225,802 Substitution 
569 
 
5.00% G -> T 221,762 None 
468 K -> E 5.00% A -> G 221,207 Substitution 
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Table 5-5: Blood-B deep sequencing results 
Codon Amino Acid 
Variant 
Frequency Change Coverage Protein Effect 
3 
 
99.80% A -> T 229,616 None 
778 
 
99.40% CC -> AG 290,402 Truncation 
664 E -> K 98.50% G -> A 296,689 Substitution 
2 
 
98.20% A -> T 226,630 None 
777 
 
97.50% GG -> TA 298,162 Truncation 
392 
 
58.00% A -> G 295,037 None 
518 
 
44.30% G -> A 301,458 None 
501 R -> L 22.70% G -> T 299,293 Substitution 
93 V -> A 16.90% T -> C 231,198 Substitution 
108 
 
14.80% T -> C 240,597 None 
742 E -> G 12.00% A -> G 401,634 Substitution 
768 
 
7.90% G -> A 314,145 Truncation 
741 V -> G 7.20% T -> G 407,234 Substitution 
753 E -> G 7.20% A -> G 357,834 Substitution 
754 D -> G 6.80% A -> G 352,630 Substitution 
116 F -> I 6.40% T -> A 244,900 Substitution 
739 
 
6.30% G -> A 417,272 None 
745 L -> F 6.10% A -> T 391,653 Substitution 
242 Q -> R 5.80% A -> G 285,366 Substitution 
551 A -> V 5.60% C -> T 291,017 Substitution 
743 R -> G 5.50% C -> G 398,715 Substitution 
698 V -> G 5.30% T -> G 560,458 Substitution 
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Table 5-6: KOD normal control selection deep sequencing results  
Codon Amino Acid Variant Frequency Change Coverage Protein Effect 
3 
 
99.80% A -> T 200,985 None 
778 
 
99.60% CC -> AG 214,727 Truncation 
2 
 
98.20% A -> T 198,417 None 
777 
 
97.70% GG -> TA 221,306 Truncation 
580 E -> D 61.50% A -> T 214,686 Substitution 
675 A -> V 38.60% C -> T 215,760 Substitution 
741 V -> A 31.60% T -> C 295,179 Substitution 
36 P -> L 29.50% C -> T 259,592 Substitution 
760 
 
24.00% (A)4 -> (A)3 247,659 Frame Shift 
97 R -> C 22.30% C -> T 191,185 Substitution 
97 R -> H 18.60% G -> A 191,667 Substitution 
739 
 
14.50% G -> A 301,524 None 
97 R -> S 13.90% C -> A 191,185 Substitution 
765 
 
13.90% (T)3 -> (T)2 237,139 Truncation 
740 A -> V 12.50% C -> T 298,744 Substitution 
649 K -> R 11.00% A -> G 213,763 Substitution 
698 V -> I 11.00% G -> A 408,070 Substitution 
763 V -> G 11.00% T -> G 241,735 Substitution 
768 
 
9.20% G -> A 233,376 Truncation 
587 F -> L 9.00% T -> C 213,638 Substitution 
477 
 
7.80% A -> G 225,358 None 
640 V -> I 7.60% G -> A 211,598 Substitution 
352 
 
6.90% A -> G 222,223 None 
614 D -> N 6.70% G -> A 212,799 Substitution 
616 
 
6.70% C -> T 210,978 None 
140 F -> L 6.60% T -> C 199,631 Substitution 
304 
 
6.00% C -> T 223,762 None 
168 A -> V 5.90% C -> T 204,448 Substitution 
143 
 
5.80% A -> G 200,387 None 
145 L -> P 5.70% T -> C 201,072 Substitution 
629 A -> V 5.70% C -> T 210,525 Substitution 
742 E -> G 5.50% A -> G 291,800 Substitution 
754 D -> G 5.50% A -> G 258,613 Substitution 
664 E -> V 5.40% A -> T 216,597 Substitution 
57 E -> K 5.20% G -> A 308,922 Substitution 
157 
 
5.10% T -> C 204,063 None 
617 E -> G 5.10% A -> G 210,941 Substitution 
779 H -> N 5.10% C -> A 2,872 Substitution 
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Figure 5-28: Blood selection survivors 
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5.4 THE DEVELOPMENT OF COMPARTMENTALIZED SELF-REPLICATION IN A 
EUKARYOTIC ORGANISM 
Introduction 
 In this section we adapt Compartmentalized Self-Replication to Saccharomyces 
cerevisiae. We refer to this as yCSR. This was an initial proof-of-concept to show that 
emulsion-based PCR selections would be compatible with yeast. Conventional wisdom 
on the third floor of MBB at the University of Texas at Austin stated that it would be 
impossible to perform emulsion PCR in yeast. For whatever reason, it was not thought 
possible. Here we describe: (1) the optimization of emulsion bubbles that would 
encapsulate single yeast cells; (2) the stabilization of emulsions to endure overcycling; 
(3) the process of expressing a thermostable DNA polymerase and amplifying its gene 
within the emulsion; and (4) the optimization of the buffering conditions to allow for in 
emulsion spheroplasting of cells. The protocols developed here are the basis for yCSR 
and yeast-based Compartmentalized Partnered Replication (yCPR). The adaptation of 
emulsion PCR-based selection methods to a eukaryotic organism enables the engineering 
of a number of protein classes not accessible to selections performed in bacterial systems. 
Results & Discussion 
Emulsion optimization 
 In order to emulsify yeast, we first attempted the same protocols outlined in the 
sections above. Unfortunately, yeast cells are much larger than E. coli, and those 
conditions proved inadequate. Our previous work in optimizing emulsion conditions for 
bacterial cells led us to change the frequency of shaking by the tissuelyzer. We tested 35-
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50 Hz in an effort to find a range where emulsion bubbles were uniform in size. We 
found that the ideal frequency laid somewhere between 35-40 Hz. Next, we determined 
the length of time (4-11 minutes) needed to produce large, uniform emulsions, capable of 
comfortably accommodating yeast cells. In the end, 37 Hz for 5 minutes was shown to be 
the optimal set of parameters to emulsify yeast in our water-in-oil emulsions. Brightfield 
images, processed by ImageJ, were used to determine the size of the emulsions, and we 
were able to accurately visualize yeast cells by constitutively expressing yeCitrine, a 
fluorescent reporter. Doing so would allow us to take images using fluorescent 
microscopy to verify that the cells were still intact after emulsification (Figure 5-29). To 
test for emulsion stability, we aliquoted the emulsion into PCR tubes and thermocycled 
them as we would in a typical CSR or CPR reaction. We used 35 cycles of PCR, as this 
would be the upper end of the number of cycles used in a directed evolution experiment. 
We optimized the amount of surfactant, oil, aqueous phase (buffer and cells), and mineral 
oil needed to produce stable emulsions, capable of enduring long cycling conditions. 
Stability was easily monitored at this stage. Unstable emulsions would phase separate, 
while stable emulsions would remain uniform (Figures 5-30 & 5-31). In the end, we 
found a number of optimal parameters that allowed us to emulsify yeast in thermostable 
emulsion bubbles (Table 5-7; Figure 5-32). 
Yeast CSR mastermix optimization 
 To perform CSR in yeast, we built strains with yeast codon-optimized KOD under 
the control of the pGal1 promoter. After induction, we emulsified yeast in our standard 
CSR buffer and ran the products out on a gel. Using our normal CSR mastermix from our 
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bacterial cell selections, we were unable to see any amplification. We reasoned that this 
may be due to the cells not lysing under normal PCR cycling conditions. The yeast cell 
wall is impervious to heat, and colony PCR of yeast requires pretreatment with softening 
agents and typically zymolyase, an enzyme that rapidly degrades the cell wall. To test 
this hypothesis, we spheroplasted cells before the putting the cells in the emulsion. In 
spheroplasted cells, we were able to see product on an agarose gel. We next determined if 
we could spheroplast within the emulsion. That is, we wanted to add zymolyase to the 
mastermix and incubate cells at 37˚C before starting the normal cycling conditions. 
Spheroplasts are fragile, and we worried that cells would rupture during the 
emulsification process. Initial attempts at adding zymolyase failed. However, we found 
that if we softened the cells using sorbitol, DTT, and EDTA, we could get detectable 
levels of amplification (Figure 5-33).  
Encouraged by these results, we then initiated a number of optimization 
experiments. We started our optimization by testing the amount of zymolyase needed. 
We found that as little as 80 uL of a 5 mg/mL stock was adequate in initial testing. There 
seemed to be diminishing returns above this value (Figure 5-34). Next, we varied the 
concentrations of dNTPs and primers in the mastermix. Commercial zymolyase 
preparations tend to have trace phosphatases and nucleases. We saw a modest 
improvement using 300 µM dNTPs (Figure 5-35) and 4 µM of each primer (Figure 5-
36), much higher than a typical PCR reaction. We then determined if adding 
tetramethylammonium  chloride (TMAC), a known PCR enhancer, had an effect on the 
emulsion PCR product.  We found that increasing concentrations improved amplification 
 
245 
(10-300 μM TMAC). Finally, we determined that polymerases were more active in the 
CSR reaction in Tris-SO4,pH 8.0 supplemented with 1 mM MgSO4. Our original CSR 
mix was conducted at pH 8.8 for historical reasons, which may be a way to tune 
stringency in both CSR and CPR evolution experiments. The optimized concentrations of 
each component can be found in Table 5-8. A full protocol can be found in Appendix II. 
 
Yeast selection strain creation 
 Homologous recombination is a benefit of using yeast over bacterial cells in 
performing CSR or CPR selections. By transforming libraries into the yeast chromosome, 
copy number variability found in plasmid-based selections is mitigated. In order to 
streamline the process, we created a number of yeast strains harboring IsceI cut sites and 
auxotrophic markers at the common Ura, Leu, and HO sites (Lee et al., 2015). For 
example, at the Ura integration site, we integrated a vector containing the IsceI cut site 
along with a histidine prototrophic marker. When transforming libraries with a uracil 
marker into this position along with a linear plasmid that transiently expressed IsceI 
nuclease, we saw an average of 7.5 x 107 transformants, which is nearly as large as we 
see in bacterial cells (~108). By changing out prototrophic markers, we eliminate 
background during library construction. Plasmid maps for these vectors can be found in 
Figures 5-37 – 5-40. 
Future directons 
The development of long-read enzymes or PCR-based replication machinery has 
remained elusive due the size constraints in plasmid-based systems. In order to select for 
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highly processive, high-fidelity replication machinery, we have adapted CSR to 
Saccharomyces cerevisiae where integration of libraries into the chromosome is trivial, 
allowing for much longer amplification reactions within the emulsion PCR.  It should 
now be possible to evolve an archaeal Family B DNA polymerase alongside its cognate 
proliferating cell nuclear antigen (PCNA) clamp. The successful selection of a DNA 
polymerase:PCNA pair will enable the amplification of much longer stretches of DNA. 
The proliferating cell nuclear antigen (PCNA) is a clamp that is used to increase 
the processivity of DNA polymerases during replication in archaeal and eukaryotic 
organisms. Typically, the clamp is loaded during replication fork creation by the RFC 
clamp loader. The combination of the clamp and polymerase ensures that tens of 
thousands of bases are faithfully replicated without loss of the DNA polymerase. An 
engineered variant (E143K) of the proliferating cell nuclear antigen (PCNA) from 
Thermococcus kodakarensis (KOD), has been shown previously to be functional in PCR 
applications (Kitabayashi et al., 2002; Kranaster and Marx, 2010). In order to enable the 
amplification of long amplicons assembled in yeast, it should be possible to insert the 
PCNA and the Family B DNA polymerase (also from T. kodakarensis) genes into our 
selection strains using pGal1 and pGal10 (Lee et al., 2015) and select long-read 
replication machinery (Figure 5-41).  
Conclusions 
 In this section we adapted CSR to yeast. To do so, a number of optimizations 
were necessary. First, we needed to enlarge the emulsion bubbles to accommodate the 
larger organism. Next, we needed to find conditions to create stable emulsions. Through 
 
247 
iterative rounds of optimization, we found conditions that were stable after 35 cycles of 
PCR. Next, we optimized the mastermix conditions, improving our amplification yields 
more than 1,000-fold. We then created selection strains, which were capable of 
integrating libraries with nearly 108 transformants with only a single electroporation. In 
addition to selecting for long-read replication systems, the methods developed here are 
also transferrable to the adaptation of Compartmentalized Partnered Replication (CPR) in 
yeast (see Chapters 6 & 7). 
 
Methods & Materials 
Emulsion optimization 
BY4741 cells expressing yeCitrine were emulsified in PCR buffer. A range of 
concentrations of the following components were used in the development of stable 
emulsions: (1) light mineral oil, (2) Tegosoft, (3) Gransurf W9 surfactant, and (4) the 
aqueous phase containing live cells. Pictures of emulsions were taken with light and 
fluorescent microscopy. Stability was monitored after thermalcycling aliquoted 
emulsions. Phase separated emulsions were judged to be broken. 
 
Yeast CSR optimization 
Geneblocks for KOD were purchased from IDT and cloned under the control of 
the pGal1 promoter in an integration vector targeting the URA3 locus using the Yeast 
Toolkit (Lee et al., 2015). Transformants were selected on SD-Ura. Overnight cultures 
were washed and induced with 2% galactosidase for 18 hours at 30˚C. Induced cells (500 
µL- 3 mL total) were spun in a tabletop centrifuge at 3,000 x g for 5 minutes. The 
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supernatant was discarded and the cell pellet was washed in water and then resuspended 
in 1 M sorbitol, 25 mM EDTA, 50 mM DTT. Cells were collected again and washed in 1 
M sorbitol. After another wash with water, cells were resuspended in 500 µL PCR 
mastermix. For optimal conditions, see Table 5-7. The resuspended cells were placed 
into a 2 mL tube with a 1mL rubber syringe plunger and 1200 µL of oil mix (876 
Tegosoft DEC, 84 Gransurf W9, and 240 µL light mineral oil (Sigma-Aldrich)). The 
emulsion was created by placing the cell and oil mix on a TissueLyser  LT  (Qiagen) with  
a program  of 37 Hz  for  minutes.  The emulsified  cells  were incubated at 37˚C for 15 
minutes, followed by 10 minutes at 95˚C, and then thermal-cycled for 35 cycles 
(Appendix II). Emulsions were broken by spinning the reaction (20,000xg) for 15 
minutes, removing the top oil phase, adding 750 µL chloroform, vortexing vigorously, 
and finally phase separating in a phase lock tube (5Prime). The aqueous phase was 
cleaned using a Promega PCR purification column. Products of the yCSR amplification 
were visualized using agarose gel electrophoresis.  
Selection strain creation and transformation 
IsceI cutter and IsceI target sites were created using the Yeast Toolkit (Lee et al., 
2015). For the IsceI cutter plasmid, the enzyme was put under the control of the pPGK1 
promoter. See figure Figure 5-39. For target sites, we again employed the use of the 
standard Yeast Toolkit parts. We chose to integrate an IsceI cut site at each of the 
common integration sites (Ura, HO, and Leu) into standard BY4741 and BY4741ΔGal2. 
We selected transformants on drop out media at 30˚C. For the Ura locus, we integrated a 
His3 marker in addition to the IsceI site. At the Leu site, we inserted the recognition 
sequence and the URA3 marker. Finally, at the HO site, we integrated the Leu2 marker 
alongside the IsceI cut site. After validating IsceI cut sites within the chromosomes of 
targeted strains, we prepared electrocompetent cells. We electroporated NotI digested 
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fragments containing (1) a different auxotrophic marker at each of the homologous sites; 
and (2) the linearized IsceI cutter plasmid. Transformation efficiency was calculated by 
dilution plating. 
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Figure 5-29: Yeast emulsion images 
 
Figure 5-29: Yeast emulsion images. Left, brightfield images of representative 
emulsions. Right, fluorescent microscopy of intact cells within emulsions. Cells are not 
disrupted upon emulsification. 
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Figure 5-30: Stability of yeast emulsions example 
 
 
Figure 5-30: Stability of yeast emulsions example. Unstable emulsions phase separate. 
Shown is a gradient of stability observed. 
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Figure 5-31: Stable yeast emulsion optimization 
 
 
 
Figure 5-31: Stable yeast emulsion optimization. Increasing the amount of cells/aqueous 
phase in the setup of the water-in-oil emulsion stabilized the emulsions.
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Figure 5-32: Final yeast emulsion stability 
 
Figure 5-32: Final yeast emulsion stability. Final stability conditions tested at 37 Hz, 5 
min in tissuelyzer. The 500 µL aqueous phase treatment showed the highest level of 
emulsion stability.
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Table 5-7: Emulsion parameters 
 
Parameter Original (E. coli) Optimal Yeast 
Surfactant 84 uL Abil 84 uL Gransurf 
Frequency of Tissuelyzer (Hz) 42 37 
Time (min) 4 5 
Cells (uL) 300 500 
Mineral oil:Tegosoft (uL) 240:876 240:876 
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Figure 5-33: Original CSR conditions using spheroplasted cells 
 
 
Figure 5-33: Original CSR conditions using spheroplasted cells. Yeast CSR-derived 
amplicons targeting a 700 bp fragment (left) of KOD and the full 2.5 kbp gene (right). 
This initial proof-of-concept was performed using pre-spheroplasted cells.
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Figure 5-34: Zymolyase optimization 
 
Figure 5-34: Zymolyase optimization. Varying amounts of zymolyase (0-80 µL) used in 
the optimization of yeast CSR. 
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Figure 5-35: dNTP optimization 
 
Figure 5-35: dNTP optimization. Varying concentrations of dNTPs (0-450 µM) used in 
the optimization of yeast CSR. 
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Figure 5-36: Primer optimization 
 
Figure 5-36: Primer optimization. Varying concentrations of primers (0-7.5 µM) used in 
the optimization of yeast CSR.
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Table 5-8: Yeast CSR/CPR Mastermix 
 
Component Volume (µL) 
10X Buffer (pH 8.0) 50 
4 mM Stock dNTPs 37.5 
F Primer (20 μM) 20 
R Primer (20 μM) 20 
TMAC 5 
Zymolyase (5 
mg/mL) 
80 
RNAse 1.75 
diH20 285.75 
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Figure 5-37: Ura-His3 IsceI site 
 
 
Figure 5-37: Ura-His3 IsceI site. Recognition site is shown between connectors S and E. 
His3 selection marker is used at the Ura3 site in targeted strains. 
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Figure 5-38: HO-Leu2 IsceI site 
 
Figure 5-38: HO-Leu2 IsceI site. Recognition site is shown between connectors S and E. 
Leu2 selection marker is used at the HO site in targeted strains. 
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Figure 5-39: Leu-Ura3 IsceI site 
 
Figure 5-39: Leu-Ura3 IsceI site. Recognition site is shown between connectors S and E. 
URA3 selection marker is used at the Leu2 site in targeted strains. 
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Figure 5-40: IsceI cutter plasmid 
 
Figure 5-40: IsceI cutter plasmid. The IsceI linear fragment is shown. The enzyme is 
expressed under the PGK1 promoter/terminator pair. The expression of the enzyme is 
transient because there is no selectable marker and the piece is linear. 
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Figure 5-41: Long-read yCSR 
 
 
 
Figure 5-41: Long-read yCSR. A library of polymerase and PCNA variants are cloned 
into S. cerevisiae. The cells are emulsified after induction of the replication machinery. 
During emPCR, replication machinery variants are guided by primers to amplify 
individual variants. Variants of higher fitness that are capable of successfully amplifying 
themselves will dominant the recovered pool. 
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Chapter 6: Functional expression of human GPCRs and plant 
cannabinoid biosynthetic pathways in yeast 
 
ABSTRACT 
This chapter explores a number of proof-of-concepts. Having shown CSR to be 
functional in yeast in the previous chapter, we turned our attention to adapting 
Compartmentalized Partnered Replication (CPR) to our emulsion-based yeast platform. 
We start by creating S. cerevisiae strains for coupling to human G-protein coupled 
receptors (GPCRs). By disrupting a number of genes in the pheromone response 
pathway, we are able to show dose-dependent signal transduction of human serotonin 
receptor (5HT1A) and cannabinoid receptor subtype 2 (CB2) with the addition of their 
native ligands to yeast growth media. To create antagonism-based circuitry, we engineer 
and proof an inverter circuit. We also explore the production of the dietary cannabinoid 
β-caryophyllene and show autoactivation of an engineered strain expressing CB2. To our 
knowledge, this is the first example of a plant biosynthetic pathway activating a human 
receptor in the same cell. Next, we start the optimization of cannabidiol (CBD) producing 
yeast strains. We discuss the implications of yeast CPR and the many applications that 
are now afforded by coupling eukaryotic signal transduction pathways to CPR circuits in 
an amendable host organism. 
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INTRODUCTION 
G-protein coupled receptors (GPCRs) are integral membrane proteins that 
regulate a number of cellular processes in eukaryotic organisms (Vassilatis et al., 2003). 
It is thought that GPCRs date to the common ancestor of all eukaryotes (de Mendoza et 
al., 2014). These 7-transmembrane helical proteins respond to vast assortment of 
extracellular molecules, and signaling mechanisms are conserved across taxa. In humans, 
these receptors are involved in neurotransmission, growth, vision, olfaction and heart rate 
regulation (Vögler et al., 2008). Humans contain over 800 GPCRs with more than 400 
dedicated to olfaction. Roughly 350 of the remaining receptors have been identified as 
potential drug targets (Tautermann, 2014). In fact, GPCRs make up the largest class of 
targeted proteins in the human proteome, making up an estimated 35% of current drug 
targets (Hutchings et al., 2010). The development of high-throughput screening 
technologies using these receptors would greatly increase the speed and development of 
pharmaceuticals (Zhang and Xie, 2012). 
While screening ligands for druggable properties has been of great utility, 
engineering human GPCRs has also proven to be a fruitful enterprise. Orthogonal GPCR 
engineering was pioneered by neuroscientists to selectively depolarize neural subtypes.  
Early iterations of this include receptors activated solely by synthetic ligand (RASSLs), 
which utilized rationally designed mutants of the human kappa opioid receptor to 
engineer GPCR mutants that responded to the synthetic agonist spiradoline but not its 
native ligands (Coward et al., 1998).  While these receptors were among the first 
chemogenetic engineered GPCRs, they were soon replaced by GPCRs engineered via a 
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platform that cleverly ported human GPCRs into Saccharomyces cerevisiae.  By 
hijacking native pheromone signaling pathways, this system offered a means to screen 
mutagenized receptors.  The chemogenetic receptors developed by this technology, 
termed DREADDS (designer receptors exclusively activated by designer drugs) were a 
far more powerful tool than their RASSL predecessors, as DREADDs offered a more 
generalizable scheme by which to evolve receptors to respond to a wide variety of drug-
like molecules (Alexander et al., 2009).  While various Gi, Gq, and Gs coupled 
DREADDs have been widely used by the neuroscience community for interrogations of 
neural function, this powerful yeast GPCR screening platform has been underutilized as a 
tool for drug discovery and moreover the autodetection of synthesized biomolecules in 
metabolic engineering projects.  By adapting yeast-based GPCR screening to 1) a 
powerful directed evolution platform developed in our lab and 2) biosynthesis pathways 
in one yeast strain, it should be possible to create a highly sensitive and powerful means 
by which to evolve metabolic synthesis pathways for drug synthesis as well as to screen 
compounds for functional activity at these receptors.  
Compartmentalized Partnered Replication (CPR) is a method in which genetic 
circuits are designed to express a PCR-ready, thermostable DNA polymerase, such as 
KOD, in response to an input. The utility of CPR is apparent when considered with 
respect to directed evolution of libraries. Here a portion of the genetic circuit is 
randomized, different cells contain different variants, and those variants that promote the 
production of the thermostable polymerase can be selectively amplified in an emulsion 
PCR.  When the emulsion is broken, the productive partners are overrepresented relative 
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to unproductive partners. Multiple rounds of cloning, emulsion, and amplification will 
lead to the identification of those partners that are most effective in generating the DNA 
polymerase. These variants can have any of a variety of functions. Our group has 
previously shown that RNA polymerases, repressors, tRNA synthetases, and tRNAs can 
be optimized for function in the context of such circuits ((Ellefson and others; Ellefson et 
al., 2014; Meyer et al., 2014a).  
Below we discuss the construction of agonist and antagonist CPR (Figure 6-1) 
and screening strains. We show functional coupling of receptor agonism to genetic 
circuits as well as autoactivation of the human CB2 receptor by cannabinoid production 
in a single strain. We conclude with the discussion of a number of technologies that are 
now possible from the groundwork performed here. 
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RESULTS & DISCUSSION 
GPCR strain construction 
The ability to manipulate native GPCR signaling in S. cerevisiae has proven to be 
a valuable tool in a number of high-throughput screening and directed evolution 
methodologies (Brown et al., 2000; Ladds et al., 2005; Nakamura et al., 2015; Reiländer 
and Weiβ, 1998; Yoshimoto et al., 2014). The deletion or disruption of Sst2p, Ste2p, and 
Far1p from the yeast genome allows downstream host signaling to be completely seized 
by heterologous receptor function. By producing chimeric and transplant Gα subunits, it 
has proven possible to couple receptor function to the production of auxotrophic markers, 
fluorescent proteins, and enzymatic reporters under the control of pFus1 or pFig1, the 
commonly used native pheromone response promoters that are activated by the MAPK 
signaling cascade. Transplanting the last 5 amino acids of the human subunit to the native 
yeast protein has proven sufficient to couple the heterologous expression and function of 
a foreign GPCR to the native pheromone response in yeast (Table 6-1). While strains 
exist with each of the necessary modifications, they are difficult to obtain, and here we 
built markerless versions using Cas9. 
We used Benchling to identify potential sgRNAs for each of the targeted genes. 
We built 3 sgRNAs for each of the targets (Table 6-2) and tested the efficiency of 
knockouts (Ste2p, SSt2p, and Far1p), gene replacements (reporters), and site directed 
mutagenesis of the carboxy terminus of the native yeast Gα subunit (Table 6-3). For gene 
disruptions or knockouts, we designed repair DNA that inserted an in-frame stop codon 
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towards the 5’ end of the gene along with a barcode that we could use with qPCR probes 
for multiplex detection of genomic alterations (Figure 6-2). For gene replacements at 
pFig1 or pFus1, we targeted the native gene and inserted either: (1) the archaeal Family B 
DNA polymerase KOD for use in agonist-driven CPR circuits; (2) the fluorescent 
reporter zsGreen1; or (3) the bacterial tetracycline repressor (tetR) to be used in inverter 
circuits for coupling antagonism of a GPCR to CPR circuits. To change the Gα subunits 
we changed the codon usage at the Cas9 cut site along with changing the terminal 5 
amino acids at the carboxy terminus for coupling to heterologous GPCRs. Strains were 
constructed in BY4741ΔGal2 to enable dose-response activity of the pGal1 and pGal10 
promoters (Table 6-4). In total, 49 strains were constructed for GPCR-dependent 
experiments. The sequence-validated strains constructed here can now be used for 
GPCR-CPR in agonist and antagonist mode as well as in FACS-based selections. Further, 
the zsGreen1 strains can be used in plate-based fluorescence assays. In addition, the tetR 
strains can be coupled with any reporter under the control of a hybrid pGal1-tetOx2 
promoter (Figure 6-3). Each of the alterations were made without using common 
auxotrophic or antibiotic resistance markers, making them easier to manipulate, engineer, 
or customize. 
Functional expression of human 5HT1A 
The human serotonin receptor (5HT1A) has been previously shown to function in 
yeast using strains similar to those outlined above (Nakamura et al., 2015). To test our 
newly created strains, we constructed expression vectors containing human 5HT1A under 
the control of the strong, constitutive pTDH3 promoter. We tested a single integration 
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vector along with a high-copy plasmid (2 micron) in JG05 strains. We found that reporter 
strains using the pFus1 promoter had high levels of background. Strains utilizing pFig1 
showed a good dose-response relationship with the 2 micron plasmid (high-copy), 
exhibiting far superior signal:noise (Figure 6-4).  
Having shown functionality of the 5HT1A receptor, we constructed CPR strains 
(JG05-1.0) using this receptor. Initial coupling to CPR circuits showed a high level of 
background. However, we were able to mitigate background by increasing the pH of the 
CPR master mix to pH 8.8 and lowering the number of cycles from 35 to 20 during the 
emulsion PCR. This resulted in a 20-fold increase in signal:noise and marked the first 
example of a CPR circuit functioning in a eukaryotic organism (Figure 6-5). Further 
optimization of expression parameters should greatly increase the signal:noise. For 
example, we expect to see a much more pronounced difference when expressing the 
receptor from a high-copy plasmid. The experiments outlined here were also performed 
with cells growing with the ligand for 18 hours. By concentrating the cells and limiting 
the time of induction, we should see a decrease in our background signal. Optimization 
experiments are currently underway in our laboratory. 
Inverter circuit design, construction, and validation 
In order to couple antagonism to CPR, we devised an inverter circuit. In this 
scheme, activation of the GPCR triggers the expression of bacterial tetR, which then in 
turn inhibits the inducible expression of a modified Gal1 promoter containing 2 tet 
operator sequences downstream of the TATA box. The details of this hybrid promoter 
have been discussed elsewhere (Nevozhay et al., 2009). If the GPCR is inhibited, then 
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tetR is not produced, and the promoter is inducible with galactosidase. This circuit could 
also be used in the engineering of receptors. Often, GPCRs show a low level of 
constitutive activity. Using the inverter circuit described here, it should prove possible to 
select against constitutive activity or receptor activation by off-target ligands, thereby 
increasing sensitivity and selectivity. 
To test the feasibility of this approach, we constructed strains with the fluorescent 
reporter zsGreen1 under the control of the hybrid Gal1-2xtetO promoter in single-copy 
integration vectors. We also created integration vectors containing tetR with a nuclear 
localization signal and tetR variants with degradation tags of varying strengths (Lee et al., 
2015). Next, we tuned expression of the tetR with low, medium, and high strength 
constitutive promoters. Our idea was to gauge the dynamic range of the system and 
potentially mimic the range of induction strengths of receptor activation. After an 18 hour 
galactosidase induction, we measured the fluorescent output of each of the strains. 
Without a degradation tag, we observed 121-fold repression when expressing tetR with a 
high strength promoter (Figures 6-6 & 6-7). In contrast, low-level expression of tetR 
resulted only 20-fold repression in comparison to the control strain lacking tetR 
expression. The addition of a weak degradation tag (Ubi-M) displayed ranges of 1-73-
fold repression when comparing low-high strength expression. The Ubi-Y degradation 
tag was only able to show low-levels of repression under high expression conditions, and 
Ubi-R did not show repression under any expression condition, due to the repressor being 
rapidly degraded. CPR strains, JGXX-3.0, have now been constructed and mock selection 
with antagonists are currently underway. 
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Functional expression of human CB2 and autoactivation by biosynthesis of β-
caryophyllene 
We tested the ability of three of our strains to couple to the human CB2 receptor 
expressed on a high-copy number plasmid. We chose Gα subunits that were predicted to 
couple to the receptor (Shim et al., 2013). We monitored the dose-response of 2-
arachidonyl glycerol, the native endocannabinoid, in strains differing only in the terminal 
5 amino acids of the Gα protein. We also built control receptors that contained stop 
codons in the middle of the gene. We refer to these as ‘broken’ receptors. Using 
zsGreen1 as a reporter, each of the three strains was capable of responding to the ligand 
in a dose-dependent manner only in the presence of a fully functional receptor (Figure 6-
8). Strains containing broken receptors did not produce a signal at any concentration 
tested. 
A powerful pathway engineering method would involve coupling the biosynthesis 
of a compound to a CPR circuit using a GPCR. This would allow the directed evolution 
of the pathway as well as the organism with the addition of more complex CPR circuitry. 
A literature search revealed that β-caryophyllene, a dietary cannabinoid, was a selective 
agonist for CB2. This was an attractive molecule because yeast only require one 
additional enzyme from Artemisia annua to convert FPP to β-caryophyllene (Reinsvold 
et al., 2011). We tested our strains and found that JG04-2.0 and JG05-2.0 both responded 
to high concentration of β-caryophyllene (Figure 6-9). 
To produce β-caryophyllene in yeast, the native isoprenoid pathway for the 
production of farnesyl diphosphate (FPP) was augmented by the heterologous expression 
of QHSI β-caryophyllene synthase from A. annua. To increase yields, the UCP2-1 
transcription factor was inserted to upregulate expression of enzymes HMG-CoA 
synthase (ERG13), mevalonate kinase (ERG12), and phosphomevalonate kinase (ERG8).  
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In addition, extra copies of the enzymes isopentenyl diphosphate isomerase (IDI1), the 
truncated HMG-CoA reductase (tHMG1), and farnesyl diphosphate synthase (ERG20) 
were constructed into expression vectors. Fragmentation mass spectrometry of extract 
was used to validate production (Figure 6-10). Next, we inserted our β-caryophyllene 
production vectors into a GPCR strain expressing the human CB2. When compared to a 
strain lacking the pathway, we found that we could activate the GPCR with β-
caryophyllene producing strains (Figure 6-11). To our knowledge, this is the first 
autoactivation of a human GPCR with a plant biosynthetic pathway in yeast. We have 
now inserted the pathway into CPR strains (KOD reporter) and are attempting to evolve 
the QHSI β-caryophyllene synthase. 
 
Biosynthesis of Cannabidiol 
The natural biosynthesis of cannabinoids in Cannabis sativa can be roughly 
divided into four distinct metabolic pathways: hexanoate, 2-C-methyl-D-erythritol 4-
phosphate (MEP), geranyl diphosphate (GPP), and the penultimate cannabinoid 
production center (Figure 6-12). A total of 20 enzymes constitute the complete pathway; 
intermediates and flux relationships have been identified, providing a framework for 
alternative biological chassis development. The yeast Saccharomyces cerevisiae is an 
attractive organism in which to port the production of cannabinoids because many of the 
precursors needed are present, mitigating the need to recreate the pathway wholesale. 
Existing strains have been engineered to overproduce GPP, which reduces the complexity 
of the complete pathway from 20 enzymes to 10. Coupled with the ability to add 
hexanoate exogenously while still obtaining substantial levels of key intermediates, only 
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5 enzymes are left to optimize to create minimal cannabinoid production strains (Stout et 
al., 2012). 
The genes for hexanoyl-CoA synthetase (CsAEE1), 3,5,7 trioxododecanoyl-CoA 
synthase (OLS), olivetolic acid cyclase (TKS), geranyl-pyrophosphate-olivetolic acid 
geranyltransferase (CsPTI), and cannabidiolic acid synthase (CBDA) were codon 
optimized for expression in S. cerevisae.  These five enzymes were cloned under the 
control of endogenous yeast promoters: ScTDH3, ScCCW12, ScPGK1, ScHHF2, and 
ScTEF11, respectively. Promoters were chosen based on published expression profiles 
and kinetics (Table 6-5). Each enzyme was also given a unique terminator to mitigate the 
potential ejection of pathway enzymes via recombination. All five were assembled along 
with the Ura3 gene into a single integration vector via a restriction-digestion reaction and 
cloned into E. coli (DH10B). The complete pathway was stably integrated into the ΔUra3 
locus of S. cerevisiae BY4741 and a BY4741 ΔPep4 knockout (Figure 6-13). To 
determine if the enzymes were being produced, we performed proteomics and found that 
each of the cytosolic enzymes was present in great abundance (Figure 6-14). We were 
unable to see spectral counts of the aromatic prenyltransferease, which is an integral 
membrane protein in the plant. We instead fused a fluorescent reporter and determined 
that the enzyme was expressed. There were no significant differences observed in protein 
abundance between BY4741 and the ΔPep4 knockout, leading us to continue with 
BY4741. 
Using this initial strain, we were able to produce a small amount of CBD with 
supplementation of 1 mM hexanoate in the growth medium after 7 days of growth. We 
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confirmed the production of CBD by HPLC (Figure 6-15). We were also able to show 
that the bulk of CBD was found within the cell pellet. This is more than likely due to the 
hydrophobicity of the molecule forcing its aggregation within cell membranes. Control 
strains, lacking pathway enzymes at the URA3 locus, did not produce CBD. 
To determine the bottleneck of our pathway, we performed growth assays with 
BY4741 cells in the presence of each of the intermediates (Figure 6-16). Hexanoic acid 
and olivetolic acid, the first two molecules in the pathway, were shown to strongly inhibit 
growth. CBGA and CBD were indistinguishable from one another. However, they 
produced a modest growth defect. From these data, we concluded that growth would be a 
suitable surrogate for determining optimal conditions or guiding engineering efforts. 
Increasing the growth rate would likely correlate to the production of at least CBGA. Due 
to the abundance of CBDA synthase in the proteomics analyses, we would not expect the 
conversion of CBGA to CBDA to be problematic unless compartmentalization of 
enzymes caused partitioning. 
Our inability to observe fragments of the aromatic prenyltransferase in our 
proteomics analyses and the strain’s poor growth in hexanoic acid led us to hypothesize 
that increasing the availability of the aromatic prenyltransferase would lead to robust 
growth and production of CBD. The aromatic prenyltransferase resides on the 
outermembrane of chloroplast in the plant. Using the bioinformatics tools TargetP and 
ChloroP, we predicted that the first 74 amino acids of the integral membrane enzyme 
were a part of a chloroplast targeting sequence (Figure 6-17), which yeast do not contain. 
The inability of the organism to interpret the plant signal sequence more than likely 
 
277 
triggers degradation, which we observed in the upregulation of the unfolded protein 
response (UPR) in our proteomics experiments (Figure 6-18).  
In an effort alleviate the growth defect and increase CBD production, we then 
rationally designed a number of aromatic prenyltransferases variants. We targeted the 
inner mitochondrial membrane, the outer mitochondrial membrane, and the plasma 
membrane using common signal peptides and motifs (Figure 6-19). Growth assays in 
hexanoic acid of these variants did little to distinguish optimal targeting of the aromatic 
prenyltransferase (Figure 6-20). 
The two substrates for the aromatic prenyltransferase are olivetolic acid and GPP. 
Given that CsAEE1, OLS, and the OAC had all been shown to be functional in yeast cells 
and lysates (Gagne et al., 2012), we concluded that we were more than likely making the 
toxic molecule olivetolic acid at this point. While yeast are able to synthesize GPP, it is in 
low abundance and a side product of Erg20, an essential gene in yeast that makes farnesyl 
pyrophosphate (FPP) as a part of the mevalonate and isoprenoid pathways. Others have 
shown that the expression of a mutant from of this enzyme (Erg20WW) can increase the 
amount of GPP available in the cell. With an additional copy of IDI1, a truncated HMG1 
(tHMG1), and a mutant transcription factor (UPC2-1), large amounts of GPP can be 
produced in the cytosol of S. cerevisiae (Figure 6-21)(Zhao et al., 2016).  
We reasoned that including these proteins along with an additional copy of the 
aromatic prenyltransferase might alleviate the growth defect if GPP was the limiting 
factor in our growth assays in hexanoic acid. We constructed integration vectors targeting 
the Leu2 and HO sites within BY4741 with each of the aromatic prenyltransferase 
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variants being expressed under the control of the pTDH3 promoter (Figure 6-22). 
Preliminary screening of strains harboring the CRC and GPP integration vectors in 10 
mM hexanoic acid and 1% acetate revealed noticeable differences in growth (Figure 6-
23). These strains have subsequently been grown in 1 L batches. We currently await 
extraction and metabolic profiling of these variants. 
The establishment of a robust CBDA-producing strain will enable the production 
of other natural cannabinoids as well as the capability to further engineer pathways for 
more exotic, tailor-made molecules. Natural derivatives will result from plugging in key 
enzymes at pathway branch points. For example, CBGA is a common intermediate in the 
synthesis of CBCA, CBDA, and THCA. By replacing CBDAS with CBC synthase or 
THC synthase, CBC or THC can be readily accessed biosynthetically (Figure 2). Another 
natural branch point occurs upstream of olivetolic acid, which produces the shorter chain 
divarinic acid derivatives (CBDV, THCV, and CDCV). Additionally, a number of other 
cannabinoid branch points from C. sativa and other cannabinoid producing plants should 
be amenable to our plug-and-play platform to create a vast array of combinatorial 
variants. The addition of other hexanoate and GPP derivatives should provide yet another 
avenue to create novel compounds not otherwise found in nature. 
Conclusions and looking forward 
Eukaryotic CPR 
We have now adapted CPR to function in the context of the yeast Saccharomyces 
cerevisiae.  This greatly expands the range of experiments that can be carried out.  By 
adapting CPR to function in the context of yeast, we can now undertake the optimization 
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of eukaryotic signal transduction pathways. This was not possible in bacteria, and the 
extension from transcription and translation to signal transduction pathways was an 
obvious first step in creating eukaryotic CPR. For example, we have cloned a human 
GPCR (5HT1A) into yeast and coupled it to the yeast pheromone response signal 
transduction pathway that ultimately leads to the expression of KOD polymerase.  This 
allows us to optimize or alter the function of this GPCR. Ultimately, similar schemes 
should be possible with almost any signal transduction protein or small molecule effector 
that can be cloned into or made in.  
Next-Generation Drug Screening using CPR  
The ability to examine signal transduction pathways in yeast further leads to the 
ability to identify drugs that can modulate signal transduction pathways. In this 
instantiation, a drug would be co-expressed with the pathway or added exogenously.  
Pathways for the production of small molecules can be co-expressed in yeast with a given 
GPCR or other signal transduction partner. The pathways will lead to the production of 
drugs, some of which may activate (or inhibit) the GPCR. We have proofed the 
production of cannabidiol, a 5HT1A receptor agonist and CB1/CB2 receptor antagonist, 
and β-caryophyllene, a CB2 receptor agonist. By including primers that can amplify the 
pathways that created the small molecule, emulsion PCR will lead to the selective 
amplification of those pathways or pathway variants that produce the most functional 
effector molecule. Using CPR for drug-discovery should now be possible by creating 
libraries of human receptors and screening drugs in either the agonist or antagonist CPR 
circuits. This is an especially powerful technique when one considers the ability to screen 
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for off-target hits in a high-throughput manner by sequencing activated or inactivated 
receptors.  
Therapeutic Antibody Selections Using CPR 
 The ability to screen small molecules is only one possibility.  Using CPR, it 
should also prove possible to select for human antibodies that activate (Agonist CPR) or 
inactivate (Antagonist CPR) GPCRs. To do so, libraries of antibodies should be co-
expressed in GPCR-expressing strains. Rather than tethering the antibody to the outside 
of the cell, as done in yeast display, antibodies are anchored inside the periplasmic space 
with a GPI-domain fusion (Flo42). Preliminary experiments with the human Glp1R using 
a fluorescent reporter suggest that this may be possible. Antibodies that can activate a 
given GPCR will lead to the production of the DNA polymerase, which leads to 
amplification of the antibody variants capable of triggering the receptor. The 
implementation of the inhibitory pathway requires the inverter circuit, in which the 
repression of a repressor led to KOD polymerase production. This method of antibody 
discovery is especially important since potentially therapeutic antibodies identified will 
be identified not only on basis of the strength of interaction (affinity), but also on 
functionality, such as whether the antibody is an antagonist or agonist of the GPCR.  
Such functional selections cannot be carried out in almost any other way and would mark 
the first directed evolution platform capable of producing human therapeutic antibodies. 
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Methods & Materials 
GPCR Strain creation and genetic manipulation 
Strains BY4741 and BY4741ΔGal2 were obtained from the Marcotte laboratory. Cas9 
plasmids were constructed as previously described (Lee et al., 2015). To cure the Cas9 
plasmid, we patch plated 15 colonies that were grown on rich media. Human receptor 
sequences were procured from Uniprot, codon optimized for expression in S. cerevisiae, 
and ordered as GeneBlocks from IDT. Entry vector stocks (YTK001) were made to allow 
for shuttling between integration, low-copy, and high-copy plasmids. Promoters and 
terminators were taken from the Yeast Toolkit. A list of GPCR strains is contained in 
Table 6-4. The copy number of receptor plasmids are indicated where necessary.  
Integration vectors were digested with NotI. All transformations were done using the EZ 
Yeast Transformation Kit (Zymo Research). For pathway engineering, vectors were 
constructed with the same procedures. Plasmid maps and sequences are available upon 
request. 
Dose-response of human receptors expressed in yeast 
For 5HT1A, overnight cultures of receptor transformants of JG05-2.0 and JG05-0.2 were 
washed and diluted 1:1000 in media containing varying amounts of serotonin. Cells were 
washed 3 times and resuspended in PBS. Fluorescent (485nm/515nm) and cell density 
(600 nm) measurements were taken on a Cytation 5. Data were plotted and analyzed 
using SigmaPlot10. For CB2, strains JG03-,JG04-, and JG05-2.0 were transformed and 
treated the same. We also included broken receptor (stop codons) in these assays. 
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CPR in yeast 
JG05-1.0-5HT1A were grown overnight and diluted into media containing 250 µM 
serotonin. Control cells were not induced. Cells (3 mL total) were collected after 18 hours 
of induction and spun in a tabletop centrifuge at 3,000 x g for 5 minutes. The supernatant 
was discarded and the cell pellet was washed in water and then resuspended in 1 M 
sorbitol, 25 mM EDTA, 50 mM DTT. Cells were collected again and washed in 1 M 
sorbitol. After another wash with water, cells were resuspended in 500 µL PCR 
mastermix (pH 8.0 or pH 8.8).The resuspended cells were placed into a 2 mL tube with a 
1mL rubber syringe plunger and 1200 µL of oil mix (876 Tegosoft DEC, 84 Gransurf 
W9, and 240 µL light mineral oil (Sigma-Aldrich)). The emulsion was created by placing 
the cell and oil mix on a TissueLyser  LT  (Qiagen) with  a program  of 37 Hz  for  
minutes.  The emulsified  cells  were incubated at 37˚C for 15 minutes, followed by 10 
minutes at 95˚C, and then thermal-cycled for 35 cycles (Appendix II). Emulsions were 
broken by spinning the reaction (20,000xg) for 15 minutes, removing the top oil phase, 
adding 750 µL chloroform, vortexing vigorously, and finally phase separating in a phase 
lock tube (5Prime). The aqueous phase was cleaned using a Promega PCR purification 
column. Products of the CPR amplification were visualized using agarose gel 
electrophoresis. 
Proteomics analysis 
Cells harboring pathways or empty integration vectors were grown at 30˚C for 24-48 hrs 
in selective media and diluted 1:25 for 6 hours. Cell pellets were collected by 
 
283 
centrifugation and given to the Marcotte laboratory for analysis. Dr. Dan Boutz 
performed all of the proteomics experiments. 
Metabolite toxicity and growth curves 
BY4741 transformed with a spacer sequence at the URA3 locus were grown for 48 hours 
and diluted 1:25 in media containing 4 mM of each metabolite (hexanoate, olivetol, 
CBGA, and CBD). Measurements of cell density (OD600) were taken in 10 min 
intervals. Each condition was tested in triplicate. For hexanoate growth conditions of 
aromatic prenyltransferase variants, transformed cells were seeded for 48 hrs and diluted 
1:25 in 96-well grow-blocks in media containing 1-5 mM hexanoate. Measurements of 
cell density were taken in 24 hr intervals using an F500 plate reader. Final screening was 
performed with 10 mM hexanoate, 1% acetate supplemented synthetic complete media in 
50 mL culture volumes. 
Metabolite extraction and analysis 
Supernatant and cell pellets were extracted with 40 mL ethyl acetat, dried under vacuum 
and resuspended in 250 µL ethanol or methanol. To decarboxylate metabolites, 
resuspensions were incubated at 65˚C for 24 hrs on a tabletop incubator. 200 µL of the 
decarboxylated product was then run on a C18 column equilibrated with 25% water, 75% 
ACN, 0.1% TFA. Metabolites were eluted along a gradient with 100% CAN, 0.1% TFA. 
Standards were run after samples. We recorded the full spectrum between 0-600 nm and 
monitored 228 nm for CBD production. Chromatograms were produced and analyzed 
within the Beckman System Gold 32 Karat software package.
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Figure 6-1: Agonist and antagonist CPR circuits 
 
Left, agonist CPR. Ligand induces the production of DNA polymerase, which is then 
used in emulsion PCR. Right, antagonist CPR circuit. Agonism of the receptor leads to 
the production of a repressor, which then in turn inhibits the production of a thermostable 
DNA polymerase for use in emulsion PCR. Only when the receptor is blocked is it 
possible to produce polymerase. 
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Table 6-1: G-alpha subunits 
Name 
Strain 
Code 
Terminal 
AA 
Gpa1p 00 KIGII 
Gαq 01 EYNLV 
Gαs 02 QYELL 
Gαo 03 GCGLY 
Gαi2 04 DCGLF 
Gαi3 05 ECGLY 
Gαz 06 YIGLC 
Gα12 07 DIMLQ 
Gα13 08 QLMLQ 
Gα14 09 EFNLV 
Gα16 10 EINLL 
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Table 6-2: sgRNA oligos used for genomic knockouts 
Oligo Sequence 
EG.sgRNA.Far1.A.F GACTTTACCAAGTTTGAAGAAAACAG 
EG.sgRNA.Far1.A.R AAACCTGTTTTCTTCAAACTTGGTAA 
EG.sgRNA.Far1.B.F GACTTTCCACCGAAGAAATTTCTAAG 
EG.sgRNA.Far1.B.R AAACCTTAGAAATTTCTTCGGTGGAA 
EG.sgRNA.Far1.C.F GACTTTATAGGCTTGGAAAGATTCAG 
EG.sgRNA.Far1.C.R AAACCTGAATCTTTCCAAGCCTATAA 
EG.sgRNA.Sst2.A.F GACTTTCAGTTCATCAGTAGAGGTGA 
EG.sgRNA.Sst2.A.R AAACTCACCTCTACTGATGAACTGAA 
EG.sgRNA.Sst2.B.F GACTTTTCAGGAAGCTATTAAAGCAA 
EG.sgRNA.Sst2.B.R AAACTTGCTTTAATAGCTTCCTGAAA 
EG.sgRNA.Sst2.C.F GACTTTACATAAATAATGTAAGAAGG 
EG.sgRNA.Sst2.C.R AAACCCTTCTTACATTATTTATGTAA 
EG.sgRNA.Ste2.A.F GACTTTACATAAATAATGTAAGAAGG 
EG.sgRNA.Ste2.A.R AAACCCTTCTTACATTATTTATGTAA 
EG.sgRNA.Ste2.B.F GACTTTTCAGTGACTTACGCTCTCAC 
EG.sgRNA.Ste2.B.R AAACGTGAGAGCGTAAGTCACTGAAA 
EG.sgRNA.Ste2.C.F GACTTTTTGCAACTCATCGAAAGTGA 
EG.sgRNA.Ste2.C.R AAACTCACTTTCGATGAGTTGCAAAA 
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Table 6-3: sgRNA knockout efficiency 
Gene Guide KO 
% effective 
sgRNA per gene 
total % 
effective 
sgRNA 
Ste2 A n 
67% 
67% 
Ste2 B KO 
Ste2 C KO 
Sst2 A n 
33% Sst2 B n 
Sst2 C KO 
Far1 A KO 
100% Far1 B KO 
Far1 C KO 
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Figure 6-2: Representative qPCR detection of barcodes 
 
 
Blue line represents sequence-verified strain containing a disrupted Ste2. Redline is the 
unaltered BY4741. qPCR could be used to distinguish between the wildtype sequence 
and a disrupted gene.
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Figure 6-3: Inverter circuit reporter design 
 
Inverter circuit reporter is depicted. We inserted the construct into the Leu2 site by 
supplying an auxotrophic marker. The reporter, zsGreen1, is driven by a modified Gal1 
promoter. Two tetO sites are located downstream of the TATA box and prevent 
transcription when bound by tetR.
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Figure 6-4: 5HT1A dose-response to serotonin 
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Dose-response of JG05-2.0 expressing human 5HT1AR from a 2 micron plasmid. Each 
point is the average of replicates. EC50 = 171.6 µM.
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Table 6-4: GPCR strains constructed in this work 
 
CODE Parental Resistance/Aux Alterations 
JG00-0.0 BY4741ΔGal2 G418 ΔFar1-KO, ΔSte2-KO, ΔSSt2-KO 
AM00-0.0 BY4741 None ΔFar1-KO, ΔSte2-KO, ΔSSt2-KO 
JG00-1.0 JG00-0.0 G418 ΔpFig1-KOD 
JG00-0.1 JG00-0.0 G418 ΔpFus1-KOD 
JG00-2.0 JG00-0.0 G418 ΔpFig1-zsGreen1 
JG00-0.2 JG00-0.0 G418 ΔpFus1-zsGreen1 
JG00-3.0 JG00-0.0 G418 ΔpFig1-tetR 
JG01-0.0 JG00-0.0 G418 ΔGpa1-hGαq 
JG01-1.0 JG01-0.0 G418 ΔpFig1-KOD 
JG01-2.0 JG01-0.0 G418 ΔpFig1-zsGreen1 
JG01-3.0 JG01-0.0 G418 ΔpFig1-tetR 
JG02-0.0 JG00-0.0 G418 ΔGpa1-hGαs 
JG02-1.0 JG02-0.0 G418 ΔpFig1-KOD 
JG02-2.0 JG02-0.0 G418 ΔpFig1-zsGreen1 
JG02-3.0 JG02-0.0 G418 ΔpFig1-tetR 
JG03-0.0 JG00-0.0 G418 ΔGpa1-hGαi2 
JG03-1.0 JG03-0.0 G418 ΔpFig1-KOD 
JG03-2.0 JG03-0.0 G418 ΔpFig1-zsGreen1 
JG03-3.0 JG03-0.0 G418 ΔpFig1-tetR 
JG04-0.0 JG00-0.0 G418 ΔGpa1-hGαo 
JG04-1.0 JG04-0.0 G418 ΔpFig1-KOD 
JG04-2.0 JG04-0.0 G418 ΔpFig1-zsGreen1 
JG04-3.0 JG04-0.0 G418 ΔpFig1-tetR 
JG05-0.0 JG00-0.0 G418 ΔGpa1-hGαi3 
JG05-1.0 JG05-0.0 G418 ΔpFig1-KOD 
JG05-0.1 JG05-0.0 G418 ΔpFus1-KOD 
JG05-2.0 JG05-0.0 G418 ΔpFig1-zsGreen1 
JG05-0.2 JG05-0.0 G418 ΔpFus1-zsGreen1 
JG05-2.2 JG05-2.0 G418 ΔpFig1-zsGreen1, ΔpFus1-zsGreen1 
JG05-3.0 JG05-2.0 G418 ΔpFig1-tetR 
JG06-0.0 JG00-0.0 G418 ΔGpa1-hGαz 
JG06-1.0 JG06-0.0 G418 ΔpFig1-KOD 
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Table 6-4 Cont. 
 
 
JG06-2.0 JG06-0.0 G418 ΔpFig1-zsGreen1 
JG06-3.0 JG06-0.0 G418 ΔpFig1-tetR 
JG07-0.0 JG00-0.0 G418 ΔGpa1-hGα12 
JG07-1.0 JG07-0.0 G418 ΔpFig1-KOD 
JG07-2.0 JG07-0.0 G418 ΔpFig1-zsGreen1 
JG07-3.0 JG07-0.0 G418 ΔpFig1-tetR 
JG08-0.0 JG00-0.0 G418 ΔGpa1-hGα13 
JG08-1.0 JG08-0.0 G418 ΔpFig1-KOD 
JG08-2.0 JG08-0.0 G418 ΔpFig1-zsGreen1 
JG08-3.0 JG08-0.0 G418 ΔpFig1-tetR 
JG09-0.0 JG00-0.0 G418 ΔGpa1-hGα14 
JG09-1.0 JG09-0.0 G418 ΔpFig1-KOD 
JG09-2.0 JG09-0.0 G418 ΔpFig1-zsGreen1 
JG10-0.0 JG00-0.0 G418 ΔGpa1-hGα16 
JG10-1.0 JG10-0.0 G418 ΔpFig1-KOD 
JG10-2.0 JG10-0.0 G418 ΔpFig1-zsGreen1 
JG10-3.0 JG10-0.0 G418 ΔpFig1-tetR 
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Figure 6-5: GPCR CPR proof-of-concept with 5HT1A 
 
Initial proof-of-concept GPCR-CPR. Human 5HT1A was constitutively expressed from a 
single-copy integration vector inserted at the HO site. Lane 1 is a 1 kb ladder. Lane 2 is 
the amplification product of cells treated with 250 µM serotonin. Lane 3 represents the 
negative control. There is a 20-fold increase in signal with cells treated with the ligand.  
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Figure 6-6: Inverter circuit proof-of-concept 
 
Normalized fluorescent measurements were taken after 18 hrs of galactosidase induction. 
SP refers to a spacer and does not contain any form of tetR. Ubi-M/Y/R are degradation 
tags added to the N-terminus of tetR. They are ordered in range of strength. Promoters 
driving the expression of tetR variants are listed below. They are arranged in order of 
high to low. 
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Figure 6-7: Inverter circuit fold repression 
 
Fold-repression calculated from figure 6-5. Numeric values are listed below. No 
detectable repression is found when using the fast or high degradation tag on tetR. 
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Figure 6-8:CB2 dose response with native ligand 
 
Dose-response of CB2 to 2-arachidonyl glycerol. Each point on the graph represents the 
average of replicate measurements. Strain JG04-2.0 was selected to be the preferred 
strain due to the superior EC50. 
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Figure 6-9: CB2 β-caryophyllene dose-response 
 
Dose-response of CB2 to β-caryophyllene. Each point on the graph represents the 
average of replicate measurements. We later found that our standard was mostly a 
degradation product, possibly explaining the large amounts of β-caryophyllene needed to 
activate the receptor. 
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Figure 6-10: MS ANALYSIS OF β-caryophyllene production 
B-caryo_2u_1a_20161220_161221154714 #1393-1443 RT: 17.01-17.43 AV: 32 NL: 2.64E5
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Figure 6-11: Autoactivation of CB2 with β-caryophyllene producing strains 
 
Autoactivation of the CB2 receptor by beta-carophyllene production in the same strain.  
QHSI was introduced on 2 micron and CEN6 origins and CB2 stimulation was read by 
ZsGreen reporter. Error bars represent the standard deviation of replicate measurements.
RFU 
 300 
 
Figure 6-12: CRC integration vector 
 
Cannabinoid reaction center (CRC). The 5 pathway enzymes are shown in yellow. 
Promoters are depicted in green. Terminators are shown in orange. 
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Figure 6-13: Proteomics analysis of pathway enzymes 
 
Spectral counts of each of the soluble CBD pathway enzymes are shown. Enzymes were 
expressed in BY4747 (wt) and ΔPep4 strains. We also measured protein abundances in 
cells grown in synthetic complete (SC) or rich (YPD) media.
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Table 6-5: Published kinetics of CBD enzymes 
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Figure 6-14: Protein abundances by strain 
 
Relative abundance of each of the soluble CBD pathway enzymes are shown. Enzymes 
were expressed in BY4747 (wt) and ΔPep4 strains in both SC and YPD. Percentages are 
relative to total protein abundances from their respective strain and growth condition. 
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Figure 6-15: HPLC of CBD from supernatant and cell pellet extractions 
 
Total ethyl acetate extractions from the supernatant as well as cell pellet are shown. CBD 
is primarily found in the cell pellet extraction (14.9 min peak). 
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Figure 6-16: Metabolite toxicity determined by growth assays 
 
BY4741 with a spacer sequence inserted into the URA3 locus were grown in 4 mM of 
each intermediate. Hexanoate and olivetol severely inhibit growth. CBGA and CBD were 
far less inhibitory when compared to growth in synthetic media only (SD-URA). 
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Figure 6-17: Predicted chloroplast targeting sequence of aromatic prenyltransferase 
 
The SignalP and ChloroP-predicted signal sequence is depicted in black. The two 
common aromatic prenyltransferase active site loops are highlighted in pink.
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Figure 6-18: Unfolded protein response observed in cells with pathway 
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Figure 6-19: Rational design of aromatic prenyltransferase variants 
 
Aromatic prenyltransferase variants are depicted. For each of the designs, the predicted 
chloroplast targeting sequence was removed. 1-3 represent mitochondrial variants. 4-7 
target the plasma membrane. 8 is the wildtype without the signal peptides, and 9 contains 
a C-terminal domain with the last 42 amino acids of Flo1p. This domain has been shown 
to anchor to the plasma membrane. 
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Figure 6-20: Aromatic prenyltransferase variants alone do not confer robust growth in 
hexanoic acid 
 
Time (hrs) 
Growth of aromatic prenyltransfersae variants in the presence of 1mM (left) and 5 mM 
(right) hexanoate-supplemented media. Each point represents the average growth of 3 
independent colonies. Time points were taken in 24 hr intervals. 
OD600 
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Figure 6-21: GPP pathway 
 
The genes involved in GPP production from acetate in yeast are depicted. Additional 
enzymes added to CBD strains are depicted in red. Erg20WW is a mutant form of the 
native Erg20 and has been shown to primarily produce GPP. Enzymes shown in orange 
are upregulated with the addition of the mutant UPC2-1 transcription factor. 
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Figure 6-22: GPP integration vector 
 
Integration vector constructed to increase GPP. Pathway enzymes are shown in yellow. 
Promoters are green, and terminators are denoted in orange. 
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Figure 6-23: Increasing GPP enables robust growth in the presence of hexanoic acid 
 
Measurements were taken after 3 days of growth in media supplemented with 10 mM 
hexanoic acid and 1% acetate. The variants are numbered the same as Figure 6-16. 
Variant 10 is the unaltered wildtype aromatic prenyltransferase. 
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Chapter 7:  Towards A Robust Ionotropic Activator for Brain-wide 
Manipulation of Neuronal Function 
ABSTRACT 
This chapter outlines methods for the rational design, directed evolution, and 
characterization of novel neuronal actuators based on the purinergic P2X receptor. The 
highly original and comprehensive engineering scheme outlined here brings together the 
various themes explored in previous chapters and will one day yield a new set of 
transformative tools for functional brain analysis. For nearly a decade, analysis of brain 
circuitry has relied on methods that allow neuronal activity to be perturbed in an intact 
brain with cell type-specificity. Genetically-encoded neural actuators have ranged from 
chimeric G-protein coupled receptors (GPCRs) with orthogonal ligands to light-gated 
ionotropic channels. While these tools have helped uncover cellular substrates of 
cognitive and behavioral states, significant limitations remain. Optical fiber implantation 
is destructive, and illumination is limited by mechanical constraints and the requirement 
that the target site be identified in advance. GPCRs are often inefficient, display poor 
temporal control, and often produce long-term functional changes in neurons. The goal of 
this chapter is to develop the computational and directed evolution methods needed to 
engineer a neuronal activator that embodies the strongest features of existing approaches, 
ligand-dependent gating of a channel with high unitary conductance and a negligible 
desensitization profile. We discuss the computational work, the functional expression of 
P2X subtypes in yeast, and validation of CPR selection components that will eventually 
lead to the engineering of orthogonal receptor:ligand pairs. We also discuss the 
development of a potential drug screening platform using yeast to express P2X receptor 
subtypes. 
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INTRODUCTION 
The ability to manipulate defined neuron populations has revolutionized in vivo 
investigations of brain circuitry (Alexander et al., 2009; Boyden et al., 2005; Zemelman 
et al., 2002). The main requirement for a genetically encoded neuronal actuator is that it 
normally be absent from the central nervous system, so that only neurons expressing the 
actuator are sensitized to an orthogonal ligand added in trans. While many actuators that 
stimulate or silence neurons have been devised, each has its own set of drawbacks, 
providing a significant opportunity for improvement. Building on lessons learned from 
modeling and directed evolution, this chapter develops and tests strategies for the 
engineering of orthogonal receptor:ligand pairs that should one day enable restricted 
activation of neurons. Based on the P2X nucleotide receptor, this activator will 
incorporate the strongest features of existing tools, while avoiding many of their 
limitations.  
There are two varieties of actuators: (1) pharmacogenetic, such as metabotropic 
G-protein coupled receptors (GPCRs), and (2) optogenetic, mostly ligand-gated ion 
channels. Hence, actuator triggers have been either small molecules or pulses of light. For 
in vivo use, light delivery is inefficient and requires potentially destructive optical fiber 
implantation. In this respect, pharmacogenetic tools have an advantage over optogenetic 
ones: (1) neurons of interest may be distributed throughout the brain, making optical 
methods impractical; and (2) cell locations may not be known ahead of time. However, 
while systemically administered small molecule ligands can theoretically reach sensitized 
neurons throughout the brain, they must cross first cross the blood-brain barrier. In 
addition, GPCRs are more difficult to regulate, but can be induced for hours; meanwhile, 
ionotropic channels offer precise temporal control, but are inadequate for long-term 
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activity management either due to rapid desensitization or because the required ligand is 
metabolized. Currently, the most widely used actuator is channelrhodopsin2 (Chr2), a 
light-gated algal cation channel (Nagel et al., 2003). The tradeoff for its very rapid on/off 
kinetics is poor single channel conductance (estimated at 150 fS) and fast desensitization. 
These features have limited the use of Chr2 for prolonged or localized stimulation, such 
as of axonal fibers and terminals. 
The functional mapping of neuronal circuits in the brain can be performed 
anatomically or behaviorally. For anatomical circuit analysis, it is necessary to choose an 
initial population of neurons within a brain region of interest and sensitize those neurons 
to activation. Genetically encoded activators that are otherwise absent from the central 
nervous system can be targeted to a selected subset of neurons using spatially confined 
viral infection and cell type-specific promoters. When the neurons are subsequently 
stimulated, their post-synaptic partners can be identified on the basis of elevated activity, 
using post hoc staining for elevated immediate-early gene (IEG) products (Bahrami and 
Drabløs, 2016), or in transgenic animals where IEG activation is coupled to the synthesis 
of a fluorescent protein tag. In both instances the pre- and post-synaptic neurons become 
labeled. Behavioral circuit mapping relies on a change in animal performance 
(DiBenedictis et al., 2017; Krakauer et al., 2017). Stimulation or silencing of cells in an 
anatomical domain produces a measurable behavioral outcome. When the manipulation is 
regional, akin to a lesion, cell types contributing to task performance cannot be readily 
deduced. When the activity of defined cell types is perturbed and a behavioral phenotype 
detected, inferences can be made about cell function. 
In both cases, experimental success is predicated on the efficiency of cellular 
perturbations. In direct circuit mapping, post-synaptic neurons will not be detected if the 
stimulus is too weak. Likewise, a behavioral change may not be apparent when the target 
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cell population is only partially affected. As a result, pharmacogenetic methods have a 
slight advantage over optogenetic ones: (1) light guides produce spatially restricted 
illumination, potentially missing many cells of interest, and can damage neuronal 
connections—both  drawbacks for behavioral analyses of cell function; (2) where the 
experimental readout is optical or the behavioral assay incorporates a visual component, 
light stimulation can confound outcomes; and (3) optical methods are often hampered by 
low conductances and rapid desensitization. Likewise, pharmacogenetic techniques that 
rely on neuromodulatory second messenger cascades can increase the sensitivity of pre- 
synaptic neurons to stimulation, but may not reliably activate their post-synaptic partners. 
Finally, for both pharmacological and optical methods, control over multiple, potentially 
intermingled cell populations has proven elusive. 
 
APPROACH 
A family of pharmacogenetic ionotropic activators addresses the enumerated 
limitations listed above. The absence of a light requirement ensures comprehensive 
stimulation of sensitized neurons irrespective of their location; the gating of a non-
specific cation channel produces rapid membrane depolarization followed by sustained 
cell firing; and the availability of multiple actuators that can be used in parallel provides 
experimental access to several cell populations.  
An activator based on the P2X receptor represents the ideal alternative for robust 
and selective stimulation of neurons. P2X channels support currents of 10-20 pS 
(exceeding that of Chr2 by nearly 100 fold). Stimulation is tunable, controlled by ligand 
concentration. Several members of this receptor family (P2X2 and P2X4) display 
negligible desensitization. Nucleotide analogs can be administered systemically or fitted 
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with a photolabile caging group to enable localized activation using visible light 
(Zemelman et al., 2003). Their stability can also vary, regulating stimulus duration. Since 
P2X receptors are abundant in the central nervous system, it is necessary to design 
synthetic variants of P2X, based on published crystal structures, along with matching 
ligands. These modified P2X receptors will be unresponsive to endogenous nucleotides, 
but instead be controlled by the orthogonal small molecule ligands. Fundamentally, three 
main tasks must be accomplished to effectively control neurons with the resulting 
orthogonal receptor-ligand pairs: (1) validation of our computational methodology in the 
design of receptors and agonists; (2) optimization of conditions for the directed evolution 
of receptors; and (3) ensure orthogonality of our engineered channels and small molecule 
ligands before functionally testing them in an organism. 
This chapter outlines the computational work, the functional expression of P2X 
subtypes in yeast, and validation of selection circuits that will eventually lead to the 
engineering of orthogonal receptor:ligand pairs. Using structural information of 
P2X4, candidate mutagenesis sites and designs for complementary ligands are discussed. 
By extending the directed evolution technique pioneered in our laboratory, 
Compartmentalized Partnered Replication (CPR), to yeast, we now have a platform to 
engineer orthogonal purinergic receptor-ligand pairs in parallel with our computational 
approach. Using alternating rounds of positive and negative selection, we envision 
libraries that converge on a small number of unique solutions for each new ligand.  
The goal of this chapter is to develop orthogonal P2X receptor-ligand pairs using 
novel computational and directed evolution methods. While computational methods for 
protein (Miklos et al., 2012; Smith et al., 2014; Tiwari et al., 2012) and small molecule 
(Rosales-Hernández and Correa-Basurto, 2015; Stanley and De Fabritiis, 2015; Verma 
and Prabhakar, 2015) engineering have existed for well over a decade, the strategies 
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typically focus on one component, either a drug-like molecule or the protein itself. For 
example, medicinal and computational chemists have developed virtual tools for in silico 
screening of compounds against targets of interest and algorithms for guiding small 
molecule design based on structure-activity relationships (Doupnik et al., 2015; 
Giacomini et al., 2015). Quantitative structure activity relationship (QSAR) data are then 
used to build numerical models for predicting and interpreting experimental results. 
Refinement by computational fragment-based drug design has also garnered experimental 
support for use with receptors and enzymes (Böhm et al., 1999; Mueller et al., 2002; 
Stürzebecher et al., 1995). Finally, techniques to generate molecules with improved drug-
like properties have recently emerged (Pierce et al., 2004).  This work  compounds  these  
methodologies  for  the  development  of  drug-like  molecules  to engineered receptors 
using computational and directed evolution methods (Figure 7-1). 
In drug development, the refinement of ligand binding through target 
modification is impossible because targets cannot be altered. In the present case, 
however, both the ligand and receptor are amenable to engineering. Protein design tools 
have benefited from better, more robust force fields and scoring methods (Barnoud and 
Monticelli, 2015; Vanommeslaeghe and MacKerell, 2015). In conjunction with  quantum  
mechanical  geometry  optimizations (Cho et al., 2005; Fu et al., 2011)  and  molecular  
dynamics  simulations,  protein-by-design strategies are widely displaying their 
effectiveness. Methodologies laid out below melds protein and ligand design strategies 
together to create a system to engineer truly orthogonal receptors and tailor-made small 
molecules. 
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RESULTS & DISCUSSION 
Structure-based design approach 
An iterative process of computational design was employed to design orthogonal 
P2X receptor-ligand pairs. Using crystal structures of the zebrafish P2X4  in both bound-
open (Figure 7-2) and unbound-closed states and homology models of the other receptor 
subtypes, a fragment-based design approach (Guarnieri, 2015; Ludington, 2015) was 
utilized to design receptors and corresponding ATP-analogs using a suite of 
computational tools described below. While the ATP binding motif of P2X family 
receptors is not otherwise found in nature (Figures 7-3 & 7-4),  the  U-shaped  binding  
orientation  is  only  crudely  observed  in  Type  II  amino-acyl  tRNA  synthetases 
(Hattori and Gouaux, 2012). Additionally,  several  agonists/antagonists  have  been  
identified  for  each  of  the  receptor  subtypes  (P2X1-7) (Dal Ben et al., 2015; North, 
2002). Together these facts offered a unique opportunity for engineering custom 
receptors to ATP-analogs and the potential to design novel drug-like molecules to 
engineered receptors. 
 
Computational design of receptors 
Using the Molecular Operating Environment (MOE09.2014) suite of protein 
design and medicinal chemistry tools, NAMD Scalable Molecular Dynamics (Phillips et 
al., 2005), and resources at the Texas Advanced Computing Center, we computationally 
derived amino acid substitutions that enhance binding to one of a number of ATP- 
analogs (Figure 7-5). As a proof-of-concept and training of our design process, we 
designed 20 P2X4 receptor variants to bind to 2-Chloro-ATP (2-Cl-ATP) (Figure 7-6), 
20 receptors that bind to 2'3'-O-(4-benzoyl-benzoyl)- adenosine 5'-triphosphate (BzATP), 
and an additional 20 receptors that bind adenylyl-imidodiphosphate (AmpPNP), a non-
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hydrolysable analog. The sets of designs independently focused on the three structural 
motifs bound by the receptor (base, sugar and phosphate) in an effort to minimize 
computational load and potentially allow design modularity. In silico selections were 
scored on binding energy, stability of the mutations in relation to the protein, and the 
overall potential energy of the agonist bound in the open state using an all atom force 
field with reaction field treatment of electrostatics. Candidate receptors were refined by 
rotamer exploration (Lovell et al., 2000), low-mode molecular dynamics (Labute, 2010b), 
and nanosecond timescale full molecular dynamics simulations in a 6 Å explicit solvent 
cage. Representative data for an in silica selection against 2-Cl-ATP are shown in Figure 
7-7.  
 
In silico screening of ATP-analogs and in cleft design of drug-like molecules 
Homology models of each of the human and zebrafish P2X receptor subtypes 
were used in template-based docking studies to ensure the orthogonality of receptor-
ligand pairs. To this end, we compiled a database of ATP-analogs that can be used to 
virtually screen candidate molecules for binding using a template-forced screening 
methodology, which restricts conformational rearrangements of docked ligands to those 
more closely matching empirically derived structures. Binding energies of these analogs 
were calculated for each of the receptor subtypes. Common motifs that resulted in 
productive binding found across multiple receptor types are eliminated from the design 
process. Unique compounds or rare functional groups can be identified using this process, 
and we anticipate the ability to create tailored molecules to abolish binding to wild-type 
(unaltered) receptors by disrupting hydrogen bonding networks and introducing 
additional, sterically unfavorable transformations in the cleft. Once candidate receptor-
ligand pairs have been identified and validated, we will replace the scaffold of the ATP-
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analog with components that are more drug-like in nature (Maass et al., 2007; Stewart et 
al., 2006). Further refinement of receptor design at this stage should create the first 
orthogonal P2X receptors and provide molecules that are usable in vivo (Figure 7-8).  
 
Directed evolution of orthogonal receptor-ligand pairs 
Selection scheme overview 
The directed evolution approach to engineer receptor-ligand pairs builds on a 
recent selection method pioneered in our lab, Compartmentalized Partnered Replication 
(CPR). In this selection scheme, the function of a genetic circuit drives the production of 
a DNA polymerase during an in vivo stage. After the initial expression of the circuit, 
individual cells are compartmentalized in emulsions and thermal cycled in the presence 
of nucleotides and primers specific to the component of interest. Libraries of individual 
components of the circuit are easily made by site saturation or error-prone PCR; variants 
that produce the most DNA polymerase will subsequently be more efficiently amplified 
(Figure 7-9). Following multiple rounds of selection, the most active variants 
predominate, and can be further analyzed by sequencing and assay. The power of CPR as 
a selection tool derives from the decoupling of host fitness from circuit function and its 
ability to screen >108 variants in a single day. The production of thermostable 
polymerase in vivo is short-lived, negating fitness effects that hamper other selection 
methodologies, and the PCR amplification of functional genes allows for the ability to 
quickly and efficiently turn multiple rounds of selection. To date, CPR has been used to 
engineer: tRNAs,  amino-acyl  tRNA  synthetases,  orthogonal  T7  RNA  polymerase  
variants (Ellefson et al., 2014),  transcription  factors,  and components of biosynthetic 
pathways (in preparation). 
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Positive Selection Design & Construction 
Positive circuits were engineered in S. cerevisiae to generate DNA polymerase 
upon binding designed agonists from a semi-synthetic promoter, consisting of 4 tandem 
repeats of a 24-bp calcium-dependent response element (CDRE), a small fragment of the 
FKS2 promoter, joined to a truncated version of the Cyc1 promoter (Stathopoulos and 
Cyert, 1997). In the presence of agonist, polymerase is made in response to receptor 
function, which will in turn allow emulsion-based amplification of functional receptor 
variants (Figure 7-10). Functional testing of the CDRE using a fluorescent reporter 
showed calcium dependent activation (Figure 7-11). 
 
Negative Selection Design & Construction 
To select against constitutively active receptors, activation by ATP, the native 
ligand, or other off-target molecules, we designed and built a counterselection circuit 
where channel opening in the absence of the target molecule results in death of the cell. 
We designed a URA3-deficient strain of yeast and replaced the polymerase in the 
construct outlined above with a functional URA3 under the control of a slightly weaker 
2xCDRE synthetic promoter. Cells are then be incubated in rich media with the addition 
of 5- Fluoroorotic acid (5-FOA). Off-target or constitutively active receptors will drive 
the expression of URA3, which converts 5-FOA to 5-Fluorouracil (5- FU), a highly toxic 
compound (Figure 7-12). Modulation between rounds of positive selection (CPR) and a 
life/death negative selection will allow for the selection of highly specific receptor 
variants to target molecules. 
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Functional Expression and Testing of P2X Subtypes in S. Cerevisiae 
 We started by expressing wt-hP2X4 receptors under the control of TDH3 and Gal 
promoters in wildtype S. cerevisiae (BY4741) and a ΔCne1p mutant, which  has been 
shown to mitigate endoplasmic reticulum-mediated degradation of heterologously 
expressed transmembrane proteins (Prinz et al., 2003). By fusing Citrine, a fluorescent 
reporter, to the carboxy terminus of the receptor, we were able to observe a modest 
increase in expression using the ΔCne1p mutant (Figure 7-13). However, microscopy 
revealed large differences in localization patterns between the two strains. As predicted, 
the wild-type BY4741 cells were unable to traffic the receptor out of the ER, presumably 
explaining the modest decrease in signal during our expression testing.  
Our results indicated that the receptor escaped the ER in the ΔCne1p mutant; 
however, the receptor was largely trapped within vacuoles or pits, leaving very few, if 
any, at the plasma membrane—likely due to tyrosine-mediated endocytosis. At this point 
we learned that the carboxy terminus of hP2X4 harbors a well-characterized non-
cononical endocytic motif (YXXGθ) (Royle et al., 2002), which is recognized by specific 
machinery in mammalian systems. Somewhat unsurprisingly, the clatherin-associated 
receptor recycling system is conserved in yeast (Chapa-y-Lazo et al., 2014; Weinberg and 
Drubin, 2012). These facts led us to truncate the C-terminus of the receptor by 11 and 14 
residues (ΔC11, ΔC14), which has been shown to increase plasma membrane localization 
in certain mammalian cell types without substantial effects on gating (Royle et al., 2005). 
Confocal microscopy revealed hP2X4ΔC14 was more efficiently trafficked and largely 
absent in the vacuoles compared to the wildtype receptor (Figure 7-14). 
To determine whether or not this truncated channel gated in yeast, we utilized an 
aequorin-based functional assay. Here aequorin, a bioluminescent protein, emits a photon 
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upon binding calcium. This is done with the aid of coelenterazine, which must be added 
exogenously to yeast. The reaction is not catalytic, and the off-rate of calcium is too slow 
to observe on the timescales utilized in our assays. To optimize conditions for expression 
of both the receptor and reporter, we built and tested a combination of integration, low-
copy, and high-copy vectors. At this point, it was only possible to produce a signal upon 
addition of ATP, the native ligand, when both the receptor and reporter were expressed 
on high-copy plasmids (Figure 7-15).  
While encouraging, the amount of activation was small and unlikely to trigger the 
CDRE. Visual inspection of the primary sequence revealed that the truncated receptor 
now contained cannonical C-terminal KKXX ER retention signals (Gaynor et al., 1994).  
In an effort to increase the amount of receptor at the plasma membrane, we engineered a 
version with the ER export signal from Kir2.1 (FCYENEV) (Stockklausner et al., 2001). 
Confocal microscopy verified that the receptor largely escaped intracellular aggregation. 
Functional testing of this variant expressed from a single-copy integration vector revealed 
almost a full order of magnitude increase in signal when compared to the truncated 
version of the receptor (Figure 7-16).  
Next, we built all 7 P2X subtypes and integrated them into the genome of 
BY4741ΔCne1p under the control of the GAL1 promoter. After verification of the 
integrations, we transformed these strains with high-copy plasmids expressing aequorin. 
Interestingly, many of the receptors were shown to be functional in our assays when 
expressed from single-copy integration vectors (Figure 7-16). Exceptions include P2X3, 
P2X5, and P2X6. For P2X3, this negative result may be a result of poor trafficking in 
yeast or desensitization of the receptor. P2X3 desensitizes rapidly, and our assay may not 
be sensitive enough to detect gating of this receptor. P2X5 and P2X6 were not expected 
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to produce signals. In humans, these receptors are typically found in heterotrimeric 
configurations with other subtypes (Lê et al., 1999; North, 2002). 
Surprisingly, the ligand-dependent signal generated by P2X2 was several orders 
of magnitude higher than any of the other subtypes. This is more than likely due to 
efficient trafficking and a lack of desensitization of the receptor to ATP. Of the 7 
subtypes, P2X2 is considered to be ‘non-desensitizing’ and displays the highest single-
channel conductance of the P2X receptor family (North, 2002). Due to the superior signal 
observed in our aequorin assay, we decided to perform a full kinetic analysis to determine 
if the receptor expressed in yeast matched data from mammalian hosts. In an ATP dose-
response assay, we calculated the EC50 to be 6.7±1.5 µM—perfectly matching reported 
values (Figure 7-17) (Lynch et al., 1999). Next, we characterized the P2X2 dose-
response to 2-Cl-ATP (Figure 7-18) and BzATP (Figure 7-19) and found that the 
receptor was agonized by these compounds with nearly identical EC50 values (26.7±3.6 
and 29.1±6.0 µM, respectively)  and in good agreement with published reports (Coddou 
et al., 2011; Jarvis and Khakh, 2009). Of particular interest, BzATP has been previously 
shown to lower the magnitude of response while increasing the time the channel is open 
(less desensitizing). Our plate-based aequorin assay recapitulated this phenomenon. The 
amplitude of the BzATP generated signal is 3 orders of magnitude lower than either ATP 
or 2-Cl-ATP, and the duration that the channel remains open is almost 10-fold longer in 
our assays. AMP-PNP, a non-hydrolyzable ATP analog, did not gate P2X2. This negative 
result was expected because AMP-PNP has not been reported to activate P2X2. Suramin 
is a known P2X2 antagonist. To determine if our assay could detect inhibition, we 
equilibrated yeast cells expressing P2X2 with varying concentration of suramin. We 
found that suramin inhibited P2X2 with an IC50 of 31.6±1.4 µM (Figure 7-20), well 
within the range of reported values (2-48 µM) (Baqi et al., 2011; Lambrecht et al., 2002). 
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Finally, a non-functional double-mutant (K81C, K83C) (Roberts et al., 2008) was shown 
to be completely non-functional in our assay (Figure 7-21), giving us confidence that our 
results were robust and adequately accounted for known P2X2 properties.  
To our knowledge, this marks the first direct evidence of a human neural receptor 
gating in yeast. We believe this plate-based aequorin assay could be used in high-
throughput drug discovery platforms. We are particularly interested in how P2X2 is able 
to gate much more efficiently than the other subtypes. It may prove possible to build 
chimeric receptors with the N- or C-termini of P2X2 affixed to the extracellular and 
transmembrane portions of the other receptor subtypes. Doing so may allow more robust 
signal generation of the other receptors. It may also be useful to construct known 
‘desensitizing’ mutations of the other receptors and test their activity using our yeast-
based assay. 
 
P2X2 selections 
Having built and proofed the individual components of the selection scheme, 
libraries of P2X2 are now under construction. To initially change the ligand specificity of 
P2X2 receptors, we saturated positions in the ATP binding pocket and will select for 
gating to AMP-PNP. Those circuits that can respond most readily to AMP-PNP should be 
readily identified within a few cycles of emulsion and amplification in the presence of 
primers specific for the P2X2 receptor. Another avenue to proof the selection 
methodology outlined above would be to evolve the ‘broken’ double mutant back to 
wildtype function using ATP or 2-Cl-ATP. 
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Conclusions 
Here we developed a methodology to engineer robust, orthogonal receptor:ligand 
pairs. By combining rational design and directed evolution approaches, it should prove 
possible to engineer both the receptor and ligand. The ability to make complementary 
modifications in channel and ligand structure will help generate a family of orthogonal 
receptor-ligand pairs for independent control over multiple cell populations within the 
brain while eliminating crosstalk with endogenous factors. The strength of this and other 
pharmacogenetic approaches is that the locations of target neurons need not be known a 
priori; however, should precise temporal regulation be needed, the ligands could 
potentially be chemically disabled, enabling brief localized photoactivation. A synthetic 
purinergic activator (SPArk) will advance functional brain mapping, provide robust 
control over discrete neuronal populations that represent known neurochemical classes or 
are selected using pioneering activity-based molecular-genetic methods. 
A panoply of tools that will be deployed brain-wide across species to control 
distinct ensembles of neurons will uncover circuit connectivity and signaling hierarchies. 
However, just as with existing technologies, much work remains to be done not only to 
engineer the synthetic receptors, but also to synthesize and screen orthogonal ligands that 
are well-tolerated, easy to administer, and that readily reach target sites in the brain. 
 
METHODS & MATERIALS 
Molecular Modeling of P2X Receptors 
Homology models of human P2X subtypes were constructed using two reference 
structures (PDB: 4DW1 and 3H9V).The templates were prepared using the Molecular 
Operating Environment (MOE.09.2015) software package from Chemical Computing 
Group. The structure was inspected for anomalies and protonated/charged with the 
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Protonate3D subroutine (310K, pH 7.4, 0.1 M salt). The protonated structure was then 
lightly tethered to reduce significant deviation from the empirically determined 
coordinates and minimized using the Amber10:EHT forcefield with R-field treatment of 
electrostatics to an RMS gradient of 0.1 kcal mol-1 Å-1.  Homology models of the other 
P2X subtypes were prepared by creating 25 main chain models with 25 sidechain 
samples at 298K (625 total) within MOE. Intermediates were refined to an RMS gradient 
of 1 kcal mol-1 Å-1, scored with the GB/VI methodology, minimized again to an RMS 
gradient of 0.5 kcal mol-1 Å-1, and protonated. The final model for each variant was 
further refined by placing the protein within a 6 Å water sphere and minimizing the 
solvent enclosed structure to an RMS gradient of 0.001 kcal mol-1 Å-1.  Models were 
evaluated by calculating Phi-Psi angles and superimposed against the reference structure. 
Agonist structures were created in cleft, and LigandInteractions subroutine was used to 
calculate binding energies. ResidueScan was used to identify potential amino acid 
substitutions for a given analog. Interactions were scored based on stability, affinity, and 
potential energy of the system. 
 
Cloning and expression of P2X subtypes in yeast 
Sequences for the wild-type receptors and aequorin were obtained from Uniprot. 
Amino acid sequences were codon optimized for expression in S. cerevisiae and 
purchased as GeneBlocks from IDT. The Yeast Toolkit was then used for the Golden 
Gate Assembly of all vectors. Aequorin was expressed under the control of the pPGK2 
promoter. P2X variants were expressed under the control of the GAL1 promoter. 
Fluorescently-tagged (Venus) constructs of receptor variants were also constructed for 
confocal microscopy and flow cytometry analyses. Flow cytometry was performed by 
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Michelle Byrom at the Core Facility at the University of Texas at Austin. Plasmid maps 
and sequences are available upon request. 
 
Confocal microscopy 
 Overnight cultures harboring fluorescently tagged (Venus) receptors were diluted 
1:20 in fresh media. After 6 hours of growth, cells were washed 3 times with PBS. A total 
of 3 mL of cells were concentrated into 100 µL. 5 µL of the concentrated cells were 
placed on a slide. A coverslip was added and sealed with clear nail polish. Images were 
taken at the University of Texas at Austin Microscopy center by Dr. Julie Hayes. 
 
Aequorin assays 
BY4741ΔCne1p cells were transformed with vectors containing P2X variants. 
Transformants were validated and made competent for a subsequent transformation with 
a vector containing aequorin under the expression of the constitutive PGK2 promoter. 
Overnight cells were induced with 2% galactosidase for 20 hours. Following receptor 
expression, cells were collected by centrifugation and concentrated to 500 µL. The 
concentrated cells were then incubated with 5 µL of 1 mg/mL coelenterazine for 30 
minutes at room temperature. Washed cells were then resuspended in softening buffer (1 
M Sorbitol, 25 mM EDTA, 50 mM DTT), followed by washes in 1 M sorbitol and water. 
Cells were then resuspended in 50 mM MES/Tris pH 6.5 and aliquoted into a 96-well 
plate. Using an F500, 25 µL of cells were monitored for luminescence for 5 seconds. 
Upon addition of ligand or buffer (100 µL), cells were monitored for luminescence for 
varying times. Cell lysis was performed with the addition of 100 µL Tween20. For 
inhibition, varying concentrations of suramin were incubated with cells. Luminescence 
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was monitored before and after the addition of 100 µL of 10 µM ATP. Areas under the 
curve were calculated and plotted against a negative control to determine the IC50.  
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Figure 7-1: Engineering approach 
 
Overview of Orthoganol P2X Receptor-Ligand Engineering. Parallel approaches of 
rational design and directed evolution are depicted. 
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Figure 7-2: hP2X4 biomolecule assembly 
 
Biomolecular assembly of the functional P2X4 homotrimer. Individual monomers are 
depicted in pink, yellow, and orange. Glycosylation sites near the ligand-binding domains 
are shown using sticks.
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Figure 7-3: P2X4 ATP binding pocket 
 
3D-depiction of a single ATP-binding pocket. Each binding domain rests between two 
monomer, depicted herein pink and yellow. Ordered water molecules from the crystal 
structure are shown in ball and stick format. 
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Figure 7-4: Ligand interactions of ATP with P2X4 
 
Left, ATP interactions with P2X4 are tabulated. Right, 2D contact map of ATP bound to 
the wildtype structure. Basic residues are highlighted in blue. Polar contacts are depicted 
with arrows.
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Figure 7-5: Training molecules 
 
 
Training molecules and amino acid residues used in the design of P2X4 receptor variants.
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Figure 7-6: 2-Cl-ATP binding to P2X4 
 
Left, 3D representation of 2-Cl-ATP in the wild-type P2X4 structure. Right, 2D contact 
map. Clashing is observed in P2X4.
 
337 
 
Figure 7-7: In silica selection of P2X4 variants to 2-Cl-ATP 
 
Left, library residues for in silica selection are shown in blue. 2-Cl-ATP is depicted in 
magenta and with a molecular surface. Right, representative in silica selection data of top 
10 computationally derived P2X4 variants.
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Figure 7-8: Analog screening methodology 
 
Methodology for selection of orthogonal receptor:ligand pairs. 1. Homology models were 
constructed for each of the P2X receptor subtypes. 2. Models are screened against a 
number of small molecules. 3. Small molecules are scored with quantitative structure 
activity relationships and given scores. 4. Candidate molecules are transformed into 
druggable molecules through by replacing the scaffold of the selected molecule.
 
339 
 
Figure 7-9: yCPR for ion channels 
 
Overview of ionotropic receptor CPR. Libraries of receptors are transformed into yeast 
and expressed. Variants are challenged with agonist in bulk. Active receptors lead to the 
production of a thermostable DNA polymerase, used in emulsion PCR. The most active 
variants produce the most polymerase and thereby resulting in more copies being made 
during the PCR step. After breaking the emulsion, variants are recloned and subjected to 
more rounds of selection or assayed individually.
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Figure 7-10: Positive selection circuit 
 
Positive Selection Circuit. DNA polymerase is induced by calcium intake from P2X 
receptor variants.via the Crz1-dependent pathway. The amount of polymerase produced 
in each cell is directly influenced by receptor function. 
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Figure 7-11: Calcium dependent response element characterization 
 
 
Top, depiction of 4xCDRE-Cyc1 hybrid promoter. Bottom left, passive diffusion of 
calcium triggers the promoter when compared to a control. Bottom right, the addition of 
an calcium ionophore triggers expression of a fluorescent reporter under the control of 1x 
and 3x CDRE hybrid promoters. 
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Figure 7-12: Negative selection circuit 
 
 
Negative Selection Circuit. URA3 is produced in the presence of constitutively active and 
off-target binding receptors. URA3 converts 5-FOA to 5-FU and kills the cell. 
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Figure 7-13: Flow cytometry reveals expression of P2X4 in yeast 
 
Flow cytometry of low-copy plasmid expression testing of fluorescently –tagged hP2X4 
receptors in BY4741 (top) and BY4741ΔCne1p (bottom). See key for traces.
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Figure 7-14: Localization of P2X4 in yeast 
 
Confocal microscopy of wtP2X4 and endocytic variants. ΔC14 was judged to be largely 
absent from intracellular vacuoles when compared to the wt receptor.
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Figure 7-15: Function assay of P2X4 
 
Functional testing of hP2X4ΔC14 using a plate-reader based aequorin assay. Each point 
represents the average of three independent test. Only when the receptor and aequorin 
were expressed from 2 micron (high-copy) plasmids could a reproducible signal be 
observed.
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Figure 7-16: Functional assays of all P2X subtypes in yeast 
 
Aequorin assay of all P2X receptor subtypes. P2X4ER+ is the truncated (ΔC14) receptor 
with the addition of an ER export signal (FCYENEV) to the carboxy terminus. All other 
receptors are wild-type sequences. Reproducible signals were observed in subtypes 1, 2, 
4, and 7.
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Figure 7-17: P2X2 dose-response with ATP 
 
Left, time course of ATP-dependent luminescence of P2X2. Each curve represents a 
different ATP concentration. Right, area under the curve from the luminescence assay 
was plotted against concentration and fit.
EC50 = 6.7 ± 1.5 μM 
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Figure 7-18: P2X2 does-response with 2-Cl-ATP 
 
Left, time course of 2-Cl-ATP-dependent luminescence of P2X2. Each curve represents a 
different 2-Cl-ATP concentration. Right, area under the curve from the luminescence 
assay was plotted against concentration and fit.
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Figure 7-19: P2X2 dose-response with BzATP 
 
Left, time course of BzATP-dependent luminescence of P2X2. Each curve represents a 
different BzATP concentration. Right, area under the curve from the luminescence assay 
was plotted against concentration and fit. 
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Figure 7-20: P2X2 is inhibited by suramin 
 
Left, luminescence of ATP-induced signaling. Right, inhibition curve generated from 
timecourse data.
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Figure 7-21: Nonfunctional P2X2 mutant does not gate 
 
wtP2X2 response is depicted in gray. Orange represents the response of the broken 
receptor (K81C, K83C). No response is observed in the double mutant. 
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